SUPPLEMENT TO

Thorax

The Journal of the British Thoracic Society

VOLUME 51

President: J E STARK

Executive Editors: J R Britton and A J Knox
Associate Editors: N C Barnes, M W Elliott, J A Fleetham, N M Foley, B G Higgins, N Høiby, S A Lewis, M R Miller, M F Muers, D F Rogers, D P Strachan, W S Walker, J O Warner, R J D Winter
Technical Editor: Elizabeth Stockman
Editorial Assistant: Hilary Hughes

Advisory Board

S H Abman *USA*
J M Anto *Spain*
P J Barnes *UK*
E D Bateman *South Africa*
P S Burge *UK*
D M Geddes *UK*
P Goldstraw *UK*
C Haslett *UK*
P J Helms *UK*
G J Laurent *UK*
F D Martinez *USA*
D M Mitchell *UK*
A J Peacock *UK*
R M Rudd *UK*
N A Saunders *Australia*
P D Sly *Australia*
M J Tobin *USA*
M Woodhead *UK*
Editor, *British Medical Journal*

BMJ Publishing Group

VOLUME 51 • AUTHOR INDEX

(E) = Editorial (L) = Letter

Aalbers R, 582
Aalders BJ, 433
Abbott J, 1233
Abbott KJ, 1109
Abboud S, 407
Abdelaziz MM, Suppl.3.A3, Suppl.3.A39
Abrahams J-P, Suppl.3.A50
Adams C, Suppl.3.A33
Adams WH, 140
Adcock IM, 1223
Addo Yobo EOD, Suppl.3.A42
Adnot S, 762
Afolabi O, Suppl.3.A23
Agustí C, 841
Ahmed AA, 1048
Aiken T, Suppl.3.A22
Akkoçlu A, 397
Akpinar O, 397
Al Jarad N, 137, Suppl.3.A9
Al-Kassimi F, 228 (L)
Al-Kattan K, 1266
Alcock SM, Suppl.3.A44
Ali N, 914
Alibhai A, Suppl.3.A40
Alimohammadi A, Suppl.3.A3
Allen DH, 159
Allen J, Suppl.3.A52
Allen JT, Suppl.3.A12
Allen MB, 323, Suppl.3.A7
Almenoff PL, 530
Alonso-Calderón JL, 420
Alonso P, 1043
Alton EWFW, Suppl 2.51, Suppl.3.A5, Suppl.3.A6, Suppl.3.A57, Suppl.3.A60
Amendola M, 1000
Amgus RM, 1048
Amies M, Suppl.3.A73
Amundson DE, 549, 1283 (L)
Anderson HR, 1109
Anderson K, 256, 654
Anderson M, 140
Anderson R, 1010, Suppl.3.A58
Ando M, 650
Andreone P, 315
Angus RM, 71, Suppl.3.A19, Suppl.3.A65
Antépara I, 867
Antó JM, 743
Antoine M, 1065
Aranda A, 929
Arias-Diaz J, 339
Armstrong L, 143
Arnold AG, Suppl.3.A55
Arrand JR, 1160
Arroyo O, 420
Asafo-Agyei AP, Suppl.3.A42
Asboe D, 228 (L)
Ascaso A, 1043
Ashbaugh DG, 193
Ashcroft T, 223
Ashman J, 1115
Ashworth F, Suppl.3.A47
Aslam M, Suppl.3.A30
Assoufi B, 664
Assoufi BK, Suppl.3.A41
Asthma Breakthrough Group, Suppl.3.A63
Ayatollahi T, 169
Ayres J, Suppl.3.A61
Ayres JG, 403, Suppl.3.A2, Suppl.3.A14, Suppl.3.A17, Suppl.3.A18, Suppl.3.A66
Ayres N, Suppl.3.A34
Ayuso MC, 841

Badminton RM, Suppl.3.A29
Baenkler HW, 919
Bagnall A, Suppl.3.A40
Bake B, 1239
Baker JC, Suppl.3.A2
Baker M, Suppl.3.A21
Bakker W, 298, 1283 (L)
Balci P, 397
Baldwin DR, 1165, Suppl.3.A7
Balibrea JL, 339
Banerjee D, Suppl.3.A32
Banerjee DJ, Suppl.3.A69, Suppl.3.A71
Banner NR, 1162
Baran R, 87
Barber L, Suppl.3.A23
Barber P, 345 (E), Suppl.3.A55
Barbour C, Suppl.3.A76, Suppl.3.A77
Barbour CJ, Suppl.3.A76
Barker RD, Suppl.3.A1
Barnes GR, Suppl.3.A28
Barnes NC, 137, 1062, 1073 (E), 1171 (E), 1223
Barnes PJ, 218, 233 (E), 793, 1178, 1223, Suppl.3.A80
Barr J, 82
Barry PW, 175, 835
Bartlett W, Suppl.3.A61
Basten G, Suppl.3.A38, Suppl.3.A60
Batchelor SA, Suppl.3.A36
Bates DV, Suppl 2.3
Battagel JM, Suppl.3.A78
Battikh M, 554
Baudouin SV, 516
Bayley DL, Suppl.3.A81, Suppl.3.A82
Bayly G, Suppl.3.A61
Bayram H, Suppl.3.A39, Suppl.3.A54
Bayston SM, Suppl.3.A55
Beckhurst C, Suppl.3.A32
Beeching NJ, 624
Beer TW, 526
Bégin R, 781
Belcher J, 484
Bell C, Suppl.3.A34
Bell D, Suppl.3.A79
Bell J, 831
Bell SC, 126, 159, 971 (E), Suppl.3.A58, Suppl.3.A59, Suppl.3.A80
Bellamy D, Suppl.3.A44, Suppl.3.A61
Bellemare F, 705
Bellia V, 694
Bellis MA, 624, Suppl.3.A9
Benckhuijsen JAW, 582
Bennett DE, Suppl.3.A8, Suppl.3.A9
Bennett JA, 989
Bennett LS, Suppl.3.A76, Suppl.3.A77
Bentham G, Suppl.3.A1, Suppl.3.A29
Bentley C, Suppl.3.A31
Benzaray S, 272, Suppl.3.A61, Suppl.3.A65
Berend N, 159
Bergeron A, 611
Bernardi M, 315
Berrill WT, Suppl.3.A22
Berrisford RG, Suppl 2.23
Bestall J, 1068 (L)
Bestall JC, Suppl.3.A10, Suppl.3.A24
Beswick PH, 389
Bianchi A, Suppl.3.A80
Biernacki W, Suppl.3.A65
Biggi A, 359
Billing JS, 903
Bilton D, Suppl.3.A60, Suppl.3.A68
Bingle L, 1273
Birchall NM, 1123
Bish R, 1100
Bishop P, 1160
Bistritzer T, 82
Blackburn LA, Suppl.3.A62
Bland M, Suppl.3.A61
Block LH, 150
Bloor CA, Suppl.3.A12
Bobbio P, 1169 (L)
Bodner C, Suppl.3.A22
Boguniewicz M, Suppl 2.55
Boissinot E, 385
Bolaños J, 929
Bölcskei PL, 919
Bolden G, Suppl.3.A80
Boldsen J, 503
Boldur I, 179
Böllert FGE, Suppl.3.A78
Bolliger CT, 1127
Bonay M, 611
Bone M, Suppl.3.A70
Booth H, 1100
Booth JI, Suppl.3.A55
Borland C, 855
Bouchaud O, 204
Bouhadiba T, 781
Bourke SJ, 169, Suppl.3.A2, Suppl.3.A43
Bown SG, Suppl.3.A8
Boyd G, 78, 656, Suppl.3.A71
Brabin BJ, Suppl.3.A14, Suppl.3.A15
Bradding P, 575
Bradshaw DA, 549, 1283 (L)
Brady AR, Suppl.3.A8
Brändli O, 277
Bredin C, Suppl.3.A33
Bredin CP, Suppl.3.A49
Brenton D, 960
Brett SJ, 89, Suppl.3.A18
Bridge P, Suppl.3.A80
Bright P, 857, Suppl.3.A42, Suppl.3.A43
Britton J, 561 (E), 670, 711
Britton JR, 1177
Britton M, Suppl.3.A79
Bromley IMJ, 1203
Bromly C, 169
Bromly CL, Suppl.3.A2
Brown J, 894, 963
Brown JM, Suppl.3.A54
Brown JS, 564
Browning J, Suppl.3.A6, Suppl.3.A60
Bruderman I, 407
Brugiere O, 1065
Brun-Buisson C, 771 (L)
Brunskill J, Suppl.3.A7
Bruscoli G, 1077
Brutel de la Rivière A, 846
BTS Research Committee, Suppl.3.A43
Bucala R, Suppl.3.A54
Buccheri G, 359
Buckley A, Suppl.3.A21
Buonaccorsi G, Suppl.3.A8
Burdick MD, Suppl.3.A52
Burdon J, 596
Burge A, Suppl.3.A9
Burge PS, 96, 484, 857, 969 (E), Suppl.3.A40, Suppl.3.A41, Suppl.3.A42, Suppl.3.A43, Suppl.3.A44
Burgess CD, Suppl.3.A72
Burgess K, 556
Burgess L, Suppl.3.A15
Burghuber OC, 9 (E)
Burke CM, 993
Burke MM, 727
Burney P, Suppl.3.A63
Burney PGJ, 924
Burns S, 78
Burt P, Suppl.3.A55
Bury T, 1270
Bush A, Suppl.3.A47, Suppl.3.A57
Butland B, 670
Butler JE, 490
Butler N, 670
Butt U, Suppl.3.A47
Buurman WA, 819
Bynner J, 670

Cabrera P, 1130
Cafferty J, Suppl.3.A47, Suppl.3.A48
Cairns AY, Suppl.3.A14
Calcagni PG, 267
Calder C, Suppl.3.A71
Calderon M, Suppl.3.A39
Calverley PMA, Suppl.2.A29, Suppl 3.19, Suppl.3.A44, Suppl.3.A65
Cameron CHS, 654
Caminero J, 929
Caminero JA, 1130
Campbell EJ, Suppl.3.A82
Campbell MJ, Suppl.3.A16
Camus F, 204
Cancio E, 1115
Cannon J, Suppl.3.A1
Cantin A, 781
Caplen NJ, Suppl.3.A6
Carbognani P, 1169 (L)
Carette M-F, 1065
Cargill RI, 262
Carrell RW, Suppl.3.A50
Carroll KB, 1160
Carroll N, Suppl.3.A60
Carton C, Suppl.3.A64
Casalino E, 204
Cater JI, 364
Cattelani L, 1169 (L)
Catterall J, Suppl.3.A79
Catterall JR, Suppl.3.A4, Suppl.3.A77
Caylà JA, 1130
Cayton RM, 403, Suppl.3.A24
Cerveri I, 424
Ceyhan B, 793
Chabasse D, 106
Chabot F, Suppl.3.A35
Chadwick M, Suppl.3.A8, Suppl.3.A9
Chadwick SL, Suppl.3.A6, Suppl.3.A60
Chakroun M, 554
Chalmers GW, 71, Suppl.3.A81
Chambers DC, Suppl.3.A17, Suppl.3.A18
Chambers DJ, Suppl.3.A69
Chambers J, Suppl.3.A18
Chambers MA, Suppl.3.A34
Chambers ST, 1010
Chan H, 1280
Chan SL, Suppl.3.A9
Chan-Yeung M, 1280
Chang JC, 306
Chang S, Suppl.3.A74
Chang W-S, Suppl.3.A51
Chapman CJ, 458 (E)
CHART Steering Committee, 1262
Chatterjee AJ, Suppl.3.A49
Cheesman AD, Suppl.3.A37
Chen CY, 103
Chen K-S, 221
Chen Y-C, 869
Cheng S, Suppl.3.A5, Suppl.3.A6
Cheng SH, Suppl.3.A6
Chereshsky A, 1010
Chinn DJ, 699
Chinn S, 1134
Christie G, Suppl.3.A15
Christie PE, 64, 1171 (E)
Christmas T, Suppl.3.A7
Chrystyn H, 658 (L)
Cihla HP, 479
Cimon B, 106
Ciofu O, 733
Clark C, Suppl.3.A43
Clark DJ, 262, 325, 658 (L), 941, 981, Suppl.3.A72
Clark G, 325
Clark MM, 989
Clark RA, 941, Suppl.3.A14, Suppl.3.A26, Suppl.3.A29
Clarke JR, 875 (E), Suppl.3.A3
Cline A, Suppl.3.A74
Clough JB, Suppl.3.A22
Coakley R, Suppl.3.A3
Coats AJS, Suppl.3.A21
Cobbe S, Suppl.3.A35
Cockroft DW, 1051
Coggon D, Suppl.3.A16
Coker R, Suppl.3.A3
Coker RJ, Suppl.3.A3, Suppl.3.A32
Cole AA, 534
Cole PJ, Suppl.3.A58
Cole RB, 1165
Collard Ph, 224
Collier DJ, 175
Collier J, 606
Collins FJ, 338
Collins MK, Suppl.3.A6
Collins PD, Suppl.3.A54
Collinson J, 1115
Colville A, 1243, 1248
Conde MK, 385
Congleton J, 936
Connolly CK, 238, Suppl.3.A44, Suppl.3.A56
Connolly MJ, 164, 520, Suppl.3.A16, Suppl.3.A17
Conry B, Suppl.3.A72
Conway S, Suppl.3.A50
Conway SP, 29, 34
Cook A, Suppl.3.A1, Suppl.3.A41
Cook HT, 1253, Suppl.3.A34
Cook PJ, Suppl.3.A14, Suppl.3.A36, Suppl.3.A67
Cooke NJ, 323
Cooper A, Suppl.3.A57
Cooper D, 1168 (L)
Cooper S, Suppl.3.A26, Suppl.3.A27
Copeland J, Suppl.3.A57
Corbishley C, 1158
Cordero PJ, 94
Corhay J-L, 1270

Corlett SA, 658 (L)
Cormier Y, 1210
Cornwall Asthma Liaison Nurse Team, Suppl.3.A62
Corrado A, 677, 1077
Corris PA, 767, 1068 (L), 1164, Suppl.3.A18, Suppl.3.A23
Cosio MG, 354
Costello C, Suppl.3.A58
Costello CM, 619
Cotes JE, 699
Coulby LJ, 1185
Coultas DB, 711, 717
Coursin DB, 479
Coutie WJ, Suppl.3.A36
Couture J, 705
Cowley AJ, Suppl.3.A46
Cox Y, 855
Craft PS, 552
Cramer D, 202
Crane J, Suppl.3.A42, Suppl.3.A72
Crisp AJ, 1243, 1248
Croall J, 256
Crocker J, 526
Crombie IK, Suppl.3.A14, Suppl.3.A29
Crompton GK, 454 (L), Suppl.3.A74, Suppl.3.A75
Crooks SW, Suppl.3.A81
Crosby J, Suppl.3.A79
Crouch S, Suppl.3.A59
Cryan B, Suppl.3.A33
Cullinan P, Suppl.3.A11
Cunningham S, Suppl.3.A61
Curnow J, 78
Curtin JJ, Suppl.3.A70
Curzen NP, Suppl.3.A36
Cushley M, Suppl.3.A70
Custovic A, Suppl.3.A41, Suppl.3.A42
Cuttitta G, 694

Dagg K, Suppl.3.A81
Dagg KD, 461 (E), 853
Dahl D, Suppl.3.A74
Dally M, Suppl.3.A41
Daniels JE, Suppl.3.A44
Dankert-Roelse JE, 207
D'Arcy EM, Suppl.3.A51
Dark JH, 1068 (L), Suppl.3.A23
Dassio G, 446
Davern S, Suppl.3.A53
Davey Smith G, Suppl.3.A23
Davidson AC, Suppl.3.A1
Davies J, Suppl.3.A47, Suppl.3.A57
Davies L, Suppl 2.29, Suppl.3.A19, Suppl.3.A21, Suppl.3.A65
Davies P, Suppl.3.A14, Suppl.3.A67
Davies PDO, 624, Suppl.3.A9, Suppl.3.A33, Suppl.3.A34
Davies R, Suppl.3.A73
Davies RJ, 1105, Suppl.3.A3, Suppl.3.A39, Suppl.3.A40, Suppl.3.A51, Suppl.3.A54
Davies RJO, Suppl 2.65, Suppl.3.A67, Suppl.3.A76, Suppl.3.A77, Suppl.3.A79
Davison AG, 564
de Bruijn R, 582
De Campos M, 793
de Gentile L, 106
de Jong JW, 684
De Paola E, 677, 1077
de Picciotto C, 204
Deane CR, 516
Decramer M, 601
Deegan PC, Suppl.3.A7, Suppl.3.A21
Delaney SJ, Suppl.3.A60
Delwiche J-P, 452
Delwiche JP, 472
Demertzis P, 137
Demissie K, 59
DeMolles D, 787
Denn DJ, Suppl.3.A62
Dent G, 647
Dentener MA, 819
Desager KN, Suppl.3.A73
Desai M, Suppl.3.A49
Desmeules M, 1210
Despas P, 341
Deuchar G, Suppl.3.A35
Devadason SG, 75, 537, 985
Devalia JL, 1105, Suppl.3.A3, Suppl.3.A39, Suppl.3.A40, Suppl.3.A51, Suppl.3.A54
Devereux G, 169
Devlin J, 1168 (L)
Dewar A, Suppl.3.A57
Dewar J, Suppl.3.A15, Suppl.3.A37
Dewar MH, Suppl.3.A74, Suppl.3.A75
Dezateux C, Suppl.3.A15
Dhillon DP, 689
Diallo AA, 385
Diaz F, 1130
Diederich S, 914
Dilworth JP, 320
Dimond PD, Suppl.3.A73
Diot P, 385
Dirksen A, 973
Dische S, 1262
Diss TC, Suppl.3.A11
Djukanovic R, 575
Dodd M, 1233, Suppl.3.A49
Dodds R, 569
Doherty MJ, Suppl.3.A20
Donald KG, 59
Donaldson GC, Suppl.3.A19, Suppl.3.A65
Donaldson K, 389, 465, 1203, 1216, Suppl.3.A53
Donath D, 354
Donnell D, Suppl.3.A73
Donnelly S, Suppl.3.A52
Donnelly SC, Suppl.3.A54
Dosman JA, 650
Douglas AS, 944
Douglas JG, Suppl.3.A22, Suppl.3.A66, Suppl.3.A71
Douglas NJ, 190, 882, Suppl.3.A4, Suppl.3.A78
Douillard JY, Suppl.3.A55
Doull IJM, 630
Dow E, Suppl.3.A37
Dow L, Suppl.3.A16
Dowlati A, 1270
Dowson LJ, Suppl.3.A69
Drazen JM, 1168 (L)
Drinnan MJ, Suppl.3.A76
Drobniewski F, Suppl.3.A8, Suppl.3.A9
du Bois RM, Suppl.3.A11
Duckworth G, Suppl.3.A9
Duffield JS, 140
Duncan-Skingle F, 936
Duncanson RD, Suppl.3.A2
Dundas I, Suppl.3.A15
Dunster C, Suppl.3.A59
Duranti R, 677, 1000
Durham SR, 664

Earis JE, Suppl.3.A57
East London COPD Collaborative Group, Suppl.3.A19, Suppl.3.A65
Eastell R, Suppl.3.A72
Eastrige C, 253
Eaton T, Suppl.3.A7
Ebden P, Suppl.3.A70
Ebels T, 638
Eber E, 985
Edenborough F, Suppl.3.A47, Suppl.3.A48, Suppl.3.A50
Edenborough FP, 374, 652, Suppl.3.A24
Edmonds DK, 1064
Edwards RJ, Suppl.3.A20
Egan JJ, 873 (L), 1160, Suppl.3.A23, Suppl.3.A68
Egan M, 343
Ekström T, 1028
El-Ebiary M, 378
El Gamel A, Suppl.3.A23
El-Henmaidi I, Suppl.3.A47
El Kamel A, 554
El Khushman H, Suppl.3.A37
Elad D, Suppl.3.A65
Elbers HRJ, 846
Elborn JS, 126, 971 (E), Suppl.3.A49, Suppl.3.A58, Suppl.3.A59, Suppl.3.A80
Elender F, Suppl.3.A1
Elliott MW, Suppl.3.A11, Suppl.3.A60, Suppl.3.A67, Suppl.3.A77
Elliott PR, Suppl.3.A50
Empey DW, 137, Suppl.3.A9
Engström C-P, 825
Ennis M, Suppl.3.A64
Enomoto T, Suppl.3.A1
Epton MJ, 1010
Eraut D, 564
Ernst P, 59
Eshel G, 82
European Study Group of Community Acquired Pneumonia of the European Respiratory Society, 1017
Evans AE, 293
Evans AJ, 1243, 1248
Evans C, Suppl.3.A19
Evans CC, 550
Evans DJ, 1178, 1185
Evans EN, Suppl.3.A70
Evans S, Suppl.3.A11, Suppl.3.A32
Evans SA, 1243, 1248
Evans TW, 89, 114 (E), Suppl.3.A18, Suppl.3.A35, Suppl.3.A36, Suppl.3.A53
Everard ML, 75, 537, 985
Evertse CE, 496

Fabbri LM, 267
Fabbri M, 315
Fábregas N, 378
Fairfax AJ, Suppl.3.A45
Falguera M, 967 (L)
Fanfulla F, 424
Farley R, Suppl.3.A60
Farrell DJ, 223
Farrell I, Suppl.3.A8, Suppl.3.A9
Farrell PJ, Suppl.3.A11
Fasano L, 315
Feather I, 575
Featherstone RL, Suppl.3.A69
Feely MP, 323
Fennerty A, Suppl.3.A57
Fenwick LJ, 1048
Fergusson RJ, 569
Fernando SSD, 1083
Ferrando JR, Suppl.3.A36
Ferrigno D, 359
Field PI, 159
Fielding DI, Suppl.3.A8
Finch SP, Suppl.3.A4
Finlay GA, 619, Suppl.3.A51
Finney S, Suppl.3.A68
Fisher M, 228 (L)
Fishwick D, 767, Suppl.3.A44
Fitch R, Suppl.3.A64
Fitt S, 1168 (L)
Fitzgerald B, Suppl.3.A1
FitzGerald MX, 619, Suppl.3.A12, Suppl.3.A18, Suppl.3.A51, Suppl.3.A53, Suppl.3.A58
Fitzharris P, Suppl.3.A42
Flanagan KL, 1062
Fleming TA, Suppl.3.A26
Flemming TA, Suppl.3.A45
Fletcher AM, Suppl.3.A41, Suppl.3.A44
Fletcher M, Suppl.3.A15
Fletcher T, Suppl.3.A14
Fletcher TJ, Suppl.3.A17, Suppl.3.A18, Suppl.3.A66
Flower CDR, 914
Folgering HThM, 1192
Fong KM, 1275
Forbes GI, 78
Forbes L, Suppl.3.A63
Forsythe P, Suppl.3.A64
Fothergill J, 959
Fountain SW, 727, 1266
Fournel P, Suppl.3.A55
Fox A, Suppl.3.A23
Fox RA, 963
Frampton C, 1010
Francis Ch, 224
Francis HC, Suppl.3.A41
Francis J, Suppl.3.A47
Franklin M, 364
Fraser IS, 932
Fraser RS, 175
Frechet M, 385
Freezer NJ, 630
Freitag L, 224
Freixinet J, 929
Frew AJ, 458 (E)
Friedman MG, 179
Friend JAR, Suppl.3.A22, Suppl.3.A66, Suppl.3.A71
Fujii T, 1199
Fujimoto K, 312, 739
Fukumura M, 155
Furuya K, 777

Gabbay E, 1068 (L), Suppl.3.A18, Suppl.3.A23
Galli S, 315
Gallon AM, 429
Gamble LA, Suppl.3.A64
Gamboa PM, 867
Gandevia SC, 490
Gandhi M, 451
Ganeshalingam K, Suppl.3.A70
Gannon PFG, 484
Garnham R, 1068 (L), Suppl.3.A24
Garrett J, Suppl.3.A7
Garrett JE, 1093
Garrido-Garcia H, 420
Garrod R, 1068 (L), Suppl.3.A24
Gates AJ, Suppl.3.A3
Gavant M, 253
Gaya H, 137
Gazzard BG, 228 (L)
Geddes D, 202
Geddes DM, 1158, Suppl.3.A5, Suppl.3.A6, Suppl.3.A47, Suppl.3.A57, Suppl.3.A60
Gelder CM, Suppl.3.A2
Gerbe J, 204
Gerritsen J, 298, 317
Ghosal S, 1229
Gialdroni-Grassi G, 1017
Gibbs AR, 327, 1074
Gibbs JSR, 89
Gibson B, 256
Gibson D, 1262
Gibson GJ, 238, Suppl.3.A4, Suppl.3.A76
Giembycz MA, 647
Giffin F, 815
Gill GV, 104
Gillen D, 959
Gillis CR, Suppl.3.A8, Suppl.3.A56
Gilmour PS, 1216, Suppl.3.A53
Ginanni R, 1077
Giwercman B, 733
Glynn P, Suppl.3.A3
Go LT, 977
Godden DJ, Suppl.3.A22
Godfrey S, Suppl 2.60
Goldstraw P, 114 (E)
González G, 867
González J, 378
Gonzalez J, 771 (L)
Gooch R, Suppl.3.A69
Gordon-Smith J, 325
Gorini M, 677, 1077
Gosney JR, 721
Gosselink R, 601
Gould FK, Suppl.3.A23
Goyal M, 320, Suppl.3.A32, Suppl.3.A33
GPs in Asthma Group (GPIAG), Suppl.3.A44
Granados A, 1043
Grandsaigne M, 611
Grassell J, Suppl.3.A74
Gratziou C, 575
Green M, 510, 1239, Suppl.3.A16, Suppl.3.A21, Suppl.3.A45
Green R, Suppl.3.A41, Suppl.3.A42
Green RM, Suppl.3.A41
Greene SA, Suppl.3.A14
Greene T, Suppl.3.A62
Greening AP, Suppl.3.A19, Suppl.3.A74
Greenough A, 815
Greenstone MA, Suppl.3.A20, Suppl.3.A55
Gregor A, 569
Griffiths C, 1071 (E)
Griffiths CJ, Suppl.3.A76
Griffiths TL, 1083
Groen HJM, 638
Grol MH, 317
Gross G, Suppl.3.A73
Grove A, 54, 262, 585, 689
Guhan AR, Suppl.3.A26, Suppl.3.A27
Guite HF, 924
Gumery L, 374, Suppl.3.A48
Gurevitch S, 82
Gurley AM, 197
Gursahaney A, 354
Gutteridge JMC, Suppl.3.A53

Haahtela T, 628
Habbema JDF, 298
Halfens RJG, 39
Halford S, Suppl.3.A62
Hall I, Suppl.3.A15
Hall IP, 351 (E), 1168 (L), Suppl.3.A37, Suppl.3.A38
Hallowes M, 1123
Hamad AM, Suppl.3.A38
Hamid S, Suppl.3.A47
Hammersley V, 1115
Hammond K, Suppl.3.A14, Suppl.3.A66
Hamnegard C-H, 510, 1239, Suppl.3.A21, Suppl.3.A16, Suppl.3.A45
Hamnett T, 29, 34
Hamour AA, 932
Hanaoka M, 312, 739
Hanby A, Suppl.3.A8
Hance AJ, 611
Hanley SP, Suppl.3.A28, Suppl.3.A70, Suppl.3.A75
Hansell DM, 1 (E), 1158
Hansen HS, 503
Hanson JA, 108
Hardy C, Suppl.3.A34
Hardy CC, Suppl.3.A17
Harrington D, Suppl.3.A21
Harris J, Suppl.3.A65
Harris JM, Suppl.3.A11
Harris ML, Suppl.3.A16, Suppl.3.A21, Suppl.3.A45
Harrison BDW, 238, 967 (L), Suppl.3.A1, Suppl.3.A29, Suppl.3.A70
Harrison DJ, Suppl.3.A52
Harrison L, Suppl.3.A74

Hart C, Suppl.3.A23
Hartley-Sharpe C, Suppl.3.A29
Harvey JE, 340
Hasleton PS, 1160
Haslett C, Suppl.3.A54
Hassantash SA, 193
Hatipoglu ON, 397
Hatton MQF, 323
Hauser R, 1127
Haward RA, 557 (E)
Hawkins T, Suppl.3.A23
Hayano T, 739
Hayasaka M, 312, 739
Hayden MJ, 985
Hayes JP, 619
Hayes MJ, 727
Haynes S, Suppl.3.A18
Hayton R, Suppl.3.A69
Hayward A, Suppl.3.A8, Suppl 2.55
Hayward AC, Suppl.3.A8
Heaf D, Suppl.3.A14
Heaney LG, Suppl.3.A64
Hearse DJ, Suppl.3.A69
Heath L, Suppl.3.A7
Hébert CA, Suppl.3.A54
Hedman J, 411
Heitz M, 1127
Helenius IJ, 628
Helms P, Suppl.3.A15
Hendrick DJ, 169, 947, Suppl 2.1, Suppl.3.A2, Suppl.3.A22, Suppl.3.A43
Hendrick V, Suppl.3.A22
Hendry J, Suppl.3.A49
Henry JA, 959
Herbert J, Suppl.3.A8, Suppl.3.A9
Hernández C, 37
Hernandez P, 354
Herva E, 185
Hetzel M, Suppl.3.A8
Hetzel MR, 226
Hextall A, 1162
Heyderman RS, Suppl.3.A33
Heymans HSA, 317
Hickey B, 369
Hicks M, Suppl.3.A35
Higenbottam T, 855
Higgins BG, 965
Higham MA, Suppl.3.A40
Hilderink HBM, 298
Hill A, Suppl.3.A9
Hill AT, Suppl.3.A24, Suppl.3.A69
Hill P, 596
Hill SL, Suppl.3.A81, Suppl.3.A82
Hillery E, Suppl.3.A5
Hills BA, 773 (E)
Hind CRK, 248, Suppl 2.1, Suppl.3.A27, Suppl.3.A29
Hirai Y, 155
Hirata K, 810, 1199
Hirayama Y, 199
Hirst SJ, Suppl.3.A15
Hizawa N, 777
Ho A, 1280
Ho LP, Suppl.3.A19
Hodge L, 805
Hodson ME, 119, 936, Suppl.3.A47, Suppl.3.A48, Suppl.3.A49
Hoiby N, 733
Hoitsma HFW, 449
Holden A, 104
Hole D, Suppl.3.A23
Holgate ST, 3 (E), 458 (E), 575, 630, Suppl.3.A16, Suppl.3.A22
Holland E, Suppl.3.A38
Holly JMP, Suppl.3.A12
Holmes WF, Suppl.3.A13
Holmskov U, 907
Honda T, 312, 739
Honeybourne D, Suppl.3.A14, Suppl.3.A30, Suppl.3.A67, Suppl.3.A71
Hooijer R, 496
Hooper J, Suppl.3.A48
Hooper RE, 369
Hopes E, Suppl.3.A15
Hopkin JM, Suppl.3.A1
Horiuchi T, 1036
Horovitz O, 179
Horowitz S, 179
Hosker HSR, Suppl.3.A54, Suppl.3.A55
Hoskins G, Suppl.3.A26, Suppl.3.A44
Howarth PH, 575
Howe M, Suppl.3.A28
Howes TQ, 516
Howitt D, Suppl.3.A9
Howland W, Suppl.3.A74
Hsieh M-J, 221
Hsu CP, 103
Hsu NY, 103
Huang L, Suppl.3.A5, Suppl.3.A6
Hubbard R, 711
Hubbard RB, 1243
Huchon G, 1017
Hughes DT, 137
Hughes J, Suppl.3.A72
Hughes JM, Suppl 2.9
Hughes JMB, 727, Suppl 2.16, Suppl.3.A37, Suppl.3.A38
Hughes MP, 717
Hughes PD, Suppl.3.A16, Suppl.3.A21, Suppl.3.A45, Suppl.3.A68
Hulse P, Suppl.3.A13
Humbert M, 664
Hunter LJ, Suppl.3.A25
Hurchison DCS, 1168 (L)
Hussain IR, 652
Hutton S, 1010
Huyer Abu-Saad H, 39
Hyldebrandt N, 503

Iandelli i, 677
Ichinose M, 199
Ikeda A, 48
Iles PB, Suppl.3.A69, Suppl.3.A71
Ind PW, Suppl.3.A37, Suppl.3.A38, Suppl.3.A40, Suppl.3.A80
Ingram CG, 689
Innes JA, Suppl.3.A19, Suppl.3.A46
Ioannides-Demos LL, 369
Ireland DC, 1115
ISOLDE Study Group, Suppl.3.A44
Israël-Assayag E, 1210
Israel-Biet D, 875 (E)
Ito K, 1036
Itoh A, 777
Izumi T, 48

Jack S, Suppl.3.A21
Jackson R, 1010
Jacobson J, Suppl.3.A74
Jain S, 552
Jamart J, 472
Jamieson A, Suppl.3.A74, Suppl.3.A75
Jamieson ID, Suppl.3.A33
Jamieson S, 624
Jarvis D, Suppl.3.A29, Suppl.3.A63
Jasani B, 1074
Jatakanon A, Suppl.3.A80
Jáuregui I, 867
Jeanfaivre T, 106
Jeffrey AA, Suppl.3.A62
Jeffrey M, Suppl.3.A62
Jeffrey RR, Suppl.3.A56
Jenkins RJ, 689
Jenkinson C, Suppl.3.A4
Jessup P, 1275
Johansen HK, 1023
Johnson A, 530
Johnson M, Suppl.3.A82
Johnson MM, Suppl.3.A81
Johnson PH, 107, Suppl.3.A7, Suppl.3.A46
Johnson S, Suppl.3.A28, Suppl.3.A75
Johnson SK, Suppl.3.A56
Johnson SR, Suppl.3.A40, Suppl.3.A66, Suppl.3.A67
Johnston CF, Suppl.3.A56
Johnston I, 711
Johnston IDA, 534, 1243, 1248, Suppl.3.A7
Joint Tuberculosis Committee of the British Thoracic Society, 111 (E)
Jones A, Suppl.3.A48, Suppl.3.A61
Jones AP, Suppl.3.A29
Jones COH, 1134
Jones M, Suppl.3.A69
Jones PW, 44, Suppl.3.A24
Jones RC, Suppl.3.A81
Jones RN, Suppl 2.9
Jones T, 727, Suppl.3.A38
Jordan N, 143
Joseph L, 59
Jourdan KB, Suppl.3.A36
Judd M, 575
Julià G, 1130
Jurriaans E, 914

Kageyama N, 199
Kahana LM, 873 (L)
Kakishima M, 650
Kamel D, 887
Kanazawa H, 1199
Kane J, Suppl.3.A71, Suppl.3.A72
Kaprio J, 288
Karlikaya C, 397
Kashyap AP, 223
Katz I, 272
Kauppinen MT, 185
Kawaguchi T, 1199
Kawakami Y, 777
Kay AB, 664
Keane E, Suppl.3.A33
Keaney NP, Suppl.3.A46
Keatings V, Suppl.3.A58
Keatings VM, Suppl.3.A12, Suppl.3.A18
Keavey P, Suppl.3.A23
Keilty SEJ, 516
Kelleher N, Suppl.3.A49
Keller R, 277
Kelly CA, 343
Kelly FJ, Suppl.3.A52, Suppl.3.A59, Suppl.3.A69
Kelly YJ, Suppl.3.A14, Suppl.3.A15
Kemp M, Suppl.3.A48
Kendrick A, Suppl.3.A79
Kendrick AH, Suppl.3.A4, Suppl.3.A77
Kennedy H, 256
Kennedy MM, Suppl.3.A56
Kennedy NJ, Suppl.3.A36
Kent J, 1115
Keogan MT, Suppl.3.A68
Kerkhoff AHM, 454 (L)
Kerr G, 569
Kerr KM, Suppl.3.A56
Ketel AG, 207
Ketelaars CAJ, 39
Keul R, 150
Khair OA, Suppl.3.A3, Suppl.3.A39
Kharitonov SA, 233 (E)
Khilnani GC, 132
Khilnani S, 132
Khoo SH, 932
Kieft GJ, 23
Kiely DG, Suppl.3.A36
Kiely JL, Suppl.3.A21, Suppl.3.A61, Suppl.3.A78
Kilgallen I, Suppl.3.A3
Killen JWW, 871
King G, Suppl.3.A56
Kingston HD, Suppl.3.A6
Kinnear W, Suppl.3.A43, Suppl.3.A45
Kinnear WJM, 534, 1279, Suppl.3.A7, Suppl.3.A46
Kir A, 87
Kitson C, Suppl.3.A5
Kiyosawa K, 312
Kizkin O, 87
Klein JJ, 454 (L)
Klin B, 82
Klockars M, 92
Knight A, Suppl.3.A61
Knight AC, Suppl.3.A46
Knight R, Suppl.3.A2
Knight RA, 119, Suppl.3.A12, Suppl.3.A52
Knox A, 799, Suppl.3.A50
Knox AJ, 561 (E), 1177, Suppl.3.A38, Suppl.3.A39, Suppl.3.A40, Suppl.3.A59, Suppl.3.A60, Suppl.3.A67
Kobayashi T, 739
Koch C, 1023
Kochhar P, 190
Kodama N, 777
Koerner SK, 606
Koëter GH, 433, 684
Kohler G, 253
Koide K, 155
Koizumi T, 739
Kojima J, 777
Kok-Jensen A, 973
Kolbe J, 1093, Suppl.3.A7
Kon OM, 959
Kooij L, 298
Koskenvuo M, 288
Kostianev S, 267
Koyama H, 48, Suppl.3.A6
Krausz T, 727
Kresch MJ, 1137
Kubo K, 312, 739
Kudoh S, 1199
Kuitert LM, 1073 (E), 1223
Kujala P, 185
Kujala UM, 288
Kunkel SL, Suppl.3.A52
Künzli N, 277
Kuo H-P, 221
Kuo P-H, 869, 1060
Kuo S-H, 1060
Kurbaan AS, 960
Kurihara N, 810, 1199
Kurtz CP, 765
Kuwabara M, 1036
Kyroussis D, 510, 1239, Suppl.3.A21, Suppl.3.A26, Suppl.3.A45
Labib M, Suppl.3.A70
Lahat E, 82
Lakhani N, Suppl.3.A30
Lamb NJ, Suppl.3.A53
Lambert L, 1165
Lambert PA, Suppl.3.A49
Lammers J-WJ, 977
Lamproye A, 1270
Land AF, Suppl.3.A48
Lane DJ, 415
Lanes SF, 1093
Langdon CG, Suppl.3.A28
Langford B, Suppl.3.A5, Suppl.3.A76
Langford IH, Suppl.3.A1
Lanng S, 1023
Larsson S, 825
Laszlo G, Suppl.3.A17
Laurent GJ, 217
Lawless G, Suppl.3.A61
Le Souëf PN, 75, 985
Le Souef PN, 537
Ledson MJ, Suppl.3.A29
Lee L-N, 869
Lee TH, 64
Legge JS, Suppl.3.A22, Suppl.3.A66, Suppl.3.A71
Lehto V-P, 887
Leiononen M, 179
Leitch AG, 78, 140, Suppl.3.A31
Leitch N, Suppl.3.A2
Lemarié E, 385
Lenclud C, 694
Leone A, 359
Leonidas JC, 1005
Leophonte P, 1017
Lesser M, 530
L'Estrange PR, Suppl.3.A78
Lesur O, 781, 1210
Leung R, 596
Lever N, Suppl.3.A72
Levine AJ, 338
Levy M, Suppl.3.A61
Levy ML, 1087, Suppl.3.A28
Levy RD, 354
Lewis RA, Suppl.3.A27
Lewis S, 670, Suppl.3.A13
Li SC, 369
Li XY, 465, 1216, Suppl.3.A53
Liaw Y-S, 1060
Lieberman D, 179
Lightfoot N, Suppl.3.A8, Suppl.3.A9
Lightowler JVJ, Suppl.3.A67
Ligtvoet EEJ, 449
Lin J-L, 661
Lin WH, 1137
Lin Y-C, 907
Lindahl M, 1028
Lindenthal U, 919
Linko L, 92
Linnane S, Suppl.3.A58
Linnett P, Suppl.3.A41
Lipworth BJ, 54, 110 (L), 262, 325, 585, 658 (L), 689, 941, 981, Suppl.3.A36, Suppl.3.A37, Suppl.3.A72
Lison M, 272
Little J, Suppl.3.A22
Liu Y-C, 661
Llewellyn-Jones CG, Suppl.3.A81
Lloberes P, 1043
Loblay RL, 805
Lok S, Suppl.3.A67
Lomas D, Suppl.3.A60
Lomas DA, Suppl.3.A50, Suppl.3.A51
Lourens MS, 317
Lovegrove J, Suppl.3.A60
Low JL, Suppl.3.A22
Lowry RC, Suppl.3.A64
Lozewicz S, Suppl.3.A51
Luburich P, 841
Lueck CJ, 108
Luh K-T, 869
Luijendijk SCM, 1192
Lukacs KV, Suppl.3.A6
Lushkov G, 82
Lyons D, Suppl.3.A16

McCarthy K, Suppl.3.A33
McCarthy TP, Suppl.3.A30
McCarville S, Suppl.3.A74
McCloskey C, Suppl.3.A47, Suppl.3.A48
McCowan C, Suppl.3.A14, Suppl.3.A29
McDonald AL, Suppl.3.A1
McDonald JC, 97, Suppl.3.A11
McDonnell TJ, Suppl.3.A53
McDonough BJ, Suppl.3.A27, Suppl.3.A29
McDougall C, Suppl.3.A15
McDowall P, Suppl.3.A71, Suppl.3.A72
McEwen J, Suppl.3.A8, Suppl.3.A56

Macfadyen UM, Suppl.3.A30
Macfarlane J, 539
Macfarlane JT, 107, Suppl.3.A13, Suppl 2.45
McFarlane L, Suppl.3.A72
McFarlane LC, Suppl.3.A37
Macfarlane RM, Suppl.3.A13
McGarvey LPA, Suppl.3.A64
McGavin CR, Suppl.3.A68
McGaw J, 1229
McGivern DV, Suppl.3.A55
McGrath D, Suppl.3.A33
McGrath DS, Suppl.3.A49
McGregor S, Suppl.3.A71
Machacek J, Suppl.3.A74
McIvor A, Suppl.3.A63
Mackarel AJ, Suppl.3.A53
Mackay J, 562
McKenzie DK, 490
Mackenzie W, Suppl.3.A50
McLean A, Suppl.3.A59, Suppl.3.A68, Suppl.3.A74, Suppl.3.A75
McLean AJ, 369
Maclean MR, Suppl.3.A35
McLellan D, 654
Macleod DP, Suppl.3.A46
McLeod DT, 444
MacLeod K, Suppl.3.A71
MacLeod KJ, Suppl.3.A81
McLoughlin P, Suppl.3.A18
MacMahon J, 293, Suppl.3.A64
McMahon K, Suppl.3.A51
McMahon KJ, Suppl.3.A12
MacNee W, 348 (E), 465, 1216, Suppl.3.A20, Suppl.3.A52, Suppl.3.A53
McNeil KD, 1275
McNicholas WT, Suppl.3.A21, Suppl.3.A61, Suppl.3.A78
McPhate G, 325
McRedmond J, Suppl.3.A58
McSharry C, Suppl.3.A81
McSharry CP, 654, Suppl.3.A71
Madden BP, 1158
Madgwick RG, 415
Madsen F, 973
Maestrelli P, 267
Mahadeva R, Suppl.3.A60
Maiello A, 446
Maier RV, 193
Mak V, Suppl.3.A79
Makker H, Suppl.3.A48, Suppl.3.A71, Suppl.3.A72
Makombe R, Suppl.3.A33
Male S, Suppl.3.A72
Malo J-L, 1168 (L)
Mamun M, Suppl.3.A44
Manisali M, 397
Manor E, 179
Manresa F, 1017
Manvell M, Suppl.3.A6
Marc I, 851
Markham AF, 878 (E)
Marks GB, 793
Marriott C, 119, Suppl.3.A74
Marshall B, Suppl.3.A32, Suppl.3.A33
Marshall BG, 1253, Suppl.3.A34
Martel M, 781
Martin-Escribano P, 420
Martin GP, Suppl.3.A74
Martin IR, 1010
Martinez ME, 94
Martini A, 424
Maskrey VL, 516
Maslen T, 1087
Mason NP, 175
Mason PR, Suppl.3.A33
Masterson JB, Suppl.3.A51
Mathur R, Suppl.3.A79
Mattman LH, 530
Matusiewicz SP, Suppl.3.A74
Maurer B, Suppl.3.A21
Maxwell JD, 944
Mayaud C, 1065
Maynard RL, 1174 (E)
Mazaira-Alvarez J, 420
Meadows K, Suppl.3.A62
Meadows KA, Suppl.3.A12
Meakin BJ, Suppl.3.A73
Mearns A, Suppl.3.A7
Mecozzi B, 446
Meecham Jones DJ, 137, 455 (E)
Meeker D, Suppl.3.A6
Meessen NEL, 1192
Meijer RJ, 433
Meliconi R, 315
Melloni B, 781
Mendes P, 1270
Mercer J, Suppl.3.A7
Meredith S, 435
Messori A, 1077
Metz C, Suppl.3.A54
Meurice J-C, 851
Michie J, 256
Middleton PM, Suppl.3.A60
Middleton WG, 238
Milburn HJ, Suppl.3.A47
Miles JF, 403, Suppl.3.A28, Suppl.3.A75
Millar A, 143
Millar EA, 71
Millard FJC, Suppl.3.A32
Milledge JS, 175
Miller MR, 175, 403
Miller R, Suppl.3.A3
Miller RF, Suppl.3.A3
Milleron B, 1065
Mills GH, 510, 1239, Suppl.3.A45
Milne D, Suppl.3.A7
Milroy R, Suppl.3.A8, Suppl.3.A56
Miniero R, 315
Minton EJ, Suppl 2.45
Mirali M, Suppl.3.A65
Mishima M, 48
Misuri G, 677
Mitchell CA, 451
Mitchell CG, 389
Mitchell D, Suppl.3.A3
Mitchell DM, 959, Suppl.3.A3
Mitchell DN, 238
Mitchell JA, Suppl.3.A35, Suppl.3.A36
Mitchell L, 767
Mitchell MI, 1178
Miura M, 199
Miyamura K, 907
Mochizuki H, 284
Mohsenifar Z, 606
Monaghan B, Suppl.3.A12
Monie R, Suppl.3.A57
Montazeri A, Suppl.3.A8, Suppl.3.A56
Montserrat JM, 1043
Moore A, Suppl.3.A69
Morales P, 94
Morgan MDL, Suppl.3.A25
Morgan WKC, 771 (L)
Morikawa A, 284
Morrell NW, Suppl.3.A35
Morris G, 256
Morris GP, 654
Morris MJ, 415
Morrison D, Suppl.3.A52
Morrison SC, Suppl.3.A20
Morritt GN, 223
Mortimore IL, 190, Suppl.3.A4
Moskowitz N, 306
Mostert R, 39
Mostgaard G, 503
Moudgil H, Suppl.3.A30
Mousley K, Suppl.3.A26
Mowat D, Suppl.3.A29
Moxham J, 510, 516, 1239, Suppl.3.A16, Suppl.3.A20, Suppl.3.A21, Suppl.3.A26, Suppl.3.A45
Moya C, 94
Mudway IS, Suppl.3.A52
Muers MF, 894, Suppl.3.A54, 238, 557 (E)
Múgica V, 867
Muhdi K, 374
Mukherji N, Suppl.3.A58
Mukhopadhyay S, 364, 1283 (L)
Murday A, 1158
Murray A, Suppl.3.A76
Murray KM, 549, 1283 (L)
Mushtaq M, Suppl.3.A69
Myers JD, Suppl.3.A37, Suppl.3.A40, Suppl.3.A80

Nagasaka Y, 769
Nagelkerke AF, 207
Nair G, Suppl.3.A15
Nair LG, 765
Nakajima S, 769
Nakamura K, 650
Nasser S, 64
Nauck M, 150
Navabi H, 1074
Negus T, Suppl.3.A5
Neill AM, 1010
Neri M, Suppl.3.A80
Neville R, Suppl.3.A44
Neville RG, Suppl.3.A14, Suppl.3.A26, Suppl.3.A28, Suppl.3.A29
Newman-Taylor A, Suppl.3.A41
Newman Taylor AJ, 541, 743
Newstead CG, 659 (E)
Newton DT, 484
Newton R, 1223
Ng Man Kwong G, Suppl.3.A55
Nicholson AG, Suppl.3.A11
Nicholson KG, 1115
Nicholson WJ, 389
Nicolaides KH, 815
Nimkoff L, 1005
Ninan TK, Suppl.3.A22
Ning A, Suppl.3.A74
Nir M, 1023
Nishimura K, 48
Niven RM, Suppl.3.A44
Niven RMcL, 632, 965
Nixon L, Suppl.3.A49
Nixon LS, Suppl.3.A58, Suppl.3.A59, Suppl.3.A80
Nkere U, Suppl.3.A23
Nogues A, 967 (L)
Nolan J, Suppl.3.A11, Suppl.3.A60
Nordman H, 435
Nordström M, Suppl.3.A79
Northampton Asthma Project, Suppl.3.A62
Norton P, Suppl.3.A63
Nuorva K, 887
Nutini S, 1077
Nyberg P, 92

Obeng R, Suppl.3.A9
Oborne J, 989
O'Callaghan C, 835, 1115
O'Connor BJ, 1178, 1185, Suppl.3.A6
O'Connor C, Suppl.3.A12, Suppl.3.A18
O'Connor CM, 619, Suppl.3.A51, Suppl.3.A53, Suppl.3.A58
O'Connor GT, 787
O'Donnell DM, Suppl.3.A12, Suppl.3.A18
O'Donnell M, Suppl.3.A57
O'Donohoe CM, Suppl.3.A12
O'Driscoll BR, Suppl.3.A32, Suppl.3.A71, Suppl.3.A72
O'Driscoll LR, Suppl.3.A51
O'Gara F, Suppl.3.A33
Ogston S, 364
O'Hickey S, 374
Ohnuma N, 777
Ohta K, 1036
Okubadejo AA, 44
Olinsky A, 590
Oliver HF, Suppl.3.A62
Oliver S, Suppl.3.A66
Olver RE, 364, 1283 (L)
Omran M, Suppl.3.A22
O'Neil RA, 552
O'Neill S, Suppl.3.A3
Ormerod LP, 111 (E), 873 (L), Suppl.3.A31
Ormerod P, 1169 (L)
O'Shea L, Suppl.3.A63
Osma E, 397
Osman LM, Suppl.3.A66, Suppl.3.A71
Osmond C, Suppl.3.A16
Ottaway P, Suppl.3.A66
Oxhoj H, 503
Özvaran K, 87

Pääkkö P, 887
Pacilli A, 315
Packe GE, Suppl.3.A32, Suppl.3.A34
Padley SPG, 1 (E)
Page RD, Suppl 2.23
Paifrey S, Suppl.3.A70
Palomera-Frade J, 420
Pan ST, 103
Pande JN, 132
Pandya HC, Suppl.3.A15
Pang LH, Suppl.3.A38, Suppl.3.A39
Pantin CFA, 484
Papakonstantinou E, 150
Parameswaran K, Suppl.3.A46
Pardo O, Suppl.3.A6
Parker RA, Suppl.3.A63
Parmar M, 1262
Parra O, 1043
Parry D, 1162
Pastorino U, Suppl.3.A6
Patel J, Suppl.3.A30
Patel KR, Suppl.3.A68, Suppl.3.A81
Patel N, Suppl.3.A75
Pathmakanthan S, 993
Patterson J, 993
Paul EA, Suppl.3.A9, Suppl.3.A19, Suppl.3.A24, Suppl.3.A65
Pavón JM, 1130
Pavord I, 799
Peacock AJ, 864, 1048
Peacock JL, 1109
Peake MD, Suppl.3.A54, Suppl.3.A65
Pearce L, Suppl.3.A27
Pearson M, Suppl.3.A26
Pearson MG, 967 (L), Suppl.3.A14, Suppl.3.A15, Suppl.3.A19, Suppl.3.A21, Suppl.3.A28, Suppl.3.A64, Suppl.3.A65
Pedersen OF, 973
Pedersen SS, 733
Pepper C, 1074
Pepper JR, 89
Pérez-Yarza E, Suppl 1.1
Perks WH, Suppl.3.A69
Peroni D, 575
Perronne C, 204
Perruchoud AP, 150, 277, 1127
Perry A, Suppl.3.A37
Perry D, Suppl.3.A60
Persson CGA, 441
Persson L-O, 825
Petersen S, Suppl.3.A4
Petersen TD, 733
Petitjean M, 705
Pettersson T, 92
Pfister R, 64
Philippe C, 1065
Phillips L, Suppl.3.A43, Suppl.3.A45
Piazza F, 1169 (L)
Pickering CAC, 632, 965, Suppl.3.A41, Suppl.3.A44
Pickles H, Suppl.3.A57
Pilgrim L, Suppl.3.A15
Piragino C, 1000
Pisati P, Suppl.3.A80
Pitson DJ, Suppl.3.A76, Suppl.3.A77
Pitt A, Suppl.3.A67
Pitt TL, Suppl.3.A49
Pitz CCM, 846
Plant PK, Suppl.3.A77
Pnatin CFA, 1165
Pohunek P, 615
Pokorná H, 615
Polkey MI, 510, 1239, Suppl.3.A16, Suppl.3.A20, Suppl.3.A21, Suppl.3.A26, Suppl.3.A45
Pöllänen R, 887
Pollard AJ, 175
Pollard RC, 175
Pond MN, 29, 34
Pooley FD, 327
Porath A, 179
Porter C, Suppl.3.A6
Postle AD, 880 (E)
Postma DS, 433, 684
Postmus PE, 638
Potter CS, Suppl.3.A64
Pouilly N, 389
Poulter LW, 993
Pounsford JC, Suppl.3.A17
Poustchi-Amin M, 1005
Prescott RJ, 238, Suppl.3.A44
Pressler T, 733
Price JF, Suppl 1.13
Pride NB, Suppl 2.1
Prigmore SE, Suppl.3.A63
Pringle M, Suppl.3.A26, Suppl.3.A27
Prior AJ, Suppl.3.A39
Probst R, 1127
Provencher S, 1168 (L)
Prowse K, 1165
Pugno F, 359
Puig de la Bellacasa J, 378, 771 (L)
Pulford EC, Suppl.3.A17
Purewal TS, Suppl.3.A75
Purrington A, Suppl.3.A74

Qing F, 727
Quaranta M, 359
Quinlan G, Suppl.3.A35
Quinlan GJ, Suppl.3.A53
Qureshi S, 1134

Radermecker M, 1270
Rafferty GF, Suppl.3.A21
Raffestin B, 762
Raffy O, 967 (L)
Rahman AN, 1160
Rahman I, 348 (E), 465, Suppl.3.A52, Suppl.3.A54
Rahman SU, Suppl.3.A38
Raiteri R, 446
Ramafi G, Suppl.3.A58
Ramage L, 689
Ramenghi B, 424
Ramirez J, 37
Ramsay SG, 461 (E), 853
Ranasinha C, 119
Range SP, Suppl.3.A38, Suppl.3.A59, Suppl.3.A60
Ravelli A, 424
Rawlinson J, 343
Rayner CFJ, Suppl.3.A32, Suppl.3.A63
Rea HH, 1093
Reading MS, 552

Redhead JBG, 959
Reed JW, 699
Rees J, Suppl.3.A20
Rees PJ, Suppl.3.A66
Regan M, Suppl.3.A33, Suppl.3.A34
Reger RB, 771 (L)
Reid A, Suppl.3.A57
Reid D, Suppl.3.A22
Reid DW, Suppl.3.A2
Reid KBM, 907
Reid P, 689
Reid PT, Suppl.3.A54
Rennalls CT, Suppl.3.A63
Renwick DS, 164, 520
Reshef A, 272
Rey A, 929
Reynaert MS, 224
Rezvani K, 960
Rhodes CG, 727, Suppl.3.A38
Riantawan P, 1277
Richards D, 670
Richardson MD, 256
Ricketts IW, Suppl.3.A14, Suppl.3.A29
Rider PL, Suppl.3.A56
Riordan JF, 963
Ripart J, 705
Riska H, 92
Road J, 510
Roberts AE, Suppl.3.A30
Roberts CM, 831
Roberts K, Suppl.3.A14
Roberts P, Suppl.3.A33
Roberts R, 590
Robertson AS, Suppl.3.A41
Robertson BD, Suppl.3.A32
Robertson CF, 590
Robertson R, Suppl.3.A66, Suppl.3.A71
Robinson DS, 664, 1158
Robinson GJ, Suppl.3.A36
Robinson VP, 1162
Roca J, 841
Rodenstein DO, 224
Rodríguez de Castro F, 929, 1130
Rodriguez-Roisin R, 37, 841, 1043
Rogers DF, 217, 546
Roizin H, 272, Suppl.3.A61
Rolfe LM, Suppl.3.A32
Rollason J, Suppl.3.A62
Rolleston S, Suppl.3.A60
Rom WN, 306
Roman T, 354
Rona RJ, 1134
Ronchi MC, 1000
Roomi J, Suppl.3.A16
Roorda RJ, Suppl 1.7
Rose D, 539
Rosenthal M, Suppl.3.A18, Suppl.3.A47
Rosi E, 1000
Ross S, Suppl.3.A22
Rossi A, Suppl.3.A54
Ross-Russell R, Suppl.3.A60
Roth M, 150
Rotondetto S, Suppl.3.A52
Roue C, 967 (L)
Rouetbi N, 554
Rowe G, Suppl.3.A61
Rowlands DC, 526
Roy S, 204
Rubilar M, 78
Rudd RM, 137, 210, 963
Rudkin ST, Suppl.3.A16, Suppl.3.A25, Suppl.3.A62
Rudolf M, Suppl.3.A26, Suppl.3.A29, Suppl.3.A57
Ruiz-Gonzalez A, 967 (L)
Rumbak M, 253
Rumley A, Suppl.3.A59
Rusca M, 1169 (L)
Russell G, Suppl.3.A22
Russell KJ, Suppl.3.A51, Suppl.3.A58
Rusznak C, 1105, Suppl.3.A39, Suppl.3.A40, Suppl.3.A51
Ryan PJ, 302, 444
Rydén A, 825
Ryland I, Suppl.3.A28, Suppl.3.A57

Sabroe I, Suppl.3.A54
Sagai M, Suppl.3.A54
Sagy M, 1005
Saikku P, 185
Samways JM, Suppl.3.A46
Sanderson R, Suppl.3.A74
Sandhu PS, Suppl.3.A43
Sanna A, 267
SAPALDIA team, 277
Sapsford RJ, Suppl.3.A3, Suppl.3.A39, Suppl.3.A40, Suppl.3.A51, Suppl.3.A54
Sarna S, 288
Sato T, 650
Saunders KB, 1083
Saunders MI, 1262
Saunders MJ, 126
Saunders N, Suppl.3.A33
Scadding JG, 448
Scallan M, Suppl.3.A6
Scano G, 677, 1000
Scarlett JF, 1109
Schaberg T, 1017
Schäfer D, 919
Schepers-Bok R, 23
Schey SA, Suppl.3.A47
Schindler Ch, 277
Schlaeffer F, 179
Schlösser MAG, 39
Schmekel B, 993
Schmitz-Schumann M, 64
Schofield L, Suppl.3.A34
Scholey S, Suppl.3.A65
Schols AMWJ, 819
Schousboe M, 1010
Schwartzman K, 354
Sciandra M, 446
Scott DM, 793
Scott J, Suppl.3.A37
Scott PH, 864
Scott SF, 119
Seaton A, 389, Suppl.3.A1
Seemungal T, Suppl.3.A19, Suppl.3.A65
Seemungal TR, Suppl.3.A10
Seidman CE, Suppl.3.A37
Seidman JG, Suppl.3.A37
Selroos O, 229 (E)
Sepsas E, 1266
Sériès F, 851
Sethi SK, Suppl.3.A2
Severo LC, 1168 (L)
Shadick NA, 787
Shah PL, 119
Shakur BH, Suppl.3.A37, Suppl.3.A40
Shale DJ, 126, Suppl.3.A58, Suppl.3.A59, Suppl.3.A80
Sharara AM, Suppl.3.A80
Shattock MJ, Suppl.3.A69
Shaw RJ, 320, 1253, Suppl.3.A11, Suppl.3.A32, Suppl.3.A33, Suppl.3.A34
Sheard JDH, 721
Shee CD, 1158
Sheehan S, Suppl.3.A33
Shepherd DRT, Suppl.3.A64
Sherwood RA, Suppl.3.A26
Shevlin P, 894
Shevlin PM, Suppl.3.A54
Shieh W-B, 221
Shiels P, 619, Suppl.3.A21
Shiga J, 1036
Shikowitz M, 1005
Shimazu S, Suppl.3.A1
Shimizu T, 284
Shindo K, 155
Shiner RJ, 272, Suppl.3.A61, Suppl.3.A65
Shirakawa T, Suppl.3.A1
Shirato K, 199
Shneerson JM, 756, 914, Suppl.3.A10, Suppl.3.A11, Suppl.3.A79
Shoji S, 1199
Shortt C, Suppl.3.A49
Shovlin CL, Suppl.3.A37
Shulimzon T, Suppl.3.A61
Shurvinton J, Suppl.3.A69
Sibille Y, 452
Siebers R, Suppl.3.A42, Suppl.3.A72
Siersted HC, 503
Silkstone V, 658 (L)
Silver P, 1005
Simmons J, Suppl.3.A73
Simmul R, 159
Simonds AK, 1069 (E)
Simpson AJ, Suppl.3.A31
Simpson JCG, Suppl.3.A13
Sing TMYS, 341
Singh M, 364
Singh SJ, Suppl.3.A25
Singh SPN, 132
Sinicco A, 446
Sinnamon DG, 293
Siriruttanapruk S, Suppl.3.A40, Suppl.3.A41
Sist M, 793
Sivasothy P, Suppl.3.A10
Skinner C, 111 (E), Suppl.3.A9
Skwarska E, Suppl.3.A20
Skwarski K, Suppl.3.A20
Slade M, 556
Sleiman C, 967 (L)
Slight J, 389
Smit EF, 638
Smith A, Suppl.3.A41, Suppl.3.A42
Smith B, Suppl.3.A26, Suppl.3.A44
Smith CAD, Suppl.3.A52
Smith DL, 374
Smith DM, Suppl.3.A5, Suppl.3.A76
Smith EC, Suppl.3.A17
Smith EG, 374
Smith IE, 914, Suppl.3.A10, Suppl.3.A11, Suppl.3.A79
Smith JA, Suppl.3.A13
Smith RP, 689, Suppl.3.A16, Suppl.3.A25
Smith SF, 1057
Smith SJ, 23
Smith SN, Suppl.3.A6, Suppl.3.A60
Smyth ET, 293
Snooks H, Suppl.3.A29
Snow RE, 458 (E)
Söderblom T, 92
Sodeyama T, 312
Sohi DK, Suppl.3.A3
Soini Y, 887
Solé A, 94
Solé-Violán J, 929
Soler P, 611
Solforosi L, 315
Solli P, 1169 (L)
Sont JK, 496
Sörensen J, 1028
Sorgi F, Suppl.3.A5, Suppl.3.A6
Soria I, Suppl.3.A74
Souhami RL, 231 (E)
Soumah S, 385
Souquet PJ, Suppl.3.A55
Sousa AR, 64
Soutar A, Suppl.3.A1
Sow O, 385
Spaethe SM, 1178
Spaggiari L, 1169 (L)
Spagnolatti L, 424
Spanevello A, Suppl.3.A80
Sparrow D, 787
Spencer DA, Suppl.3.A49
Spicer WJ, 369
Spina D, 335
Spiteri MA, Suppl.3.A2, Suppl.3.A12, Suppl.3.A52
Splinter TAW, 638
Sprikkelman AB, 317
Spurzem JR, 956
Sreenan S, 993
Srichana T, Suppl.3.A74
Sriram S, Suppl.3.A71
Staal-van den Brekel AJ, 819
Stableforth D, Suppl.3.A47, Suppl.3.A48, Suppl.3.A50
Stableforth DE, 302, 374, 652, Suppl.3.A24, Suppl.3.A36
Stableforth P, 444
Stack BHR, Suppl.3.A59
Stack M, Suppl.3.A49
Stampone P, Suppl.3.A73
Stanbridge RDeL, 963
Stanescu D, 267, 1283 (L)
Stanford JL, 932
Stead ML, Suppl.3.A54
Steele A, 624
Steele E, Suppl.3.A7
Stell I, Suppl.3.A21
Stell IM, Suppl.3.A20
Stenius-Aarniala BSM, 411
Stenmark KR, Suppl.3.A35
Stenton SC, 169, Suppl.3.A2, Suppl.3.A43
Sterk PJ, 496
Stern M, Suppl.3.A6
Stevens J, Suppl.3.A41
Stevens S, Suppl.3.A7
Stevenson C, 1087
Stevenson FK, 458 (E)
Stewart JP, 1160
Stobart M, Suppl.3.A5
Stockley RA, Suppl.3.A69, Suppl.3.A81, Suppl.3.A82
Stocks J, Suppl.3.A15
Stout R, 345 (E), Suppl.3.A55
Strachan A, Suppl.3.A48
Strachan D, 670
Strachan DP, 944, 1109
Stradling JR, Suppl 2.65, Suppl.3.A4, Suppl.3.A5, Suppl.3.A76, Suppl.3.A77, Suppl.3.A79
Strauss S, 82
Strieter RM, Suppl.3.A52
Striz I, 615
Struthers AD, Suppl.3.A36
Struthers JK, Suppl.3.A13
Subhannachart P, 1277
Suga M, 650
Sullivan M, 825
Sumitomo M, 155
Summers QA, 985
Sunyer J, 743
Suzuki N, 1036
Swann L, Suppl.3.A9
Swift GL, 871
Swindells JP, Suppl.3.A45
Swystun VA, 1051
Syed Q, 624, Suppl.3.A9, Suppl.3.A33, Suppl.3.A34
Sykes KM, Suppl.3.A64
Sykes L, Suppl.3.A49
Symon FA, 1155
Syrjälä H, 185

Tagesson C, 1028
Taggart SCO, Suppl.3.A42
Tahaoglu K, 87
Takahashi M, 769
Takeda T, 810
Takizawa H, 1036
Tam CM, Suppl.3.A9
Tan KS, Suppl.3.A37
Tanaka S, 810
Tandon RK, 132
Tansupasawasdikul S, 1277
Tattersfield A, 799
Tattersfield AE, 13, 989, Suppl.3.A26, Suppl.3.A27, Suppl.3.A40, Suppl.3.A66, Suppl.3.A67
Taylor CJ, 1229
Taylor GW, Suppl.3.A58
Taylor IK, Suppl.3.A46
Taylor PM, Suppl.3.A13, Suppl.3.A17
Tazi A, 611
Tchou-Wong K-M, 306
Tee RD, Suppl.3.A1
Tee SK, Suppl.3.A74
ten Kate LP, 298
Teramo KA, 411
Tetley TD, 1273
Theron AJ, Suppl.3.A58
Thio BJ, 207
Thomas A, Suppl.3.A47, Suppl.3.A48
Thomas DJ, 108
Thomas GE, Suppl.3.A14
Thomas SR, Suppl.3.A49
Thompson CS, Suppl.3.A5
Thomson L, Suppl.3.A81
Thomson LJ, 853
Thomson NC, 71, 461 (E), 853, Suppl.3.A81
Thoracic Group of the Yorkshire Cancer Organisation, 894
Thornell S, Suppl.3.A46
Thrall RS, 1137
Tijmstra T, 298
Tikkanen HO, 628
Tocque K, 624, Suppl.3.A9, Suppl.3.A33, Suppl.3.A34
Tohda Y, 769
Tokuyama K, 284
Tolstuchow N, 106
Tomaki M, 199
Tor M, 87
Torres A, 378, 771 (L)
Torres-Melero J, 339
Touw DJ, 1283 (L)
Town GI, 1010
Townsend ER, 1266
Tozzi D, 1077
Trask C, 564
Treurniet FEE, 23
Tsai Y-H, 221
Tse KS, 1280
Tsukino M, 48
Tuchais E, 106
Tunnicliffe W, 403, Suppl.3.A14, Suppl.3.A61
Tunnicliffe WS, Suppl.3.A2, Suppl.3.A17, Suppl.3.A18, Suppl.3.A66
Türker H, 87
Turner A, Suppl.3.A23
Turton P, Suppl.3.A62
Twort CHC, Suppl.3.A15

Uçan ES, 397
Ueda T, 1036
Ueshima H, 769
Ulrik CS, 110 (L)
Upton M, Suppl.3.A23
Urrutia I, 867
Usehwokunze S, Suppl.3.A33

Vähäkangas K, 887
van Aalderen WMC, 317
van Alstyne EL, 1178
Van Bever HP, Suppl.3.A73
Van de Weyer R, 472
van den Bos J-W, 582
van den Bosch JMM, 846
van der Grinten CPM, 1192

van der Heyden AHM, 449
van der Mark ThW, 433
van der Mark TW, 684
Van der Palen J, 454 (L)
Van Embden JDA, Suppl.3.A33
van Essel T, 582
Van Gansbeke D, 694
Van Herwaarden CLA, 454 (L)
van Keeken BL, 207
van Krieken JHJM, 496
Van Muylem A, 694
van Rossum AB, 23
van Velzen E, 582
Vandenburgt J, Suppl.3.A73
Vandenplas O, 452, 472
Vassallo G, 359
Vathenen SV, 323
Veale D, 767
Vedel AM, 973
Venables K, Suppl.3.A41
Venables KM, Suppl.3.A1
Venning MC, Suppl.3.A68
Vera F, 94
Verheij JBGM, 298
Veriter C, 267
Veriter CL, 1283 (L)
Vermeire PA, Suppl.3.A73
Vernon DRH, 654
Verrier ED, 193
Vickery PJM, Suppl.3.A62
Vilaseca I, 1043
Villa I, 424
Villar T, Suppl.3.A16
Visconti A, 694
von Mutius E, Suppl 1.3

Wagenaar JPM, 449
Wagenaar RC, 601
Wagner M, 919
Wainwright B, Suppl.3.A60
Waldron J, Suppl.3.A62
Waldron M, Suppl.3.A62
Wales D, Suppl.3.A71, Suppl.3.A72
Wales J, 111 (E)
Walker QJ, 1275
Wallace W, Suppl.3.A54
Waller H, Suppl.3.A61
Waller RE, 1174 (E)
Wallis D, Suppl.3.A1
Walls A, 64, 575
Walmsley JM, Suppl.3.A55
Walsh LJ, Suppl.3.A26, Suppl.3.A27
Walshaw MJ, 248, Suppl.3.A29
Walters EH, 1100
Walters J, 1100
Wang H-C, 1060
Wang J-Y, 907
Wang JH, Suppl.3.A40
Wang M, 799
Wangoo A, 1253, Suppl.3.A11, Suppl.3.A34
Warburton CJ, 965, Suppl.3.A21, Suppl.3.A44, Suppl.3.A57
Ward EM, Suppl.3.A10
Ward JPT, Suppl.3.A15
Ward R, 169
Ward S, 202
Wardlaw AJ, 1155
Wareham N, Suppl.3.A29
Warley ARH, Suppl.3.A5
Warner F, Suppl.3.A44
Warner FC, Suppl.3.A14, Suppl.3.A29
Warner JO, 880 (E)
Warren DA, Suppl.3.A75
Warwick M, Suppl.3.A79
Watson A, 29, 34
Watson JM, Suppl.3.A8, Suppl.3.A9
Watson JP, Suppl.3.A11, Suppl.3.A27
Watson L, 534, Suppl.3.A43, Suppl.3.A45
Watt B, 78, Suppl.3.A8, Suppl.3.A9, Suppl.3.A31
Watt G, Suppl.3.A23
Watts T, Suppl.3.A69
Webb AK, 1233, Suppl.3.A49
Webb JK, 534
Webb K, 873 (L), Suppl.3.A50, Suppl.3.A60
Weber T, 1270
Wedzicha JA, 44, 137, 455 (E), 831, 1068 (L), Suppl 2.35, Suppl.3.A10, Suppl.3.A19, Suppl.3.A24, Suppl.3.A65
Wei M-C, 661
Weill H, 97, Suppl 2.9
Weir DC, Suppl.3.A28, Suppl.3.A70, Suppl.3.A75
Weir R, 1010
Weiss P, Suppl.3.A61
Weiss ST, 787, 1168 (L)
Welch J, Suppl.3.A1
Weller PH, Suppl.3.A49
Wells A, Suppl.3.A7
Wells FC, 903
Wells T, Suppl.3.A74
Wendon J, 1168 (L)
West JV, 590
Westerbeek R, Suppl.3.A60
Westermann CJJ, 846
Wheatley A, Suppl.3.A15
White AJ, Suppl.3.A68
White E, Suppl.3.A14
White JES, 767
White M, Suppl.3.A62
White RJ, 871, Suppl.3.A16, Suppl.3.A25
Whitehead F, 1100
Whitehouse D, Suppl.3.A60
Whittle AT, Suppl.3.A4, Suppl.3.A78
Whyte M, Suppl.3.A9
Wickremasinghe M, 962
Wijkstra PJ, 117 (E)
Wildhaber JH, 985
Wildhagen MF, 298
Wilding PJ, 989
Wiles CM, Suppl 2.40
Wilkins EGL, 932
Wilkinson IB, 1279
Wilkinson J, 3 (E)
Willems LNA, 496
Williams AA, 630
Williams AJ, Suppl.3.A20
Williams CSD, 624
Williams EA, 114 (E)
Williams ED, Suppl.3.A46
Williams J, Suppl.3.A25
Williams JG, Suppl.3.A43
Williams R, 1168 (L), Suppl.3.A8, Suppl.3.A9
Williams TJ, 369, Suppl.3.A54
Williamson JD, Suppl.3.A3
Wilsher M, Suppl.3.A7
Wilsher ML, 197, 1123
Wilson AM, Suppl.3.A72
Wilson GE, 248, 550
Wilson R, Suppl.3.A58
Wilson RSE, 652
Wilson SJ, Suppl.3.A17
Wiltshire N, Suppl.3.A4, Suppl.3.A77, Suppl.3.A79
Winer-Muram H, 253
Winter JH, 689
Wise R, Suppl.3.A14, Suppl.3.A67
Wisniewski A, 799
Withers NJ, Suppl.3.A22
Wong CA, 534, Suppl.3.A26, Suppl.3.A27
Wong KP, 341
Wood AJ, Suppl.3.A51
Wood CN, Suppl.3.A26, Suppl.3.A45
Wood PJ, 369
Woodcock A, Suppl.3.A41, Suppl.3.A42
Woodcock AA, 873 (L), 1160, Suppl.3.A23
Woodhead M, 970 (E), 1017, Suppl.3.A13, Suppl.3.A17, Suppl.3.A34
Woodhead MA, Suppl.3.A13
Wouters EFM, 39, 819
Wragg S, 510
Wragg SD, 1239
Wright CL, 451
Wright SC, 293
Wrightson N, 1068 (L), Suppl.3.A23
Wynford-Thomas D, 1074
Wysocki A, 306

Xaubet A, 841

Yacoub M, Suppl.3.A36
Yacoub MH, 1162
Yamaguchi E, 777
Yamaguchi S, 312, 739
Yamasaki H, 650
Yamauchi H, 199
Yan KY, 805
Yang P-C, 869
Yap PL, Suppl.3.A78
Yates DH, 793
Yates VM, Suppl.3.A31
Yeh T-F, 907
Yernault J-C, 694
Yohannes A, Suppl.3.A16
Yonan N, 1160, Suppl.3.A23
Yorkshire Thoracic Group, Suppl.3.A54
Yoshida K, 650
Yoshikawa J, 810, 1199
Young DB, 320, Suppl.3.A32, Suppl.3.A33, Suppl.3.A34
Young N, 341
Yu T-J, 221
Yuksel B, 815
Yüksel C, 397
Yung B, Suppl.3.A47, Suppl.3.A48, Suppl.3.A58, Suppl.3.A59, Suppl.3.A80

Zach MS, 750
Zalavra K, Suppl.3.A1
Zaman F, Suppl.3.A60
Zamprogna C, 446
Zanen P, 977
Zaretzky U, Suppl.3.A65
Zeebregts CJAM, 449
Zeng XM, Suppl.3.A74
Zhang Y, 306
Zimmerman PV, 1275
Zizhou S, Suppl.3.A33
Zoia MC, 424

VOLUME 51 • SUBJECT INDEX

Abdominal muscle strength, Abdominal muscle strength measured by gastric pressure during maximal cough, **Suppl.3.A45**
Abdominal muscles, Effect of maximum ventilation on abdominal muscle relaxation rate, **510**
Accident and emergency department, Characteristics of those asthmatics who repeatedly self-refer to the accident and emergency department, **Suppl.3.A29**
Accuhaler, Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**
Accuracy of certification, Accuracy of recording of deaths from asthma in the UK: the false negative rate, **924**
ACE gene polymorphism, Deletion polymorphism in the angiotensin I converting enzyme gene as a genetic risk factor for sarcoidosis, **777**
Acetylcysteine, Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy, **429**
Acoustic myography, Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**
Acramin, Epidemic outbreak of interstitial lung disease in aerographics textile workers - the "Ardystil syndrome": a first year follow up, **94**
Actinomycosis
Commentary: yet more to see down the bronchial tree?, **226**
Pulmonary actinomycosis appearing as a "ball-in-hole" on chest radiography and bronchoscopy, **221**: *commentary*, **226**: *letter*, **1168**
Transphrenic dissemination of actinomycosis, **449**
Activity monitors, Are activity monitors sensitive enough to detect speeds prescribed to patients with COPD? **Suppl.3.A25**
Acute respiratory distress syndrome, Epithelial cells are a source for macrophage migration inhibitory factor – potential role in acute respiratory distress syndrome, **Suppl.3.A54**
Adenoid cystic carcinoma, Adenoid cystic carcinoma of the left main bronchus mimicking MacLeod's syndrome, **451**
Adenosine, Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease, **1083**
Adenosine monophosphate, Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate, **793**
Adenosine 5′-monophosphate, Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma, **799**
Adherence, Health perceptions and treatment adherence in adults with cystic fibrosis, **1233**
Adolescence
Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study, **503**
Issues in adolescent asthma: what are the needs? **Suppl.1.13**
Issues in adolescent asthma, Symposium of the European Congress of Allergy and Clinical Immunology, Madrid, June 1995, **Suppl.1.1–17**; introduction, **Suppl.1.1**
Prognostic factors for the outcome of childhood asthma in adolescence, **Suppl.1.7**
Progression of allergy and asthma through childhood to adolescence, **Suppl.1.3**
Study of the aetiology of wheezing illness at age 16 in two national British birth cohorts, **670**
Adrenal suppression
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients, **262**
Adrenomedullin, Potentiation of the bronchoprotective effects of vasoactive intestinal peptide, isoprenaline, and theophylline against histamine challenge in anaesthetised guinea pigs by adrenomedullin, **1199**
Adult respiratory distress syndrome, Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride, **82**
Aerolizer, Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**
Aerosol therapy, Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Aerosols
In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system, **75**
Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**
Africa, Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France), **385**
Afro-Caribbean origin patients, *Chlamydia pneumoniae* antibody titres are significantly associated with Afro-Caribbean and Asian origin, **Suppl.3.A67**
Age
Age and the treatment of lung cancer, **564**
Impact of obstructive airways disease on quality of life in older adults, **520**
Management of lung cancer: *editorial*, **557**
Tuberculin testing in two Liverpool social clubs: the effects of a tuberculosis outbreak on background positivity, **624**
AIDS
Alveolar lymphocytes and macrophages are an important source of HIV-1 in patients with AIDS, **Suppl.3.A3**
Genotypic variants of HIV-1 from peripheral blood and lung of AIDS patients, **Suppl.3.A3**
Interactions between opportunistic micro-organisms and HIV in the lung: *editorial*, **875**
Pulmonary diseases and HIV infection: *letter*, **228**
Air pollutants, Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants, **1105**
Air pollution
Acute effects of summer air pollution on respiratory function in primary school children in southern England, **1109**
Air pollution: brown skies research: Altounyan address, **13**
Asthma, airways responsiveness and air pollution in two contrasting districts of northern England, **169**
Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**
Particulate air pollution, **Suppl.2.3**
Pro-inflammatory effect of particulate air pollution (PM_{10}) in vivo and in vitro, **Suppl.3.A53**
Suspended particulate matter and health: new light on an old problem: *editorial*, **1174**
Air quality, Suspended particulate matter and health: new light on an old problem: *editorial*, **1174**
Air travel, Assessment of oxygen supplementation during air travel, **202**
Airflow obstruction, Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**
Airspace permeability, Mechanisms of cigarette smoke induced increased airspace permeability, **465**
Airway inflammation
Airways inflammation in chronic non-productive cough, **Suppl.3.A64**
Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD, **1000**
Airway inflammatory cells, Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms, **575**
Airway obstruction
Compliance with oral corticosteroids during steroid trials in chronic airways obstruction, **323**
Functional upper airways obstruction: two patients with persistent symptoms, **965**
Prevalence and treatment of chronic airways obstruction in adults over the age of 45, **164**
Spiral computed tomographic scanning of the chest with three dimensional imaging in the diagnosis and management of paediatric intrathoracic airway obstruction, **1005**
Airway reactivity, Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants, **1105**

Airway receptor barrier, Asthma: is there an airway receptor barrier? *editorial*, 773
Airway resistance, Evaluation of nocturnal bronchoconstriction by all night tracheal sound monitoring, 694
Airway responsiveness
Asthma, airways responsiveness and air pollution in two contrasting districts of northern England, 169
Atopy, airway responsiveness, and genes, **Suppl.2.55**
Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma, 1185
Effect of influenza vaccination on airway responsiveness in patients with stable asthma, **Suppl.3.A2**
Airway sensory nerves, Airway sensory nerves: a burning issue in asthma? 335
Airway smooth muscle, Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? 647
Airway tone, Humoral control of airway tone: *editorial*, 461
Allergen avoidance, Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma, 582
Allergen challenge
Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma, 1185
Regional ventilation and perfusion lung scan abnormalities in atopic asthmatics following allergen challenge: comparison with airway function and gas exchange, **Suppl.3.A46**
Allergen exposure, Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms, 575
Allergens, Occupational asthma in a coal miner, 867
Allergic inflammation, Candidate gene loci in asthmatic and allergic inflammation: *editorial*, 3
Allergy, Progression of allergy and asthma through childhood to adolescence, **Suppl.1.3**
α_1-antichymotrypsin, Identification of a novel conformation of α_1-antichymotrypsin: an explanation for the inactive species found in lung lavage from patients with chronic bronchitis and emphysema, **Suppl.3.A51**
α_1-antitrypsin,
α_1-antitrypsin mutations and the severity of cystic fibrosis lung disease, **Suppl.3.A60**
Human α_1-antitrypsin gene transfer with cationic liposomes *in vitro* and *in vivo*, **Suppl.3.A6**
Inhibitory conformation of the reactive loop of α_1-antitrypsin, **Suppl.3.A50**
α_1-antitrypsin deficiency
Bronchiectasis and homozygous (PiZZ) α_1-antitrypsin deficiency: *letter*, 228
Out-patient management of α_1 antitrypsin deficiency: current practice in the West Midlands 1996, **Suppl.3.A69**
Altitude, Effect of altitude on spirometric parameters and the performance of peak flow meters, 175
Alveolar epithelial cells, Transcriptional induction of gamma-glutamylcysteine synthetase by oxidants is associated with AP-1 in human alveolar epithelial cells, **Suppl.3.A52**
Alveolar haemorrhage syndrome, Acute severe alveolar haemorrhage syndrome: a single centre experience, **Suppl.3.A68**
Alveolar lymphocytes and macrophages, Alveolar lymphocytes and macrophages are an important source of HIV-1 in patients with AIDS, **Suppl.3.A3**
Alveolar macrophages
Effect of exposure to silica on human alveolar macrophages in supporting growth activity in type II epithelial cells, 781
Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-α) from human alveolar macrophages and peripheral blood monocytes, 143
Manganese superoxide dismutase mRNA expression is decreased in LPS-stimulated alveolar macrophages from cigarette smokers, **Suppl.3.A52**
Matrixmetalloproteinases expression by alveolar macrophages in emphysema, **Suppl.3.A51**
Alveolitis
Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection, 312
Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis, 841
Ambulatory oxygen, Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking, 831
Amiloride, Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis mouse, 1229
Aminoglycosides, Minimisation of aminoglycoside toxicity in patients with cystic fibrosis, 369
Amplicor, Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis, 320
Angiography, Bronchoscopic and angiographic findings in tracheobronchial endometriosis, 1060: *commentary*, 1064
Angiotensin converting enzyme inhibitor, Angiotensin converting enzyme inhibitor-induced cough and substance P, 199
Angiotensin I converting enzyme, Deletion polymorphism in the angiotensin I converting enzyme gene as a genetic risk factor for sarcoidosis, 777
Angiotensin II, Angiotensin II causes proliferation of rat pulmonary microvascular smooth muscle cells, **Suppl.3.A35**
Annual Report, October 1995 to September 1996, 1177
Anterior spinal surgery, Pulmonary function before and after anterior spinal surgery in adult idiopathic scoliosis, 534
Anti-asialo GM1 antibody, *Pseudomonas aeruginosa* adherence to cystic fibrosis respiratory epithelium is reduced by anti-asialo GM1 antibody and neuraminidase inhibition, **Suppl.3.A57**
Anti-CEA immunoscintigraphy, Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer, 359
Antibiotic resistance
Antibiotic resistance in *Streptococcus pneumoniae:* one hospital's experience, **Suppl.3.A13**
Antibiotic resistant *Streptococcus pneumoniae*, **Suppl.2.45**
Antibiotics
Acute lower respiratory tract illness in general practice: a study of the views of 787 patients and their influence on antibiotic prescribing, **Suppl.3.A13**
Effect of intravenous antibiotic therapy on markers of oxidative stress in cystic fibrosis, **Suppl.3.A59**
Inflammatory markers and clinical response to intravenous antibiotics in adults with cystic fibrosis colonised with *Burkholderia cepacia* and *Pseudomonas aeruginosa*, **Suppl.3.A49**
Influence of antibiotics and other factors on reconsultation for acute lower respiratory tract illness in primary care, **Suppl.3.A13**
Anticholinergic aerosol, Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, 977
Anticholinergic agents, The effect of inhaled beta agonists and anticholinergic agents upon heart rate variability, **Suppl.3.A60**
Antioxidant responsive element, Transcriptional induction of gamma-glutamylcysteine synthetase by oxidants is associated with AP-1 in human alveolar epithelial cells, **Suppl.3.A52**
Antioxidant status, Antioxidant status in children with different respiratory symptoms, **Suppl.3.A15**
Antioxidants, Antioxidants and bronchial reactivity, **Suppl.3.A1**
Antistatic treatment, Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, 981
Antituberculosis drugs
Hepatotoxicity of antituberculosis drugs: *editorial*, 111: *letters*, 873, 1168
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study, 132
Antituberculous resistance, Understanding the different inflammatory responses to live and dead BCG: a prerequisite for improved vaccine design, **Suppl.3.A34**
Arachidonic acid, Cultured human airway smooth muscle cells release PGE_2 in response to bradykinin, growth factors and arachidonic acid, **Suppl.3.A38**
Ardystil syndrome, Epidemic outbreak of interstitial lung disease in aerographics textile workers – the "Ardystil syndrome": a first year follow up, 94
Arginine, Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease, 516
Arterial puncture, Local anaesthetic infiltration prior to arterial puncture: survey of current practice and a randomised double blind placebo controlled trial, **Suppl.3.A67**
Arterial saturation, Dips in overnight arterial saturation during NIPPV: relationships with sleep stages and ventilators, **Suppl.3.A11**

Asbestos
Asbestos exposure, asbestosis, and asbestos-attributable lung cancer, **Suppl.1.9**
New developments in asbestos-related pleural disease, **210**
Two dimensional protein patterns of bronchoalveolar lavage fluid from non-smokers, smokers, and subjects exposed to asbestos, **1028**
Ascites, Pleural fluid accumulation due to intra-abdominal endometriosis: a case report and review of the literature, **1062**: *commentary*, **1064**
Asian origin patients, *Chlamydia pneumoniae* antibody titres are significantly associated with Afro-Caribbean and Asian origin, **Suppl.3.A67**
Asian patients
Differences in asthma management between white European and Indian subcontinent groups, **Suppl.3.A30**
Do white European and Indian-subcontinent asthmatics differ in their quality of life? **Suppl.3.A30**
Predicted lung function for Asians, **Suppl.3.A44**
Study of cultural issues relating to asthma and its management among Asian patients, **Suppl.3.A30**
Aspergillomas, Topical treatment of life threatening haemoptysis from aspergillomas, **253**
Aspergillosis
Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air, **256**
Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma, **869**
Aspergillus fumigatus
Binding of *Aspergillus fumigatus* spores to lung epithelial cells and basement membrane proteins: relevance to the asthmatic lung, **1203**
Inhibition of the alveolar macrophage oxidative burst by a diffusible component from the surface of the spores of the fungus *Aspergillus fumigatus*, **389**
Aspirin-sensitive asthma, Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects, **64**
Asthma
Accessibility and health service utilisation for asthma in Norfolk, England, **Suppl.3.A29**
Accuracy of recording of deaths from asthma in the UK: the false negative rate, **924**
Actual/best function as a predictor in the long term outcome of asthma, **Suppl.3.A44**
Acute asthma during pregnancy, **411**
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**
Airway response of asthmatic subjects to inhaled allergen after exposure to pollutants, **1105**
Airway sensory nerves: a burning issue in asthma? **335**
Analysis of attitudes of adult patients towards asthma management, **Suppl.3.A28**
Analysis of the data produced by the Asthma Chronic Disease Management Programme and the Prescribing Analysis and Cost data in Suffolk, **Suppl.3.A27**
Assessing the quality of life of asthma in family practice, **Suppl.3.A63**
Assessment of food chemical intolerance in adult asthmatic subjects, **805**
Asthma: is there an airway receptor barrier? *editorial*, **773**
Asthma, airways responsiveness and air pollution in two contrasting districts of northern England, **169**
Asthma, its treatment and social deprivation – the effect on growth in children, **Suppl.3.A14**
Asthma and other pulmonary diseases in former elite athletes, **288**
Beta$_2$-adrenoceptor polymorphism determines susceptibility to bronchodilator desensitisation in asthmatics, **Suppl.3.A37**
Beta$_2$-adrenoceptor regulation and function in female asthmatics receiving the oral combined contraceptive pill, **Suppl.3.A37**
Binding of *Aspergillus fumigatus* spores to lung epithelial cells and basement membrane proteins: relevance to the asthmatic lung, **1203**
Bronchiolitis and asthma in infancy and early childhood, **Suppl.2.60**
Candidate gene loci in asthmatic and allergic inflammation: *editorial*, **3**
Causes of thunderstorm-related asthma, **Suppl.3.A1**
Cell counts in spontaneous sputum during exacerbations of asthma and COPD, **Suppl.3.A80**
Characteristics of those asthmatics who repeatedly self-refer to the accident and emergency department, **Suppl.3.A29**
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients, **262**
Comparison of the effect of non-chlorofluorocarbon-containing salbutamol and conventional chlorofluorocarbon salbutamol in asthmatic children, **Suppl.3.A73**
Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care, **1087**
Comparison of soybean epidemic asthma and occupational asthma, **743**
Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma, **799**
Current management of asthma in primary and secondary schools in Wolverhampton, **Suppl.3.A30**
Death from airways obstruction: accuracy of certification in Northern Ireland, **293**
Descriptive study of cough, wheeze and school absence in childhood, **630**
Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma, **484**
Diagnosis of occupational asthma from serial measurements of lung function at and away from work, **857**
Differences in asthma management between white European and Indian subcontinent groups, **Suppl.3.A30**
Do home nebulisers prevent readmission for asthma, **Suppl.3.A28**
Do white European and Indian-subcontinent asthmatics differ in their quality of life? **Suppl.3.A30**
Double blind placebo controlled food challenge in type 1 and type 2 brittle asthma, **Suppl.3.A2**
Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients, **853**
Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma, **582**
Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma, **1185**
Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects, **64**
Effect of influenza vaccination on airway responsiveness in patients with stable asthma, **Suppl.3.A2**
Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide, **71**
Effect of a leukotriene B_4 receptor antagonist, LY293111, on allergen induced responses in asthma, **1178**
Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms, **575**
Effect of ozone thunderstorms and other weather conditions on the respiratory function of asthmatics, **Suppl.3.A1**
Effect of salmeterol on sleep architecture of asthmatic patients of different ages, **Suppl.3.A17**
Effects of prior treatment with salmeterol and formoterol on airway and systemic β_2 responses to fenoterol, **585**
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis, **1223**
Endothelin-1 levels in induced sputum from asthmatics, normal subjects and smokers – comparison with plasma and saliva levels, **Suppl.3.A81**
Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys, **590**
Evaluation of nocturnal bronchoconstriction by all night tracheal sound monitoring, **694**
Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide-induced bronchoconstriction, **159**
Exercise-induced asthma and cardiovascular fitness in asthmatic children, **207**
Exercise-induced bronchoconstriction by ethnicity and presence of asthma in British nine year olds, **1134**
Experience with long-term methotrexate in steroid-dependent asthma over six years, **Suppl.3.A61**

Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**
General practitioner prescribing habits in asthma/COPD, **Suppl.3.A26**
Glu27 β_2-adrenoceptor polymorphism is associated with childhood asthma, **Suppl.3.A15**
Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients, **433**: *correction*, **1068**
Impact of an asthma nurse specialist on patients admitted to hospital with acute severe asthma, **Suppl.3.A27**
Impact of severe asthma on the lives of women, **Suppl.3.A64**
Impaired reflex responses to airway occlusion in the inspiratory muscles of asthmatic subjects, **490**
Improved delivery beclomethasone dipropionate 400 mcg daily achieves equivalent asthma symptom control as 800 mcg BDP from conventional CFC inhalers, **Suppl.3.A73**
Improving the emergency care of asthma patients by London ambulance service, **Suppl.3.A29**
In vivo veritas: the continuing importance of discoveries in complex biosystems, **441**
Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges, **472**
Induced sputum profiles in asthma of differing severity, **Suppl.3.A80**
Influence on mortality trends of 'false positive' asthma death certification in elderly subjects, **Suppl.3.A22**
Inhalational drug delivery from seven different spacer devices, **835**
Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study, **503**
Issues in adolescent asthma: what are the needs? **Suppl.1.13**
Issues in adolescent asthma, Symposium of the European Congress of Allergy and Clinical Immunology, Madrid, June 1995, **Suppl.1.1–17**; introduction, **Suppl.1.1**
Leukotriene B_4 and asthma: *editorial*, **1171**
Measurement of serum prednisolone and cortisol in patients with severe asthma, **Suppl.3.A61**
NO or no NO in asthma? **218**
Northampton asthma survey: results of a postal questionnaire, **Suppl.3.A62**
Observations on the structure, process and clinical outcomes of asthma care in general practice, **Suppl.3.A26**
Occupational asthma in a coal miner, **867**
Occupational asthma due to latex in health care workers, **1280**
Occupational asthma due to latex in a hospital administrative employee, **452**
Occupational asthma in healthcare workers: results from the Shield Surveillance Scheme in the West Midlands, UK, **Suppl.3.A40**
Occupational asthma: measures of frequency from four countries, **435**: *letter*, **1168**
One years asthma admissions in Cornwall – still deficiencies in basic care, **Suppl.3.A62**
Outcome of occupational asthma due to platinum salts, **Suppl.3.A41**
Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? **647**
Potential effects of correction of inaccuracies of the mini-Wright peak expiratory flow meter on the use of an asthma self-management plan, **403**
Prevalence of diagnosed asthma and COPD in a community population in Nottinghamshire, **Suppl.3.A26**
Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients, **155**
Prognostic factors for the outcome of childhood asthma in adolescence, **Suppl.1.7**
Progression of allergy and asthma through childhood to adolescence, **Suppl.1.3**
Provision of primary care asthma services in the United Kingdom, **Suppl.3.A28**
Pulmonary eosinophilia due to *Trichomonas tenax*, **554**
Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma, **284**
Relationship between hospital admissions for asthma and prescribing in general practice, **Suppl.3.A27**
Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids, **496**
Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma, **993**
Risk of severe life threatening asthma: *editorial*, **1073**
Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity, **1093**
Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD, **1000**
Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks, **664**
Salmeterol tachyphylaxis in steroid treated asthmatic subjects, **1100**
Social deprivation, childhood asthma and health service utilisation, **Suppl.3.A29**
Steroids in exacerbations of asthma: tablets or inhalers? *editorial*, **1071**
Study of the aetiology of wheezing illness at age 16 in two national British birth cohorts, **670**
Study of cultural issues relating to asthma and its management among Asian patients, **Suppl.3.A30**
Study of occupational asthma surveillance in hospitals in the West Midlands, UK, **Suppl.3.A41**
Study to assess the need for a referral book for patients with asthma, **Suppl.3.A62**
Survey of health monitoring data at European level for asthma, **Suppl.3.A63**
Treatment of asthma and COPD in a general practice population, **Suppl.3.A27**
Unsuspected chest radiographic abnormalities in young and elderly acute asthma admissions, **Suppl.3.A17**
Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children, **317**
Usual dietary salt intake and asthma in children: a case-control study, **59**
Who should look after asthma: *letter*, **967**
see also Inhalers

Asthma Liaison Nurse Team, One years asthma admissions in Cornwall – still deficiencies in basic care, **Suppl.3.A62**

Athletes
Asthma and other pulmonary diseases in former elite athletes, **288**
Exercise-induced bronchospasm at low temperature in elite runners, **628**

Athymic mice, T lymphocytes and silica-induced pulmonary inflammation and fibrosis in mice, **1036**

Atopic asthmatics, Regional ventilation and perfusion lung scan abnormalities in atopic asthmatics following allergen challenge: comparison with airway function and gas exchange, **Suppl.3.A46**

Atopic disorder, Inverse association between tuberculin responses and atopic disorder, **Suppl.3.A1**

Atopic rhinitis
Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhiitics following exposure for six hours to 400ppb nitrogen dioxide, **Suppl.3.A40**
Fluticasone propionate and beclomethasone dipropionate attenuate ozone-induced release of inflammatory cytokines from nasal epithelial cells of atopic rhinitic subjects, **Suppl.3.A39**

Atopy
Atopy, airway responsiveness, and genes, **Suppl.2.55**
Bronchial hyperresponsiveness, and peak flow variability in children with mild occasional wheezing, **272**
Exercise-induced bronchospasm at low temperature in elite runners, **628**

Atrial fibrillation, Comparison of different levels of nasal continuous positive airway pressure in patients with severe congestive heart failure in sinus rhythm and atrial fibrillation, **Suppl.3.A21**

Atrial natriuretic peptide, Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide, **71**

Audit
Audit of an open access lung function laboratory service for general practitioners (1991–1996), **Suppl.3.A45**
Audit of a respiratory nurse tuberculosis service, **Suppl.3.A34**
Audit of a sleep study service 1993–1995, **Suppl.3.A79**
Audit of tuberculosis treatment, **Suppl.3.A34**
Re-audit of pulmonary function laboratories, **Suppl.3.A69**

Autonomic arousals, Relationship between autonomic arousals, EEG arousals, respiratory events and subjective sleepiness in patients undergoing investigation for obstructive sleep apnoea, **Suppl.3.A76**
Autonomic dysfunction, Autonomic dysfunction in patients with nocturnal hypoventilation, **Suppl.3.A11**

Barometric pressure, Effect of altitude on spirometric parameters and the performance of peak flow meters, **175**
BCG vaccination
Administration of the BCG vaccination using the multipuncture method in schoolchildren – a comparison with the intradermal method, **Suppl.3.A9**
Understanding the different inflammatory responses to live and dead BCG: a prerequisite for improved vaccine design, **Suppl.3.A34**
Beclomethasone
Measuring systemic effects of inhaled beclomethasone: *letter*, **968**
Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**
Beclomethasone dipropionate
Fluticasone propionate and beclomethasone dipropionate attenuate ozone-induced release of inflammatory cytokines from nasal epithelial cells of atopic rhinitic subjects, **Suppl.3.A39**
Improved delivery beclomethasone dipropionate 400 mcg daily achieves equivalent asthma symptom control as 800 mcg BDP from conventional CFC inhalers, **Suppl.3.A73**
Pharmacokinetics of beclomethasone dipropionate from CFC-free ultrafine aerosol and conventional CFC inhalers in asthmatics, **Suppl.3.A74**
Bed occupancy, The combined role of the respiratory health practitioner and the physiotherapist in reducing bed occupancy in patients with chronic respiratory disease, **Suppl.3.A63**
Behavioural test, Comparison of a behavioural test to assess daytime sleepiness with the traditional MWT, **Suppl.3.A77**
Beta adrenergic receptors, Reduced β adrenoceptor density in vivo in human lung tumours: a preliminary study with positron emission tomography, **727**
Beta agonists
Effect of regular terbutaline on the airway response to inhaled budesonide, **989**
Risk of severe life threatening asthma: *editorial*, **1073**
The effect of inhaled β agonists and anticholinergic agents upon heart rate variability, **Suppl.3.A60**
Beta-galactosidase gene, In vivo transfer of the β-galactosidase gene into malignant mesothelioma cells induces tumour rejection, **Suppl.3.A6**
Beta-lactamase, Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal *Pseudomonas aeruginosa* β-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry, **733**
β_2 adrenergic receptor expression, Regulation of pulmonary β_2 adrenergic receptor expression: correlation between receptor density, function and genotypes, **Suppl.3.A38**
β_2-adrenoceptor, β_2-adrenoceptor regulation and function in female asthmatics receiving the oral combined contraceptive pill, **Suppl.3.A37**
β_2-adrenoceptor gene, The Glu27 β_2-adrenoceptor polymorphism is associated with childhood asthma, **Suppl.3.A15**
β_2-adrenoceptor polymorphisms
β_2-adrenoceptor polymorphism determines susceptibility to bronchodilator desensitisation in asthmatics, **Suppl.3.A37**
β_2 adrenoceptor polymorphisms: are they clinically important? *editorial*, **351**: *letter*, **1168**
β_2 agonist, Functional antagonism: tolerance produced by inhaled β_2 agonists, **1051**
β_2 agonist aerosol, Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**
β_2 agonist/antagonist, Evaluation of the β_2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol, **54**
Bicarbonate buffer, Comparison of a modified bicarbonate buffer and EuroCollins solution for hypothermic storage of rat lungs: effect on lung function, **Suppl.3.A69**
Bilateral hilar lymphadenopathy, Silicosis presenting as bilateral hilar lymphadenopathy, **1165**
Blood inflammatory markers, Blood and sputum sol inflammatory markers, **Suppl.3.A80**
Blood pressure
Effect of regression dilution bias on the nocturnal hypoxaemia v blood pressure relationship, **Suppl.3.A79**
Effect of snoring on respiratory effort measured indirectly by beat to beat blood pressure, **Suppl.3.A76**
Body mass, Longitudinal effects of change in body mass on measurements of ventilatory capacity, **699**
Bone density, A phase III open parallel group study to compare the effects of inhaled fluticasone proprionate (500mcg bd) and budesonide (800mcg bd) on bone density measurements over 1 year in stable chronic asthmatics, **Suppl.3.A72**
Book notices (reviews)
Bauernfeind A, Marks MI, Strandvik B. Cystic fibrosis pulmonary infections: lessons from around the world, **1170**
Bordow RA, Moser KM. Manual of clinical problems in pulmonary medicine, 4th edition, **1170**
Cahill DR, Orland MJ, Miller GM. Atlas of human cross-sectional anatomy, 3rd edition, **556**
Carney DN. Lung cancer, **556**
Chadwick DJ, Goode JA. The molecular biology and pathology of elastic tissue, **874**
Department of Health: Committee on the Medical Effects of Air Pollutants. Asthma and outdoor air pollution, **556**
Department of Health: Committee on the Medical Effects of Air Pollutants. Non-biological particles and health, **454**
Derenne J-P, Whitelaw WA, Similowski T. Acute respiratory failure in chronic obstructive pulmonary disease (Lung biology in health and disease series, volume 92), **1170**
Doll, Sir Richard; Crofton, Sir John, *scientific editors.* Tobacco and health, **772**
Mindel A, Miller R. AIDS – a pocket book of diagnosis and management, 2nd edition, **658**
Morgan WKC, Seaton A. Occupational lung diseases, **1068**
O'Donohue WJ. Long-term oxygen therapy, **228**
Peacock AJ. Pulmonary circulation – a handbook for clinicians, **1169**
Proctor DF. A history of breathing physiology, **344**
Roussos C. The thorax. Part A: Physiology; Part B: Applied physiology; Part C Disease. (Lung Biology in Health and Disease Series, No 85). 2nd edition, revised and expanded, **874**
Simonds AK. Non invasive respiratory support, **968**
Stern EJ, Swenson SJ. High resolution CT of the chest – comprehensive atlas, **968**
Webb WR, Muller NL, Naidich DP. High resolution CT of the lung, 2nd edition, **968**
Brachytherapy
High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation, **354**
High dose rate endobronchial brachytherapy for the treatment of lung cancer: current status and indications: *editorial*, **345**
Bradykinin, Cultured human airway smooth muscle cells release PGE_2 in response to bradykinin, growth factors and arachidonic acid, **Suppl.3.A38**
Brain dead organ donors, Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia, **929**
Breathhold, Influence of breathhold on peak and plateau concentrations of nitric oxide in the exhaled air of adults, **Suppl.3.A17**
Breathing, Reliability of a commercially available threshold loading device in healthy subjects and in patients with chronic obstructive pulmonary disease, **601**
Breathing pattern, Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease, **677**
Breathlessness, Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease, **596**
Breathlessness score, The Medical Research Council Breathlessness Score is useful in selecting COPD patients for pulmonary rehabilitation, **Suppl.3.A24**
Bricanyl Turbohaler, Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**
British Thoracic Society, British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment, **238**
Bronchi, Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest, **914**
Bronchial biopsy specimens
Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia, **929**

Effect of prostaglandin E_2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa, **919**

Bronchial casts, Lymphangiomatosis presenting with bronchial cast formation, **765**

Bronchial epithelial cells

Cigarette smoke enhances house dust mite allergen (*Der p*1)-induced changes in permeability of human bronchial epithelial cell cultures, **Suppl.3.A51**

Diesel exhaust particulates enhance the release of pro-inflammatory mediators from human bronchial epithelial cells *in vitro*, **Suppl.3.A54**

Effect of *Haemophilus influenzae* endotoxin on the expression of transcription factors by cultured human bronchial epithelial cells and the influence of anti-inflammatory agents, **Suppl.3.A3**

Effect of loratadine on nitrogen dioxide-induced release of pro-inflammatory mediators from cultured human bronchial epithelial cells, **Suppl.3.A39**

Nedocromil sodium attenuates bronchial epithelial cell-induced eosinophil adhesion and release of sICAM-1 from endothelial cells *in vitro*, **Suppl.3.A39**

Pre-exposure of a rhinoviral-infected human bronchial epithelial cell line to cytokines affects surface ICAM-1 levels, **Suppl.3.A2**

Bronchial hyperresponsiveness

Atopy, bronchial hyperresponsiveness, and peak flow variability in children with mild occasional wheezing, **272**

Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma, **582**

Impact of obstructive airways disease on quality of life in older adults, **520**

Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids, **496**

Usual dietary salt intake and asthma in children: a case-control study, **59**

Bronchial inflammation, The use of a sputum colour chart in the assessment of bronchial inflammation, **Suppl.3.A82**

Bronchial obstruction, Expandable metal stents for non-malignant bronchial obstruction, **963**

Bronchial provocation tests (testing)

Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges, **472**

Occupational asthma in a coal miner, **867**

Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate, **793**

Bronchial reactivity, Antioxidants and bronchial reactivity, **Suppl.3.A1**

Bronchial responsiveness

Assessment of food chemical intolerance in adult asthmatic subjects, **805**

Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma, **284**

Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children, **317**

Bronchial stenosis, Thin-section spiral volumetric CT for the assessment of lobar and segmental bronchial stenosis, **Suppl.3.A70**

Bronchial stent, Expandable metal stents for non-malignant bronchial obstruction, **963**

Bronchial washings, How valuable are routine bronchial washings for TB studies? **Suppl.3.A32**

Bronchiectasis

Bronchiectasis and homozygous (PiZZ) α_1-antitrypsin deficiency: *letter*, **228**

Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest, **914**

Exhaled nitric oxide is not elevated in patients with cystic fibrosis or bronchiectasis compared to normals, **Suppl.3.A19**

Inflammatory activity in sputum chronic bronchitis and bronchiectasis during clinical stability, **Suppl.3.A81**

Knowledge and compliance with respiratory physiotherapy techniques in adults with bronchiectasis, **Suppl.3.A68**

Bronchiolitis

Bronchiolitis and asthma in infancy and early childhood, **Suppl.2.60**

Diffuse panbronchiolitis in an Asian immigrant, **1065**

Broncho-Vaxom, Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-86 BV) via C-Fos/serum responsive element, **150**

Bronchoalveolar alveolitis, Exhaled nitric oxide is normal in sarcoidosis patients with active alveolitis, **Suppl.3.A18**

Bronchoalveolar lavage

Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection, **312**

Bronchoalveolar lavage with trypsin in pulmonary alveolar proteinosis, **769**

Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia, **929**

Comparison of cell profiles in separately evaluated fractions of bronchoalveolar lavage (BAL) fluid in children, **615**

Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan, **739**

Elevated expression of insulin-like growth factor binding protein-3 in bronchoalveolar lavage fluid of patients with pulmonary fibrosis, **Suppl.3.A12**

Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease, **1270**

Growth hormone and insulin-like growth factor-1 gene expression in bronchoalveolar lavage cells using RT-PCR, **Suppl.3.A12**

Two dimensional protein patterns of bronchoalveolar lavage fluid from non-smokers, smokers, and subjects exposed to asbestos, **1028**

Bronchoconstriction

Attenuation of propranolol-induced bronchoconstriction by nebulised frusemide, **Suppl.3.A40**

Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide-induced bronchoconstriction, **159**

Exercise-induced bronchoconstriction by ethnicity and presence of asthma in British nine year olds, **1134**

Histamine induced bronchoconstriction and end tidal inspiratory activity in man, **1192**

Bronchodilation, Effects of prior treatment with salmeterol and formoterol on airway and systemic beta$_2$ responses to fenoterol, **585**

Bronchodilator response, Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients, **853**

Bronchodilators

β_2-adrenoceptor polymorphism determines susceptibility to bronchodilator desensitisation in asthmatics, **Suppl.3.A37**

Compliance in an assessment programme for domiciliary nebulised bronchodilators in patients with chronic obstructive airways disease, **Suppl.3.A28**

Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide, **71**

Inhaler technique among adult patients prescribed bronchodilators, **Suppl.3.A71**

Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**

Reversibility to bronchodilators: are forced expiratory manoeuvres the best? **Suppl.3.A46**

Scorpion venoms: taking the sting out of lung disease, **546**

Smoking and quality of life among adult patients prescribed bronchodilators, **Suppl.3.A66**

Bronchoplasty, Expandable metal stents for non-malignant bronchial obstruction, **963**

Bronchoprotection, Potentiation of the bronchoprotective effects of vasoactive intestinal peptide, isoprenaline, and theophylline against histamine challenge in anaesthetised guinea pigs by adrenomedullin, **1199**

Bronchopulmonary dysplasia, Serum dependence of oxygen stimulated DNA synthesis in human fetal airway smooth muscle cells: implications for the pathogenesis of bronchopulmonary dysplasia, **Suppl.3.A15**

Bronchoscopy

Adenoid cystic carcinoma of the left main bronchus mimicking MacLeod's syndrome, **451**

Bronchoscopic and angiographic findings in tracheobronchial endometriosis, **1060**: *commentary*, **1064**

Bronchoscopy software development: costs and benefits, **Suppl.3.A70**

Comparison of oximetry and transcutaneous carbon dioxide levels in patients undergoing fibreoptic bronchoscopy, **Suppl.3.A70**
Intrathoracic tuberculous lymphadenopathy: clinical and bronchoscopic features in 17 adults without parenchymal lesions, **87**: *letter*, **967**
Pulmonary actinomycosis appearing as a "ball-in-hole" on chest radiography and bronchoscopy, **221**: *commentary*, **226**: *letter*, **1168**
Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks, **664**
Transtracheal aspiration using rigid bronchoscopy and a rigid needle for investigating mediastinal masses, **197**
Bronchospasm
Exercise-induced bronchospasm at low temperature in elite runners, **628**
Exercise-induced bronchospasm in Ghana: prevalence in urban and rural children, **Suppl.3.A42**
Bronchus, Primary malignant melanoma of the bronchus, **223**; *commentary*, **226**
Budesonide
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients, **262**
Comparison of pMDI plus Nebuhaler and Turbohaler in asthmatic patients with dysphonia, **Suppl.3.A74**
Effect of regular terbutaline on the airway response to inhaled budesonide, **989**
Phase III open parallel group study to compare the effects of inhaled fluticasone proprionate (500mcg bd) and budesonide (800mcg bd) on bone density measurements over 1 year in stable chronic asthmatics, **Suppl.3.A72**
Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**
Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**
Building-related disease
Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air, **256**
Pulmonary infiltration after exposure to home renovation dust: histopathology and microanalysis, **654**: *commentary*, **656**
Bulla, Spontaneous regression of a giant pulmonary bulla, **549**: *letter*, **1283**
Burkholderia cepacia
Inflammatory markers and clinical response to intravenous antibiotics in adults with cystic fibrosis colonised with *Burkholderia cepacia* and *Pseudomonas aeruginosa*, **Suppl.3.A49**
Referral for lung transplantation: experience of a Birmingham Adult Cystic Fibrosis Centre between 1987 and 1994, **302**: *letters*, **873**, **1068**
Byssinosis, Byssinosis: a review, **632**

Calcium metabolism, Dysregulation of calcium metabolism in human neutrophils exposed to the *Pseudomonas aeruginosa* pigment 1-hydroxyphenazine, **Suppl.3.A58**
Calibrating, Calibrating the calibrators: *editorial*, **969**
Cancer care delivery, Cancer care delivery: are the standards in the Whitehouse report attainable, **Suppl.3.A7**
Candidate gene loci, Candidate gene loci in asthmatic and allergic inflammation: *editorial*, **3**
Capsaicin, Cough sensitivity to nebulised capsaicin and low chloride solution in laryngectomees, **Suppl.3.A37**
Carbon dioxide
Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease, **677**
Carbon dioxide replacement during exercise in patients with idiopathic hyperventilation, **Suppl.3.A21**
Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease, **1083**
Carbon monoxide, Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension, **855**
Cardiovascular fitness, Exercise-induced asthma and cardiovascular fitness in asthmatic children, **207**
Carers, The impact on carers of disability due to chronic obstructive pulmonary disease, **Suppl.3.A16**

Cat allergen
Correlation between levels of major cat allergen *Fel d* 1 in reservoir and settling dust in homes with and without cats, **Suppl.3.A42**
Distribution and aerodynamic characteristics of major cat allergen *Fel d* 1, **Suppl.3.A41**
Reducing exposure to cat allergen in hospitals: the effect of regular vacuum cleaning on *Fel d* 1 in upholstered chairs, **Suppl.3.A41**
Catamenial haemoptysis, Bronchoscopic and angiographic findings in tracheobronchial endometriosis, **1060**: *commentary*, **1064**
Cationic liposomes
Human alpha$_1$-antitrypsin gene transfer with cationic liposomes *in vitro* and *in vivo*, **Suppl.3.A6**
Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers, **Suppl.3.A6**
CD4 counts, Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts, **932**
CD4$^+$, *Pneumocystis carinii* in a patient with pulmonary sarcoidosis and idiopathic CD4$^+$ T lymphocytopenia, **446**: *commentary*, **448**
CD4$^+$ T-cell recognition, Human CD4$^+$ T-cell recognition of influenza A haemagglutinin is precisely defined by HLA-DR, **Suppl.3.A2**
Cell counts
Cell counts in spontaneous sputum during exacerbations of asthma and COPD, **Suppl.3.A80**
Reproducibility of induced sputum cell counts and fluid phase ECP, **Suppl.3.A80**
Cell profiles, Comparison of cell profiles in separately evaluated fractions of bronchoalveolar lavage (BAL) fluid in children, **615**
Cell signalling, Cell signalling in pulmonary vascular cells: do not shoot the messenger!, **864**
Cephalosporin resistance, Antibiotic resistant *Streptococcus pneumoniae*, **Suppl 2.45**
CHART, Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by the CHART Steering Committee, **1262**
Chemoattractant-induced neutrophil cross-desensitisation, Cross-desensitisation of neutrophil IL-8 receptors involves differential receptor subtype regulation, **Suppl.3.A54**
Chemodectoma, Chemodectoma of the trachea, **341**
Chemotherapy, Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes: *editorial*, **231**
Chest radiography
Pulmonary actinomycosis appearing as a "ball-in-hole" on chest radiography and bronchoscopy, **221**; *commentary*, **226**: *letter*, **1168**
Radiographic features of staphylococcal pneumonia in adults and children, **539**
Respiratory tract infection in the community. Does a chest radiograph influence treatment? **Suppl.3.A13**
Unsuspected chest radiographic abnormalities in young and elderly acute asthma admissions, **Suppl.3.A17**
Chest wall invasion, Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement, **846**
Children
Acute effects of summer air pollution on respiratory function in primary school children in southern England, **1109**
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**
Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air, **256**
Bronchiolitis and asthma in infancy and early childhood, **Suppl.2.60**
Comparison of cell profiles in separately evaluated fractions of bronchoalveolar lavage (BAL) fluid in children, **615**
Descriptive study of cough, wheeze and school absence in childhood, **630**
Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys, **590**
Exercise-induced bronchoconstriction by ethnicity and presence of asthma in British nine year olds, **1134**
Prognostic factors for the outcome of childhood asthma in adolescence, **Suppl.1.7**
Progression of allergy and asthma through childhood to adolescence, **Suppl.1.3**

Pulmonary function in children with systemic lupus erythematosus, **424**
Randomised controlled assessment of a 'Windmill Trainer' device in the measurement of PEF in children, **Suppl.3.A61**
Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma, **284**
Spiral computed tomographic scanning of the chest with three dimensional imaging in the diagnosis and management of paediatric intrathoracic airway obstruction, **1005**
Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children, **317**
Usual dietary salt intake and asthma in children: a case-control study, **59**

Chlamydia pneumoniae
Chlamydia pneumoniae antibody titres are significantly associated with Afro-Caribbean and Asian origin, **Suppl.3.A67**
Chlamydia pneumoniae antibody titres are significantly associated with the use of steroid medication in respiratory disease, **Suppl.3.A14**
Clinical picture of community-acquired *Chlamydia pneumoniae* pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia, **185**: *letter*, **967**

Chronic airways obstruction
Compliance with oral corticosteroids during steroid trials in chronic airways obstruction, **323**
Impact of obstructive airways disease on quality of life in older adults, **520**
Prevalence and treatment of chronic airways obstruction in adults over the age of 45, **164**

Chronic bronchitis
Analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections, **1017**
Identification of a novel conformation of α_1-antichymotrypsin: an explanation for the inactive species found in lung lavage from patients with chronic bronchitis and emphysema, **Suppl.3.A51**
Inflammatory activity in sputum chronic bronchitis and bronchiectasis during clinical stability, **Suppl.3.A81**
Sputum leukotriene B_4 during infective exacerbations of chronic bronchitis, **Suppl.3.A81**

Chronic cough, Effect of loratadine, an H_1 antihistamine, on induced cough in non-asthmatic patients with chronic cough, **810**

Chronic Disease Management Programme, An analysis of the data produced by the Asthma Chronic Disease Management Programme and the Prescribing Analysis and Cost data in Suffolk, **Suppl.3.A27**

Chronic hypoxic lung disease, Doppler assessment of pulmonary haemodynamics in chronic hypoxic lung disease: *editorial*, **9**

Chronic obstructive pulmonary disease
Acute steroid trials in COPD: lessons from the ISOLDE trial, **Suppl.3.A44**
Airways obstruction, chronic expectoration, and rapid decline of FEV_1 in smokers are associated with increased levels of sputum neutrophils, **267**
Are activity monitors sensitive enough to detect speeds prescribed to patients with COPD? **Suppl.3.A25**
Assessment of the appropriateness of admissions of patients with exacerbation of chronic obstructive pulmonary disease, **Suppl.3.A20**
Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease, **677**
Calibrating the calibrators: *editorial*, **969**
Cell counts in spontaneous sputum during exacerbations of asthma and COPD, **Suppl.3.A80**
Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease, **1048**
Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking, **831**
Compliance in an assessment programme for domiciliary nebulised bronchodilators in patients with chronic obstructive airways disease, **Suppl.3.A28**
COPD guidelines and general practice – use of spirometers, **Suppl.3.A44**
Criteria for non-invasive ventilation in chronic obstructive pulmonary disease. Who is eligible? **Suppl.3.A20**
Death from airways obstruction: accuracy of certification in Northern Ireland, **293**
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease, **39**
Difference between functional residual capacity and elastic equilibrium volume in patients with chronic obstructive pulmonary disease, **415**
Do anxiety and depression affect outcome of rehabilitation in severe chronic obstructive pulmonary disease, **Suppl.3.A25**
Do patients with chronic obstructive pulmonary disease attending a pulmonary rehabilitation programme adhere to their prescribed home exercise programme? **Suppl.3.A25**
Domiciliary ventilation in chronic obstructive pulmonary disease: where are we? *editorial*, **455**
Doppler assessment of pulmonary haemodynamics in chronic hypoxic lung disease: *editorial*, **9**
Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease, **48**
Effect of adenosine infusion on oxygen induced carbon dioxide retention in severe chronic obstructive pulmonary disease, **1083**
Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease, **516**
Effect of outdoor temperature on daily lung function and exacerbations in patients with COPD, **Suppl.3.A19**
Effectiveness of four different inhalers in COPD: *letter*, **454**
Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease, **684**
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease, **689**
Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease, **819**
Factors predisposing to exacerbations in patients with COPD, **Suppl.3.A19**
Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**
Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study, **825**
Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease, **1270**
General practitioner prescribing habits in asthma/COPD, **Suppl.3.A26**
Impact on carers of disability due to chronic obstructive pulmonary disease, **Suppl.3.A16**
Inhaler use in chronic obstructive pulmonary disease, **Suppl.3.A66**
Long-term benefits of pulmonary rehabilitation in elderly patients with chronic obstructive pulmonary disease, **Suppl.3.A16**
Long term effects of non-invasive intermittent positive pressure ventilation on chronic ventilatory failure due to COPD, **Suppl.3.A10**
Lung volume reduction surgery in chronic obstructive pulmonary disease, **Suppl.2.29**
Medical Research Council Breathlessness Score is useful in selecting COPD patients for pulmonary rehabilitation, **Suppl.3.A24**
Negative pressure ventilation in acute hypercapnic chronic obstructive pulmonary disease: *editorial*, **1069**
Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease, **Suppl.2.35**
Occupation and chronic obstructive pulmonary disease, **947**
Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease: *editorial*, **348**
Patterns of symptom change during an exacerbation of chronic obstructive pulmonary disease, **Suppl.3.A65**
Peak inspiratory flow through Turbuhaler in chronic obstructive pulmonary disease, **Suppl.3.A75**
Prevalence of diagnosed asthma and COPD in a community population in Nottinghamshire, **Suppl.3.A26**
Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia, **44**
Randomised controlled trial of outpatient pulmonary rehabilitation in COPD: preliminary results, **Suppl.3.A24**

Randomised crossover study of inspiratory positive airway pressure on gas exchange and dyspnoea during nasal ventilation in stable COPD, **Suppl.3.A10**
Reliability of a commercially available threshold loading device in healthy subjects and in patients with chronic obstructive pulmonary disease, **601**
Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD, **1000**
Salmeterol in smokers with COPD: *letter*, **110**
Severity of COPD, autonomic nerve function, cardiac arrhythmias and mortality, **Suppl.3.A65**
Severity scoring in acute exacerbations of chronic obstructive airways disease, **Suppl.3.A20**
Symptomatic and spirometric change during exacerbations of chronic obstructive pulmonary disease, **Suppl.3.A19**
Time series analysis of FEV_1 in patients with exacerbations of COPD, **Suppl.3.A65**
Treatment of asthma and COPD in a general practice population, **Suppl.3.A27**
Chronic respiratory disease
Administration of the chronic respiratory disease questionnaire: Combined role of the respiratory health practitioner and the physiotherapist in reducing bed occupancy in patients with chronic respiratory disease, **Suppl.3.A63**
Chronic respiratory insufficiency, Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency, **1077**
Chyloptysis, Lymphangiomatosis presenting with bronchial cast formation, **765**
Chylothorax, Bilateral chylothorax complicating massive osteolysis (Gorham's syndrome), **1277**: *commentary*, **1279**
Cigarette smoke, Cigarette smoke enhances house dust mite allergen (*Der p*1)-induced changes in permeability of human bronchial epithelial cell cultures, **Suppl.3.A51**
Cisapride, Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride, **82**
Cisplatin, A phase II of cisplatin, ifosfamide and increasing dosage of navelbine in unresectable non-small cell lung cancer, **Suppl.3.A55**
Coal miners
Effects of cigarette smoking and duration of work on the lung function of coal miners, **Suppl.3.A43**
Occupational asthma in a coal miner, **867**
Cocaine, "Crack lung" caused by an impure preparation, **959**: *commentary*, **962**
Colds, Effects of upper respiratory tract infections in patients with cystic fibrosis, **1115**
Collagen, Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis, **1253**
Collagenases, Effect of *Mycobacterium tuberculosis* and its components on macrophages and the release of matrix metalloproteinases, **306**
Coma, Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency, **1077**
Community-acquired pneumonia
Analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections, **1017**
Circulating neutrophil β_2-integrin expression and intracellular oxidative metabolism in community acquired pneumonia, **Suppl.3.A3**
Clinical picture of community-acquired *Chlamydia pneumoniae* pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia, **185**: *letter*, **967**
Community acquired pneumonia: aetiology and usefulness of severity criteria on admission, **1010**
Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France), **385**
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients, **179**
Predicting death from pneumonia: *editorial*, **970**
Compliance
Compliance with oral corticosteroids during steroid trials in chronic airways obstruction, **323**
Compliance with treatment in adult patients with cystic fibrosis, **29**
Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance, **1130**
Computed tomography
Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer, **359**
Continuous volume computed tomography in pulmonary embolism: the answer, or just another test? *editorial*, **1**
Influence of thoracic CT and guided fine needle biopsy on management of solitary pulmonary nodules ≤ 3 cm in diameter, **Suppl.3.A7**
Role of spiral volumetric computed tomographic scanning in the assessment of patients with clinical suspicion of pulmonary embolism and an abnormal ventilation/perfusion lung scan, **23**
Thin-section spiral volumetric CT for the assessment of lobar and segmental bronchial stenosis, **Suppl.3.A70**
Confounding by severity
Risk of severe life threatening asthma: *editorial*, **1073**
Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity, **1093**
Congestive heart failure, Comparison of different levels of nasal continuous positive airway pressure in patients with severe congestive heart failure in sinus rhythm and atrial fibrillation, **Suppl.3.A21**
Continuous positive airway pressure
Do CPAP titration studies predict subsequent CPAP usage or effectiveness?, **Suppl.3.A78**
Effect of chronic continuous positive airway pressure therapy on upper airway size in patients with sleep apnoea/hypopnoea syndrome, **190**
Continuous volume computed tomography, Continuous volume computed tomography in pulmonary embolism: the answer, or just another test? *editorial*, **1**
Contraceptive pill, β_2-adrenoceptor regulation and function in female asthmatics receiving the oral combined contraceptive pill, **Suppl.3.A37**
Contractile properties, Contractile properties of the elderly human diaphragm, **Suppl.3.A16**
Coronary heart disease, The rate of decline of forced expiratory volume in one second (FEV_1) predicts mortality from coronary heart disease in men and women, **Suppl.3.A23**
Corrections, **556**, **1068**
Corticosteroid reversibility trials, Compliance with oral corticosteroids during steroid trials in chronic airways obstruction, **323**
Corticosteroids
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment, **238**
Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients, **262**
Diffuse panbronchiolitis in an Asian immigrant, **1065**
Effect of regular terbutaline on the airway response to inhaled budesonide, **989**
Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma, **993**
Salmeterol tachyphylaxis in steroid treated asthmatic subjects, **1100**
Cortisol, The measurement of serum prednisolone and cortisol in patients with severe asthma, **Suppl.3.A61**
Cost of care, Cost of care of patients with cystic fibrosis in The Netherlands in 1990–1, **298**
Costs, Bronchoscopy software development: costs and benefits, **Suppl.3.A70**
Cough
Abdominal muscle strength measured by gastric pressure during maximal cough, **Suppl.3.A45**
Airways inflammation in chronic non-productive cough, **Suppl.3.A64**
Clinical significance of excess cough as a solitary symptom, **Suppl.3.A14**
Descriptive study of cough, wheeze and school absence in childhood, **630**
Effect of loratadine, an H_1 antihistamine, on induced cough in non-asthmatic patients with chronic cough, **810**
Prevalence of anxiety and depression in patients with chronic non-productive cough, **Suppl.3.A64**
Cough remedies, Can short term effects of cough remedies be measured? **Suppl.3.A64**
Cough threshold, Relationship between the acid-induced cough response and airway responsiveness and obstruction in children with asthma, **284**

Crack lung, "Crack lung" caused by an impure preparation, **959**: *commentary*, **962**
Cryptogenic fibrosing alveolitis
Cryptogenic fibrosing alveolitis – a comparison of presentation, respiratory lung function and outcome between Caucasians and Asians, **Suppl.3.A71**
Cryptogenic fibrosing alveolitis does not appear associated with Epstein-Barr virus infection, **Suppl.3.A11**
Cryptogenic fibrosing alveolitis and lung cancer – is there an association? **Suppl.3.A11**
Mortality rates from cryptogenic fibrosing alveolitis in seven countries, **711**
Crystalline silica, Exposure of crystalline silica and risk of lung cancer: the epidemiological evidence, **97**: *letter*, **772**
Cyclic guanosine monophosphate
Effect of cyclic guanosine monophosphate on ovine airway epithelial transport, **Suppl.3.A60**
Synthesis of cyclic guanosine monophosphate in cultured human airway smooth muscle cells, **Suppl.3.A38**
Cyclic nucleotides, Prostaglandin E_2 production by ovine tracheal epithelium: control by cyclic nucleotides, **Suppl.3.A38**
Cyclooxygenase-2, Interleukin-1β causes induction of cyclooxygenase-2 in cultured human airway smooth muscle cells, **Suppl.3.A39**
Cyclophosphamide
Cyclophosphamide treatment of paraquat poisoning: *editorial*, **659**
Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**
Cyclosporin, Frusemide and cyclosporin do not inhibit early antigen response in sensitised guinea pig tracheal tubes, **Suppl.3.A40**
Cystic fibrosis
α_1-antitrypsin mutations and the severity of cystic fibrosis lung disease, **Suppl.3.A60**
Circulating immunoreactive interleukin-6 in cystic fibrosis, **Suppl.3.A59**
Clinical significance of the auxotrophic phenotype of *Pseudomonas aeruginosa* in cystic fibrosis, **Suppl.3.A49**
Compliance with treatment in adult patients with cystic fibrosis, **29**
Cost of care of patients with cystic fibrosis in The Netherlands in 1990–1, **298**
Cystic fibrosis related diabetes: a retrospective survey of adult cystic fibrosis patients of Royal Brompton Hospital from 1966–1996, **Suppl.3.A47**
Effect of intravenous antibiotic therapy on markers of oxidative stress in cystic fibrosis, **Suppl.3.A59**
Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis, **619**
Effect of pregnancy on maternal cystic fibrosis vs nulliparous severity matched controls, **Suppl.3.A50**
Effects of upper respiratory tract infections in patients with cystic fibrosis, **1115**
Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis, **1223**
Exhaled nitric oxide is not elevated in patients with cystic fibrosis or bronchiectasis compared to normals, **Suppl.3.A19**
Free radical activity and antioxidant levels in serum of diabetic and non-diabetic cystic fibrosis patients, **Suppl.3.A59**
Gastrostomy feeding significantly improves lung function in children with cystic fibrosis, **Suppl.3.A47**
Health perceptions and treatment adherence in adults with cystic fibrosis, **1233**
In vivo assessment of potential novel pharmacological agents to activate CFTR in cystic fibrosis, **Suppl.3.A60**
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, **119**
Inflammatory markers and clinical response to intravenous antibiotics in adults with cystic fibrosis colonised with *Burkholderia cepacia* and *Pseudomonas aeruginosa*, **Suppl.3.A49**
Is Fusarium species a cause of fungal atopy in adult cystic fibrosis? **Suppl.3.A49**
Is the risk of fetal anomalies greater in mothers with cystic fibrosis? **Suppl.3.A50**
Knowledge of adult patients with cystic fibrosis about their illness, **34**
Long term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre, **1023**
Lower airway potential difference measurements in non-CF and CF subjects, **Suppl.3.A6**
Mild variant of cystic fibrosis, **Suppl.2.51**
Minimisation of aminoglycoside toxicity in patients with cystic fibrosis, **369**
Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis mouse, **1229**
Nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure, **Suppl.3.A24**
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks, **364**: *letter*, **1283**
Neutrophil responsiveness in cystic fibrosis patients is affected by clinical state, **Suppl.3.A58**
Nutrition, diabetes, pancreatic function and survival in a Birmingham cystic fibrosis clinic, **Suppl.3.A47**
Nutrition and survival in cystic fibrosis: *editorial*, **971**
Outcome of 72 pregnancies in 55 CF women: a United Kingdom survey 1977–1995, **Suppl.3.A50**
Outcome for patients colonised with *Burkholderia cepacia* in a Birmingham adult cystic fibrosis clinic and the end of an epidemic, **374**
Physiotherapy and nebulised drug use in a Birmingham adult cystic fibrosis unit: patient practice, knowledge and adherence, **Suppl.3.A48**
Progress in treatment in a Birmingham adult cystic fibrosis clinic slows functional decline, **Suppl.3.A48**
Protease content of circulating neutrophils from patients with cystic fibrosis, **Suppl.3.A58**
Pseudomonas aeruginosa adherence to cystic fibrosis respiratory epithelium is reduced by anti-asialo GM1 antibody and neuraminidase inhibition, **Suppl.3.A57**
Quality of life in adults with cystic fibrosis, **936**
Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal *Pseudomonas aeruginosa* beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry, **733**
Referral for lung transplantation: experience of a Birmingham Adult Cystic Fibrosis Centre between 1987 and 1994, **302**: *letters*, **873**, **1068**
Responsiveness of circulating neutrophils from acutely infected and stable cystic fibrosis patients to stimulation, **Suppl.3.A58**
Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis, **126**
Results of pulmonary transplantation in patients with cystic fibrosis colonised by multiply resistant pseudomonads, **Suppl.3.A23**
Role of ELISA in the early diagnosis of *Pseudomonas aeruginosa* infection in cystic fibrosis, **Suppl.3.A49**
Role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems, **750**
Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers, **Suppl.3.A6**
Short term effect of nebulised human recombinant DNAse on neutrophil inflammatory products in cystic fibrosis, **Suppl.3.A59**
Symptomatic hypomagnesaemia in cystic fibrosis precipitated by treatment of infection, **Suppl.3.A48**
Use of raised random blood glucose alone is unreliable in the diagnosis of cystic fibrosis related diabetes, **Suppl.3.A48**
Cytokines
Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan, **739**
Flow cytometric analysis of cytokine production in the lymphocytic alveolitis of sarcoidosis, **Suppl.3.A12**
Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis, **1253**
Cytomegalovirus pneumonitis, Quantitative PCR for the diagnosis of CMV disease in lung and heart transplant, **Suppl.3.A23**

Daytime sleepiness
Comparison of a behavioural test to assess daytime sleepiness with the traditional MWT, **Suppl.3.A77**
Inter-observer variability in the assessment of EEG arousal, **Suppl.3.A76**
Death certificates
Accuracy of mortality data for interstitial lung diseases in New Mexico, USA, **717**

Accuracy of recording of deaths from asthma in the UK: the false negative rate, **924**
Death from airways obstruction: accuracy of certification in Northern Ireland, **293**
Influence on mortality trends of 'false positive' asthma death certification in elderly subjects, **Suppl.3.A22**
Deaths, Accuracy of recording of deaths from asthma in the UK: the false negative rate, **924**
Decortication, Pleural non-Hodgkin's lymphoma arising in a patient with a chronic pyothorax, **103; *commentary*, 107**
Delayed inhalation, Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, **981**
Demand oxygen delivery system, Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking, **831**
Dental implications, Dental implications of obstructive sleep apnoea, **Suppl.3.A78**
Dental surgery, Pneumomediastinum secondary to use of a high speed air turbine drill during a dental extraction, **339; *commentary*, 340**
Dexamethasone
Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome, **907**
Steroids, surfactant and lung disease: *editorial*, **880**
Diabetes
Cystic fibrosis related diabetes: a retrospective survey of adult cystic fibrosis patients of Royal Brompton Hospital from 1966–1996, **Suppl.3.A47**
Free radical activity and antioxidant levels in serum of diabetic and non-diabetic cystic fibrosis patients, **Suppl.3.A59**
Nutrition, diabetes, pancreatic function and survival in a Birmingham cystic fibrosis clinic, **Suppl.3.A47**
Pulmonary actinomycosis appearing as a "ball-in-hole" on chest radiography and bronchoscopy, **221; *commentary*, 226**: *letter*, **1168**
Use of raised random blood glucose alone is unreliable in the diagnosis of cystic fibrosis related diabetes, **Suppl.3.A48**
Diagnostic delay, Delays in the diagnosis and surgical treatment of lung cancer, **903**
Diaphragm
Clinical assessment of diaphragm strength by cervical magnetic stimulation of the phrenic nerves, **1239**
Contractile properties of the elderly human diaphragm, **Suppl.3.A16**
Diaphragm and quadriceps strength in chronic heart failure, **Suppl.3.A21**
Diaphragm strength measured using magnetic phrenic nerve stimulation in the intensive care unit, **Suppl.3.A45**
Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**
Frequency dependence of the length-tension relationship of the diaphragm in man, **Suppl.3.A21**
Diaphragmatic pacemaker, Transdiaphragmatic pressure in quadriplegic individuals ventilated by diaphragmatic pacemaker, **420**
Diesel exhaust particulates, Diesel exhaust particulates enhance the release of pro-inflammatory mediators from human bronchial epithelial cells *in vitro*, **Suppl.3.A54**
Diffuse panbronchiolitis, Diffuse panbronchiolitis in an Asian immigrant, **1065**
Directly observed intermittent therapy, Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance, **1130**
Directly observed therapy, A programme of directly observed therapy for tuberculosis in London, **Suppl.3.A32**
Distilled water challenge, Effect of loratadine, an H_1 antihistamine, on induced cough in non-asthmatic patients with chronic cough, **810**
Diurnal variation, Comparison of mean daily diurnal variation in peak expiratory flow and FEV_1, **Suppl.3.A43**
DNA content, In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, **119**
DNA fingerprinting
DNA fingerprinting of *Mycobacterium tuberculosis:* a tool for prevention and control, **Suppl.3.A34**
Epidemimology and molecular ecology of *Mycobacterium tuberculosis* from clinical sources: DNA fingerprinting of *M. tuberculosis* isolates from clinical specimens, **Suppl.3.A33**
DNA:liposome complexes, Divided doses of DNA:liposome complexes produce suboptimal gene expression for a given DNA dose, **Suppl.3.A5**
Domiciliary ventilation, Domiciliary ventilation in chronic obstructive pulmonary disease: where are we? *editorial*, **455**
Donors, Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia, **929**
Doppler assessment, Doppler assessment of pulmonary haemodynamics in chronic hypoxic lung disease: *editorial*, **9**
Doxapram, Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease, **1048**
Drug addiction, Lung disease induced by drug addiction: *letter*, **556**
Drug administration, Inhalational drug delivery from seven different spacer devices, **835**
Drug discovery, In vivo veritas: the continuing importance of discoveries in complex biosystems, **441**
Drug resistance
Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours, **526**
Drug resistant tuberculosis in England and Wales, 1993–1995, **Suppl.3.A8**
Rapid detection of MDR-TB in clinical samples, **Suppl.3.A32**
Risk factors for drug resistance in patients with tuberculosis in England and Wales 1993–94, **Suppl.3.A8**
Dry powder inhaler
Comparison of the systemic effects of salbutamol and terbutaline when inhaled from a metered dose inhaler or as a dry powder in healthy volunteers, **Suppl.3.A72**
Improving the delivery efficiency of dry powder inhalers by adding fine carrier particles to powder formulations, **Suppl.3.A74**
In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system, **75**
In vitro deposition of lactose carrier from dry powder inhaler formulations, **Suppl.3.A74**
Particle size selection device for use with the Turbohaler, **537**
Dysphonia, Comparison of pMDI plus Nebuhaler and Turbohaler in asthmatic patients with dysphonia, **Suppl.3.A74**
Dyspnoea, Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate, **793**

Ecstasy, Ecstasy induced pneumomediastinum, **960**: *commentary*, **962**
Editorial Office, Thorax: from the new Editorial Office, **561**
EEG arousals
Detection of cortical EEG arousals from a neural network analysis, **Suppl.3.A76**
Inter-observer variability in the assessment of EEG arousal, **Suppl.3.A76**
Relationship between autonomic arousals, EEG arousals, respiratory events and subjective sleepiness in patients undergoing investigation for obstructive sleep apnoea, **Suppl.3.A76**
Eicosanoid metabolism, Effect of prostaglandin E_2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa, **919**
Eicosanoids, Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis, **1223**
Eikenella corrodens, Pleuropulmonary infection with chest wall infiltration by *Eikenella corrodens*, **871**
Elastic equilibrium volume, Difference between functional residual capacity and elastic equilibrium volume in patients with chronic obstructive pulmonary disease, **415**
Elderly
Contractile properties of the elderly human diaphragm, **Suppl.3.A16**
Increasing incidence of tuberculosis in the young and elderly in Scotland, **140**
Influence on mortality trends of 'false positive' asthma death certification in elderly subjects, **Suppl.3.A22**
Long-term benefits of pulmonary rehabilitation in elderly patients with chronic obstructive pulmonary disease, **Suppl.3.A16**
Respiratory symptoms, smoking and mortality in older men and women: an epidemiological study, **Suppl.3.A16**

Electrostatic charge, Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
ELISA, The role of ELISA in the early diagnosis of *Pseudomonas aeruginosa* infection in cystic fibrosis, **Suppl.3.A49**
Embolisation, Chemodectoma of the trachea, **341**
Emergency care, Improving the emergency care of asthma patients by London ambulance service, **Suppl.3.A29**
Emphysema
Identification of a novel conformation of α_1-antichymotrypsin: an explanation for the inactive species found in lung lavage from patients with chronic bronchitis and emphysema, **Suppl.3.A51**
Matrix metalloproteinases in emphysema, **Suppl.3.A51**
Matrix metalloproteinases expression by by alveolar macrophages in emphysema, **Suppl.3.A51**
Pneumomediastinum secondary to use of a high speed air turbine drill during a dental extraction, **339**; *commentary*, **340**
Empyema
Commentary: pleural empyema and malignancy - another dimension, **107**
Malignant pleural effusion infected with *Salmonella enteritidis*, **104**; *commentary*, **107**
Pleural effusion and toxocariasis, **106**; *commentary*, **107**
End tidal inspiratory activity, Histamine induced bronchoconstriction and end tidal inspiratory activity in man, **1192**
Endobronchial lesions, Whipple's disease presenting with lung involvement, **343**
Endobronchial lysine aspirin, Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects, **64**
Endocrine cells, Endocrine cells in tumour-bearing lungs, **721**
Endoglin, A reduction in functional endoglin leads to pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia, **Suppl.3.A37**
Endometriosis
Bronchoscopic and angiographic findings in tracheobronchial endometriosis, **1060**: *commentary*, **1064**
Pleural fluid accumulation due to intra-abdominal endometriosis: a case report and review of the literature, **1062**: *commentary*, **1064**
Endorphins, Effects of naloxone of upper airway collapsibility in normal sleeping subjects, **851**
Endothelial dysfunction, Peroxynitrite is a vasodilator of rat pulmonary arteries at concentrations that do not cause endothelial dysfunction, **Suppl.3.A35**
Endothelin-1, Endothelin-1 levels in induced sputum from asthmatics, normal subjects and smokers – comparison with plasma and saliva levels, **Suppl.3.A81**
Endothelium
Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension, **89**
Pulmonary hypertension: NO therapy?, **762**
Endotracheal tube, In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system, **75**
Eosinophilia, Pleural effusion and toxocariasis, **106**; *commentary*, **107**
Eosinophils
Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects, **64**
Nedocromil sodium attenuates bronchial epithelial cell-induced eosinophil adhesion and release of sICAM-1 from endothelial cells *in vitro*, **Suppl.3.A39**
Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients, **155**
Epidemiology
Asthma, airways responsiveness and air pollution in two contrasting districts of northern England, **169**
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients, **179**
Epithelial cells
Effect of exposure to silica on human alveolar macrophages in supporting growth activity in type II epithelial cells, **781**
Epithelial cells are a source for macrophage migration inhibitory factor – potential role in acute respiratory distress syndrome, **Suppl.3.A54**
Epithelial lining fluid, Modelling the interaction between ozone and pulmonary epithelial lining fluid antioxidants, **Suppl.3.A52**
Epithelial permeability, Epithelial permeability *in vivo* and *in vitro* and TNFα in non-smokers and smokers, **Suppl.3.A52**
Epstein-Barr virus
Cryptogenic fibrosing alveolitis does not appear associated with Epstein-Barr virus infection, **Suppl.3.A11**
Epstein-Barr virus associated graft failure following heart/lung transplantation, **1160**: *commentary*, **1164**
Erythromycin, Diffuse panbronchiolitis in an Asian immigrant, **1065**
Ethnic groups, Scottish national survey of tuberculosis notifications 1993 with special reference to the prevalence of HIV seropositivity, **78**
Ethnicity, Exercise-induced bronchoconstriction by ethnicity and presence of asthma in British nine year olds, **1134**
EuroCollins solution, Comparison of a modified bicarbonate buffer and EuroCollins solution for hypothermic storage of rat lungs: effect on lung function, **Suppl.3.A69**
European Union, Survey of health monitoring data at European level for asthma, **Suppl.3.A63**
Exercise
Carbon dioxide replacement during exercise in patients with idiopathic hyperventilation, **Suppl.3.A21**
Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease, **48**
Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease, **596**
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease, **689**
Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys, **590**
Exercise-induced asthma and cardiovascular fitness in asthmatic children, **207**
Exercise-induced bronchoconstriction by ethnicity and presence of asthma in British nine year olds, **1134**
Exercise-induced bronchospasm at low temperature in elite runners, **628**
Exercise induced bronchospasm in Ghana: prevalence in urban and rural children, **Suppl.3.A42**
Is ventilatory breakaway in heavy exercise really due to metabolic acidaemia? **Suppl.3.A20**
Exhaled nitric oxide, Exhaled nitric oxide: a new lung function test: *editorial*, **233**
Expiratory flow, Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma, **484**
External irradiation, High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation, **354**
Extracellular matrix, Function at the junction: dynamic interactions between lung cells and extracellular matrix, **956**

^{18}F-Fluorodeoxyglucose, ^{18}F-Fluorodeoxyglucose PET scans in lung cancer, **Suppl 2.16**
Farmer's lung, Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung, **1210**
Fatigue, Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**
Fenoterol
Effects of prior treatment with salmeterol and formoterol on airway and systemic β_2 responses to fenoterol, **585**
Risk of severe life threatening asthma: *editorial*, **1073**
Risk of severe life threatening asthma and β agonist type: an example of confounding by severity, **1093**
Fetal airway smooth muscle cells, Serum dependence of oxygen stimulated DNA synthesis in human fetal airway smooth muscle cells: implications for the pathogenesis of bronchopulmonary dysplasia, **Suppl.3.A15**
Fetal anomalies, Is the risk of fetal anomalies greater in mothers with cystic fibrosis?, **Suppl.3.A50**
Fibreoptic bronchoscopy
Comparison of oximetry and transcutaneous carbon dioxide levels in patients undergoing fibreoptic bronchoscopy, **Suppl.3.A70**
Fibreoptic bronchoscopy for diagnosis of isolated tuberculous mediastinal lymphadenopathy: *letter*, **967**
Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks, **664**

Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope, **248**

Fibrinolysis, The systemic fibrinolytic activity of intra-pleural streptokinase in humans, **Suppl.3.A67**

Fine needle biopsy, Influence of thoracic CT and guided fine needle biopsy on management of solitary pulmonary nodules ≤ 3 cm in diameter, **Suppl.3.A7**

Finger clubbing, Finger clubbing in malignant pleural mesothelioma, **Suppl.3.A68**

Flow cytometry, Flow cytometric analysis of cytokine production in the lymphocytic alveolitis of sarcoidosis, **Suppl.3.A12**

Fluid phase ECP, Reproducibility of induced sputum cell counts and fluid phase ECP, **Suppl.3.A80**

Fluticasone, Systemic effects of high dose inhaled steroids (budesonide beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**

Fluticasone propionate

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**

Adrenal suppression with inhaled fluticasone propionate and triamcinolone acetonide in normal subjects, **Suppl.3.A72**

Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients, **262**

Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care, **1087**

Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhiitics following exposure for six hours to 400ppb nitrogen dioxide, **Suppl.3.A40**

Fluticasone propionate and beclomethasone dipropionate attenuate ozone-induced release of inflammatory cytokines from nasal epithelial cells of atopic rhinitic subjects, **Suppl.3.A39**

Phase III open parallel group study to compare the effects of inhaled fluticasone propionate (500mcg bd) and budesonide (800mcg bd) on bone density measurements over 1 year in stable chronic asthmatics, **Suppl.3.A72**

Steroids in exacerbations of asthma: tablets or inhalers? *editorial*, **1071**

Flutter bag, Treatment of pneumothorax during pregnancy, **338**; *commentary*, **340**

Foods, Assessment of food chemical intolerance in adult asthmatic subjects, **805**

Foradil, Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**

Forced expiratory volume

Comparison of mean daily diurnal variation in peak expiratory flow and FEV_1, **Suppl.3.A43**

Longitudinal effects of change in body mass on measurements of ventilatory capacity, **699**

Predicted lung function for Asians, **Suppl.3.A44**

Rate of decline of forced expiratory volume in one second (FEV_1) predicts mortality from coronary heart disease in men and women, **Suppl.3.A23**

Reversibility to bronchodilators: are forced expiratory manoeuvres the best? **Suppl.3.A46**

Time series analysis of FEV_1 in patients with exacerbations of COPD, **Suppl.3.A65**

Forced vital capacity, Predicted lung function for Asians, **Suppl.3.A44**

Formoterol

Effects of prior treatment with salmeterol and formoterol on airway and systemic β responses to fenoterol, **585**

Evaluation of the β_2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol, **54**

Free radical activity, Free radical activity and antioxidant levels in serum of diabetic and non-diabetic cystic fibrosis patients, **Suppl.3.A59**

Frusemide

Attenuation of propranolol-induced bronchoconstriction by nebulised frusemide, **Suppl.3.A40**

Frusemide and cyclosporin do not inhibit early antigen response in sensitised guinea pig tracheal tubes, **Suppl.3.A40**

Functional antagonism, Functional antagonism: tolerance produced by inhaled β_2 agonists, **1051**

Functional residual capacity, Difference between functional residual capacity and elastic equilibrium volume in patients with chronic obstructive pulmonary disease, **415**

Functional upper airways obstruction, Functional upper airways obstruction: two patients with persistent symptoms, **965**

Fungal atopy, Is Fusarium species a cause of fungal atopy in adult cystic fibrosis? **Suppl.3.A49**

Fungi, Occupational asthma in a coal miner, **867**

Fusarium, Is Fusarium species a cause of fungal atopy in adult cystic fibrosis? **Suppl.3.A49**

FVC test, Assessment of a new transtelephonic portable spirometer, **407**

Galactosidase gene, In vivo transfer of the β-galactosidase gene into malignant mesothelioma cells induces tumour rejection, **Suppl.3.A6**

Gamma-glutamylcysteine synthetase, Transcriptional induction of gamma-glutamylcysteine synthetase by oxidants is associated with AP-1 in human alveolar epithelial cells, **Suppl.3.A52**

Gamma/delta cells, Gamma/delta cells in tissue from patients with sarcoidosis, **1123**

Gas exchange, Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease, **1048**

Gastric intramural pH, Gastric intramural pH in mechanically ventilated patients, **606**

Gastric pressure, Abdominal muscle strength measured by gastric pressure during maximal cough, **Suppl.3.A45**

Gastrin, Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease, **1270**

Gastrostomy feeding, Gastrostomy feeding significantly improves lung function in children with cystic fibrosis, **Suppl.3.A47**

General practice (practitioners)

Audit of an open access lung function laboratory service for general practitioners (1991–1996), **Suppl.3.A45**

COPD guidelines and general practice – use of spirometers, **Suppl.3.A44**

Relationship between hospital admissions for asthma and prescribing in general practice, **Suppl.3.A27**

Treatment of asthma and COPD in a general practice population, **Suppl.3.A27**

Genes

Atopy, airway responsiveness, and genes, **Suppl.2.55**

Divided doses of DNA:liposome complexes produce suboptimal gene expression for a given DNA dose, **Suppl.3.A5**

Human alpha 1-antitrypsin gene transfer with cationic liposomes *in vitro* and *in vivo*, **Suppl.3.A6**

In vitro and ex vivo approaches to determining the mechanisms of liposome-mediated gene transfer, **Suppl.3.A5**

Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-86 BV) via C-Fos/serum responsive element, **150**

Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers, **Suppl.3.A6**

Genetics, Genetic analysis of IgE: *editorial*, **458**

Genotypes, Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis, **315**

Genotypic variants, Genotypic variants of HIV-1 from peripheral blood and lung of AIDS patients, **Suppl.3.A3**

Ghana, Exercise induced bronchospasm in Ghana: prevalence in urban and rural children, **Suppl.3.A42**

Giant pulmonary bulla, Spontaneous regression of a giant pulmonary bulla, **549**: *letter*, **1283**

Glasgow, Clinical features and epidemiology of malignant pleural mesothelioma in Glasgow 1987–92, **Suppl.3.A68**

Glu27 β_2-adrenoceptor polymorphism, The Glu27 β_2-adrenoceptor polymorphism is associated with childhood asthma, **Suppl.3.A15**

Glucocorticosteroids

Glucocorticosteroids and pulmonary sarcoidosis: *editorial*, **229**

Lipocortin 1: glucocorticoids caught in the act?, **1057**

NO or no NO in asthma?, **218**

Glucose, The use of raised random blood glucose alone is unreliable in the diagnosis of cystic fibrosis related diabetes, **Suppl.3.A48**

Glutathione

Mechanisms of cigarette smoke induced increased airspace permeability, **465**

Transcriptional induction of gamma-glutamyl-cysteine synthetase by oxidants is associated with AP-1 in human alveolar epithelial cells, **Suppl.3.A52**

Glutathione peroxidase, Pulmonary effects of short term selenium deficiency, **479**
Gorham's syndrome
Bilateral chylothorax complicating massive osteolysis (Gorham's syndrome), **1277**: *commentary*, **1279**
Gorham's syndrome: a usually fatal cause of pleural effusion treated successfully with radiotherapy, **1275**: *commentary*, **1279**
Graft failure, Epstein-Barr virus associated graft failure following heart/lung transplantation, **1160**: *commentary*, **1164**
Granulocyte-macrophage CSF, Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X, **611**
Granuloma, Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis, **1253**
Growth, Asthma, its treatment and social deprivation – the effect on growth in children, **Suppl.3.A14**
Growth factors, Cultured human airway smooth muscle cells release PGE_2 in response to bradykinin, growth factors and arachidonic acid, **Suppl.3.A38**
Growth hormone, Growth hormone and insulin-like growth factor-1 gene expression in bronchoalveolar lavage cells using RT-PCR, **Suppl.3.A12**

H_1 antihistamine, Effect of loratadine, an H_1 antihistamine, on induced cough in non-asthmatic patients with chronic cough, **810**
***Haemophilus influenzae* endotoxin**, The effect of *Haemophilus influenzae* endotoxin on the expression of transcription factors by cultured human bronchial epithelial cells and the influence of anti-inflammatory agents, **Suppl.3.A3**
Haemoptysis
Bronchoscopic and angiographic findings in tracheobronchial endometriosis, **1060**: *commentary*, **1064**
Chemodectoma of the trachea, **341**
Topical treatment of life threatening haemoptysis from aspergillomas, **253**
Hand held turbine spirometer, Long term performance of a hand held spirometer, **973**
Health care workers
Occupational asthma due to latex in health care workers, **1280**
Occupational asthma in healthcare workers: results from the Shield Surveillance Scheme in the West Midlands, UK, **Suppl.3.A40**
The study of occupational asthma surveillance in hospitals in the West Midlands, UK, **Suppl.3.A41**
Tuberculosis in health care workers in the West Midlands 1992 to 1995, **Suppl.3.A9**
Health perceptions, Health perceptions and treatment adherence in adults with cystic fibrosis, **1233**
Health service utilisation
Accessibility and health service utilisation for asthma in Norfolk, England, **Suppl.3.A29**
Social deprivation, childhood asthma and health service utilisation, **Suppl.3.A29**
Heart failure
Comparison of different levels of nasal continuous positive airway pressure in patients with severe congestive heart failure in sinus rhythm and atrial fibrillation, **Suppl.3.A21**
Coronary ligated rabbit as a model for pulmonary hypertension secondary to heart failure: role of 5-hydroxytryptamine, **Suppl.3.A35**
Diaphragm and quadriceps strength in chronic heart failure, **Suppl.3.A21**
Heart rate variability, The effect of inhaled beta agonists and anticholinergic agents upon heart rate variability, **Suppl.3.A60**
Heart transplantation, Quantitative PCR for the diagnosis of CMV disease in lung and heart transplant, **Suppl.3.A23**
Heart/lung transplantation, Epstein-Barr virus associated graft failure following heart/lung transplantation, **1160**: *commentary*, **1164**
Hepatitis C virus
Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection, **312**
Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis, **315**
Hepatotoxicity
Hepatotoxicity of antituberculosis drugs: *editorial*, **111**: *letters*, **873, 1168**
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study, **132**
Hereditary haemorrhagic telangiectasia, A reduction in functional endoglin leads to pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia, **Suppl.3.A37**
High altitude, Effect of allergen avoidance at high altitude on direct and indirect bronchial hyperresponsiveness and markers of inflammation in children with allergic asthma, **582**
High altitude pulmonary oedema, Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan, **739**
High dose rate endobronchial brachytherapy
High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation, **354**
High dose rate endobronchial brachytherapy for the treatment of lung cancer: current status and indications: *editorial*, **345**
High dose-rate intraluminal radiotherapy, High dose-rate intraluminal radiotherapy for tracheal carcinoma, **Suppl.3.A55**
High resolution computed tomography
Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest, **914**
Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis, **841**
High resolution computed tomographic findings in pulmonary tuberculosis, **397**
Hilar lymphadenopathy, Silicosis presenting as bilateral hilar lymphadenopathy, **1165**
Histamine
Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma, **1185**
Histamine induced bronchoconstriction and end tidal inspiratory activity in man, **1192**
Histiocytosis X, Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X, **611**
Histological confirmation rates, Histological confirmation rates and survival in lung cancer in Yorkshire, **Suppl.3.A56**
HIV
Culture positive tuberculosis in HIV seropositive patients in the UK, 1993–94, **Suppl.3.A9**
Interactions between opportunistic micro-organisms and HIV in the lung: *editorial*, **875**
Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts, **932**
Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia, **446**: *commentary*, **448**
Pulmonary capillary blood volume in patients with probable pulmonary Kaposi's sarcoma, **204**
Pulmonary diseases and HIV infection: *letter*, **228**
Scottish national survey of tuberculosis notifications 1993 with special reference to the prevalence of HIV seropositivity, **78**
HIV-1
Alveolar lymphocytes and macrophages are an important source of HIV-1 in patients with AIDS, **Suppl.3.A3**
Genotypic variants of HIV-1 from peripheral blood and lung of AIDS patients, **Suppl.3.A3**
HLA-DR, Human CD4+ T-cell recognition of influenza A haemagglutinin is precisely defined by HLA-DR, **Suppl.3.A2**
HLA-typing, HLA-typing in patients with sleep apnoea/hypopnoea syndrome, **Suppl.3.A78**
Home care, Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease, **39**
Home nebulisers, Do home nebulisers prevent readmission for asthma, **Suppl.3.A28**
Home oximetry
District general hospital sleep service based on home oximetry, **Suppl.3.A5**
Home oximetry versus full polysomnography in the detection of obstructive sleep apnoea, **Suppl.3.A4**
Home rehabilitation, Pulmonary rehabilitation at home: *editorial*, **117**: *letter*, **1068**
Hong Kong, Long-term trends in tuberculosis: comparison of age-cohort data in Hong Kong and England and Wales, **Suppl.3.A9**
Hospital admissions, One years asthma admissions in Cornwall – still deficiencies in basic care, **Suppl.3.A62**
Hospitalisation, An analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections, **1017**

House dust mite allergen
Cigarette smoke enhances house dust mite allergen (*Der p*1)-induced changes in permeability of human bronchial epithelial cell cultures, **Suppl.3.A51**
House dust mite allergen accumulation on sheepskins, **Suppl.3.A42**
Human papillomavirus, Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, **887**
Human pulmonary artery endothelial cells, Interleukin 1β induces neutrophil adhesion to human pulmonary artery endothelial cells, **Suppl.3.A53**
Human pulmonary artery endothelial monolayers, An *in vitro* model of neutrophil migration across human pulmonary artery endothelial monolayers, **Suppl.3.A53**
Human rhinoviruses, Pre-exposure of a rhinoviral-infected human bronchial epithelial cell line to cytokines affects surface ICAM-1 levels, **Suppl.3.A2**
Humoral control, Humoral control of airway tone: *editorial*, **461**
Hyaline membrane disease, Surfactant replacement therapy, **1137**
1-Hydroxyphenazine, Dysregulation of calcium metabolism in human neutrophils exposed to the *Pseudomonas aeruginosa* pigment 1-hydroxyphenazine, **Suppl.3.A58**
5-Hydroxytryptamine, The coronary ligated rabbit as a model for pulmonary hypertension secondary to heart failure: role of 5-hydroxytryptamine, **Suppl.3.A35**
Hypercapnia, Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease, **677**
Hypercapnic chronic obstructive pulmonary disease, Negative pressure ventilation in acute hypercapnic chronic obstructive pulmonary disease: *editorial*, **1069**
Hypercapnic respiratory failure, Nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure, **Suppl.3.A24**
Hyperoxia
Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients, **853**
Pulmonary effects of short term selenium deficiency, **479**
Hypersensitivity pneumonitis, Hypersensitivity pneumonitis induced by a smut fungus *Ustilago esculenta*, 650: *commentary*, **656**
Hyperventilation, Carbon dioxide replacement during exercise in patients with idiopathic hyperventilation, **Suppl.3.A21**
Hypomagnesaemia, Symptomatic hypomagnesaemia in cystic fibrosis precipitated by treatment of infection, **Suppl.3.A48**
Hypoxaemia
Effect of regression dilution bias on the nocturnal hypoxaemia v blood pressure relationship, **Suppl.3.A79**
Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia, **44**
Hypoxanthine, Pro-oxidant hypoxanthine and xanthine in the plasma of patients with ARDS, **Suppl.3.A53**
Hypoxia
Autonomic dysfunction in patients with nocturnal hypoventilation, **Suppl.3.A11**
Cell signalling in pulmonary vascular cells: do not shoot the messenger!, **864**
Pro-oxidant hypoxanthine and xanthine in the plasma of patients with ARDS, **Suppl.3.A53**
Hypoxic hypercapnic coma, Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency, **1077**

ICAM-1
Nedocromil sodium attenuates bronchial epithelial cell-induced eosinophil adhesion and release of sICAM-1 from endothelial cells *in vitro*, **Suppl.3.A39**
Pre-exposure of a rhinoviral-infected human bronchial epithelial cell line to cytokines affects surface ICAM-1 levels, **Suppl.3.A2**
'ICE' regimen, A phase II study of an intensive modified 'ICE' regimen in patients with good prognosis small cell lung cancer, **Suppl.3.A54**
Ifosfamide, A phase II of cisplatin, ifosfamide and increasing dosage of navelbine in unresectable non-small cell lung cancer, **Suppl.3.A55**
Immigration, Recent increases in tuberculosis notifications in Liverpool: the influence of immigration, **Suppl.3.A33**
Immune cell infiltrates, Immune cell infiltrates and prognosis in primary lung cancer, **Suppl.3.A56**
Immunoglobulin E
Genetic analysis of IgE: *editorial*, **458**
Relationship of serum IgE concentration to level and rate of decline of pulmonary function: the Normative Aging Study, **787**
Immunoglobulin G, Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal *Pseudomonas aeruginosa* beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry, **733**
Immunopathology, Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma, **993**
Immunoscintigraphy, Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer, **359**
Immunosuppression, Aspergillosis in immunocompromised paediatric patients: associations with building hygiene, design, and indoor air, **256**
Incremental threshold loading, Measurement of inspiratory muscle performance using incremental threshold loading: a normal range, **Suppl.3.A46**
Indian subcontinent
Differences in asthma management between white European and Indian subcontinent groups, **Suppl.3.A30**
Do white European and Indian-subcontinent asthmatics differ in their quality of life? **Suppl.3.A30**
Inducible nitric oxide synthase, NO or no NO in asthma? **218**
Infants
Bronchiolitis and asthma in infancy and early childhood, **Suppl.2.60**
Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Premorbid infant respiratory function and wheezing in the first year of life: a population based study in London, **Suppl.3.A15**
Tidal breathing parameters in the first week of life and subsequent cough and wheeze, **815**
Inflammatory activity, Inflammatory activity in sputum chronic bronchitis and bronchiectasis during clinical stability, **Suppl.3.A81**
Inflammatory cells, Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? **647**
Inflammatory infiltrate, Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids, **496**
Inflammatory markers
Blood and sputum sol inflammatory markers, **Suppl.3.A80**
Interrelationships of inflammatory markers in bronchial disease, **Suppl.3.A81**
Inflammatory mediators, Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease, **819**
Influenza A haemagglutinin, Human CD4+ T-cell recognition of influenza A haemagglutinin is precisely defined by HLA-DR, **Suppl.3.A2**
Influenza vaccination
Effect of influenza vaccination on airway responsiveness in patients with stable asthma, **Suppl.3.A2**
Simultaneous administration of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with chronic respiratory disease, **Suppl.3.A14**
Inhalation
Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges, **472**
Inhalational drug delivery from seven different spacer devices, **835**
Inhalation devices, Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Inhaled beclomethasone, Measuring systemic effects of inhaled beclomethasone: *letter*, **968**
Inhaled bronchodilators, Prevalence and treatment of chronic airways obstruction in adults over the age of 45, **164**
Inhaled corticosteroids
Acute asthma during pregnancy, **411**
Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children, **941**
Exercise-induced asthma and cardiovascular fitness in asthmatic children, **207**
Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma, **993**

Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**

Inhaled morphine, Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease, **596**

Inhalers

Adrenal suppression with inhaled fluticasone propionate and triamcinolone acetonide in normal subjects, **Suppl.3.A72**

Comparison of the systemic effects of salbutamol and terbutaline when inhaled from a metered dose inhaler or as a dry powder in healthy volunteers, **Suppl.3.A72**

Effectiveness of four different inhalers in COPD: *letter*, **454**

Improved delivery beclomethasone dipropionate 400 mcg daily achieves equivalent asthma symptom control as 800 mcg BDP from conventional CFC inhalers, **Suppl.3.A73**

Improving the delivery efficiency of dry powder inhalers by adding fine carrier particles to powder formulations, **Suppl.3.A74**

In vitro deposition of lactose carrier from dry powder inhaler formulations, **Suppl.3.A74**

Inhaler technique among adult patients prescribed bronchodilators, **Suppl.3.A71**

Inhaler use in chronic obstructive pulmonary disease, **Suppl.3.A66**

Moderately severe asthma controlled at a significantly lower dose from a new CFC-free steroid inhaler, **Suppl.3.A73**

Peak inspiratory flow through Turbuhaler in chronic obstructive pulmonary disease, **Suppl.3.A75**

Pharmacokinetics of beclomethasone dipropionate from CFC-free ultrafine aerosol and conventional CFC inhalers in asthmatics, **Suppl.3.A74**

Phase III open parallel group study to compare the effects of inhaled fluticasone proprionate (500mcg bd) and budesonide (800mcg bd) on bone density measurements over 1 year in stable chronic asthmatics, **Suppl.3.A72**

Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**

Turbohaler: objective assessment of patient generated flow, **Suppl.3.A75**

Inorganic mineral particles, Analysis and interpretation of inorganic mineral particles in "lung" tissues, **327**

Input impedance measurements, Effect of salbutamol on input impedance measurements in laryngectomized subjects during tidal breathing, **Suppl.3.A46**

Inspiratory muscle performance, Measurement of inspiratory muscle performance using incremental threshold loading: a normal range, **Suppl.3.A46**

Inspiratory pressure support, Could inspiratory pressure support be a useful adjunct in pulmonary rehabilitation? **Suppl.3.A26**

Insulin-like growth factor, Elevated expression of insulin-like growth factor binding protein-3 in bronchoalveolar lavage fluid of patients with pulmonary fibrosis, **Suppl.3.A12**

Insulin-like growth factor-1, Growth hormone and insulin-like growth factor-1 gene expression in bronchoalveolar lavage cells using RT-PCR, **Suppl.3.A12**

Integrin, Function at the junction: dynamic interactions between lung cells and extracellular matrix, **956**

Intensive care unit, Diaphragm strength measured using magnetic phrenic nerve stimulation in the intensive care unit, **Suppl.3.A45**

Intercellular adhesion molecule-1

Nedocromil sodium attenuates bronchial epithelial cell-induced eosinophil adhesion and release of sICAM-1 from endothelial cells *in vitro*, **Suppl.3.A.39**

Pre-exposure of a rhinoviral-infected human bronchial epithelial cell line to cytokines affects surface ICAM-1 levels, **Suppl.3.A2**

Interleukin-1β

Interleukin 1β induces neutrophil adhesion to human pulmonary artery endothelial cells, **Suppl.3.A53**

Interleukin-1β causes induction of cyclooxygenase-2 in cultured human airway smooth muscle cells, **Suppl.3.A39**

Interleukin-6, Circulating immunoreactive interleukin-6 in cystic fibrosis, **Suppl.3.A59**

Interleukin 10, Interleukin 10 (IL-10) regulation of tumour necrosis factor α (TNF-α) from human alveolar macrophages and peripheral blood monocytes, **143**

Interleukins, Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-86 BV) via C-Fos/serum responsive element, **150**

Intermittent negative pressure ventilation, Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency, **1077**

Intermittent positive pressure ventilation, Long term effects of non-invasive intermittent positive pressure ventilation on chronic ventilatory failure due to COPD, **Suppl.3.A10**

Interstitial laser photocoagulation, Effects of interstitial laser photocoagulation on normal lung parenchyma, **Suppl.3.A8**

Interstitial lung disease

Accuracy of mortality data for interstitial lung diseases in New Mexico, USA, **717**

Epidemic outbreak of interstitial lung disease in aerographics textile workers – the "Ardystil syndrome": a first year follow up, **94**

Mortality rates from cryptogenic fibrosing alveolitis in seven countries, **711**

Pulmonary infiltration after exposure to home renovation dust: histopathology and microanalysis, **654**: *commentary*, **656**

Interstitial lung fibrosis, Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis, **841**

Interstitial pneumonia, Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation, **1158**: commentary, **1164**

Intra-abdominal endometriosis, Pleural fluid accumulation due to intra-abdominal endometriosis: a case report and review of the literature, **1062**: *commentary*, **1064**

Intracellular organisms, Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia, **378**

Intracellular oxidative metabolism, Circulating neutrophil β_2-integrin expression and intracellular oxidative metabolism in community acquired pneumonia, **Suppl.3.A3**

Intraluminal radiotherapy, High dose-rate intraluminal radiotherapy for tracheal carcinoma, **Suppl.3.A55**

Intrinsic activity, Evaluation of the β_2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol, **54**

Ipratropium bromide aerosol

Dose response study of ipratropium bromide aerosol on maximum exercise performance in stable patients with chronic obstructive pulmonary disease, **48**

Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**

Irritants, Respiratory irritants encountered at work, **541**

IS6110, Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis, **320**

Isoprenaline, Potentiation of the bronchoprotective effects of vasoactive intestinal peptide, isoprenaline, and theophylline against histamine challenge in anaesthetised guinea pigs by adrenomedullin, **1199**

8-Isoprostaglandin (PG)F2α, 8-iso PGF2α constricts and dilates rat pulmonary artery, **Suppl.3.A36**

8-Isoprostanes, Differential release of 8-isoprostanes and prostaglandin E_2 by human pulmonary artery, **Suppl.3.A36**

Israel, Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients, **179**

K^+ channels, Scorpion venoms: taking the sting out of lung disease, **546**

Kaposi's sarcoma, Pulmonary capillary blood volume in patients with probable pulmonary Kaposi's sarcoma, **204**

L-arginine, Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease, **516**

L form, Growth of acid fast L forms from the blood of patients with sarcoidosis, **530**

Lactose, The in vitro deposition of lactose carrier from dry powder inhaler formulations, **Suppl.3.A74**

Langerhans' cells, Role of granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenesis of adult pulmonary histiocytosis X, **611**

Large volume spacer, Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**

Laryngectomized subjects

Cough sensitivity to nebulised capsaicin and low chloride solution in laryngectomees, **Suppl.3.A37**

Effect of salbutamol on input impedance measurements in laryngectomized subjects during tidal breathing, **Suppl.3.A46**

Larynx, Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma, **869**
Latex
Occupational asthma due to latex in health care workers, **1280**
Occupational asthma due to latex in a hospital administrative employee, **452**
Leucocytes, Selectins and their counter receptors: a bitter sweet attraction, **1155**
Leukotriene B_4
Effect of a leukotriene B_4 receptor antagonist, LY293111, on allergen induced responses in asthma, **1178**
Leukotriene B_4 and asthma: *editorial*, **1171**
Sputum leukotriene B_4 during infective exacerbations of chronic bronchitis, **Suppl.3.A81**
Leukotriene C_4, Priming effect of platelet activating factor on leukotriene C_4 from stimulated eosinophils of asthmatic patients, **155**
Leukotrienes, Eicosanoid mediator expression in mononuclear and polymorphonuclear cells in normal subjects and patients with atopic asthma and cystic fibrosis, **1223**
Lipid formulation, Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers, **Suppl.3.A6**
Lipocortin 1, Lipocortin 1: glucocorticoids caught in the act?, **1057**
Lipoid pneumonia, Severe lipoid pneumonia following attempted suicide by mineral oil immersion, **652**: *commentary*, **656**
Liposomes
Human alpha 1-antitrypsin gene transfer with cationic liposomes *in vitro* and *in vivo*, **Suppl.3.A6**
In vitro and ex vivo approaches to determining the mechanisms of liposome-mediated gene transfer, **Suppl.3.A5**
Safety of aerosol administration of escalating doses of a cationic lipid (lipid 67) formulation to the lungs of normal volunteers, **Suppl.3.A6**
Liver function tests, Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study, **132**
Loaded breathing, Reliability of a commercially available threshold loading device in healthy subjects and in patients with chronic obstructive pulmonary disease, **601**
Lobectomy, Expandable metal stents for non-malignant bronchial obstruction, **963**
Local anaesthesia, Local anaesthetic infiltration prior to arterial puncture: survey of current practice and a randomised double blind placebo controlled trial, **Suppl.3.A67**
Long-term oxygen therapy
Evaluation of domiciliary long-term oxygen therapy with oxygen concentrators, **Suppl.3.A65**
Patient acceptability of a combined oxygen concentrator and nebuliser unit, **Suppl.3.A66**
Long term reproducibility, Long term performance of a hand held spirometer, **973**
Loperamide, Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis mouse, **1229**
Loratadine
Effect of loratadine, an H_1 antihistamine, on induced cough in non-asthmatic patients with chronic cough, **810**
Effect of loratadine on nitrogen dioxide-induced release of proinflammatory mediators from cultured human bronchial epithelial cells, **Suppl.3.A39**
Low chloride solution, Cough sensitivity to nebulised capsaicin and low chloride solution in laryngectomees, **Suppl.3.A37**
Lower airway potential difference measurements, Lower airway potential difference measurements in non-CF and CF subjects, **Suppl.3.A6**
Lower respiratory tract illness
Acute lower respiratory tract illness in general practice: a study of the views of 787 patients and their influence on antibiotic prescribing, **Suppl.3.A13**
Analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections, **1017**
Influence of antibiotics and other factors on reconsultation for acute lower respiratory tract illness in primary care, **Suppl.3.A13**
Lung, Interactions between opportunistic micro-organisms and HIV in the lung: *editorial*, **875**
Lung adenocarcinoma, Rising incidence of primary lung adenocarcinoma in north east Scotland, **Suppl.3.A56**
Lung bioavailability, Lung bioavailability of generic and innovator salbutamol metered dose inhalers, **325**: *letter*, **658**
Lung cancer (carcinoma)
Age and the treatment of lung cancer, **564**
Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer, **359**
Asbestos exposure, asbestosis, and asbestos-attributable lung cancer, **Suppl.1.9**
Carcinoma of the lung: warts and all: *editorial*, **878**
Cryptogenic fibrosing alveolitis and lung cancer – is there an association? **Suppl.3.A11**
Delays in the diagnosis and surgical treatment of lung cancer, **903**
Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours, **526**
Endocrine cells in tumour-bearing lungs, **721**
Exposure of crystalline silica and risk of lung cancer: the epidemiological evidence, **97**: *letter*, **772**
^{18}F-Fluorodeoxyglucose PET scans in lung cancer, **Suppl.2.16**
Factors affecting long term survival following resection for lung cancer, **1266**
Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease, **1270**
High dose rate brachytherapy for the local control of endobronchial carcinoma following external irradiation, **354**
High dose rate endobronchial brachytherapy for the treatment of lung cancer: current status and indications: *editorial*, **345**
Histological confirmation rates and survival in lung cancer in Yorkshire, **Suppl.3.A56**
Immune cell infiltrates and prognosis in primary lung cancer, **Suppl.3.A56**
In-patients with lung cancer: a study of the extent of non-referral to specialist care, **Suppl.3.A7**
Lung cancer: local review of services, **Suppl.3.A57**
Lung cancer service provision in a large teaching hospital, **Suppl.3.A57**
Management of lung cancer: *editorial*, **557**
Management of lung cancer in South East Scotland, **569**
Named nurse programme for the care of patients with lung cancer, **Suppl.3.A57**
Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, **887**
Quality of life in patients with lung cancer: an important prognostic factor, **Suppl.3.A8**
Quality of life in patients with lung cancer: does the treatment matter? **Suppl.3.A56**
Reduced beta adrenoceptor density in vivo in human lung tumours: a preliminary study with positron emission tomography, **727**
Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement, **846**
Transtracheal aspiration using rigid bronchoscopy and a rigid needle for investigating mediastinal masses, **197**
Waiting times in lung cancer: what is achievable by a multidisciplinary team? **Suppl.3.A7**
Lung disease
Function at the junction: dynamic interactions between lung cells and extracellular matrix, **956**
Lung disease induced by drug addiction: *letter*, **556**
Lung fibroblasts, Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-86 BV) via C-Fos/serum responsive element, **150**
Lung function
Calibrating the calibrators: *editorial*, **969**
Effect of outdoor temperature on daily lung function and exacerbations in patients with COPD, **Suppl.3.A19**
Effect of regular terbutaline on the airway response to inhaled budesonide, **989**
Effects of cigarette smoking and duration of work on the lung function of coal miners, **Suppl.3.A43**
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease, **689**
Exercise-induced bronchospasm at low temperature in elite runners, **628**
Gastrostomy feeding significantly improves lung function in children with cystic fibrosis, **Suppl.3.A47**
Longitudinal effects of change in body mass on measurements of ventilatory capacity, **699**
Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population, **277**

Lung function is generally preserved following peripheral blood stem cell transplant, **Suppl.3.A47**
Predicted lung function for Asians, **Suppl.3.A44**
Lung function laboratory service, Audit of an open access lung function laboratory service for general practitioners (1991–1996), **Suppl.3.A45**
Lung function tests
Actual/best function as a predictor in the long term outcome of asthma, **Suppl.3.A44**
Diagnosis of occupational asthma from serial measurements of lung function at and away from work, **857**
Exhaled nitric oxide: a new lung function test: *editorial*, **233**
Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study, **503**
Re-audit of pulmonary function laboratories, **Suppl.3.A69**
Review of the impact pulmonary function testing has in a large teaching hospital in Birmingham, **Suppl.3.A69**
Severity of impairment in lung function tests – comparison of standardised residuals with percent predicted, **Suppl.3.A43**
Lung immunology, Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung, **1210**
Lung inflammation, Selectins and their counter receptors: a bitter sweet attraction, **1155**
Lung injury, Acute lung injury following lung resection: is one lung anaesthesia to blame? *editorial*, **114**
Lung parenchyma, Effects of interstitial laser photocoagulation on normal lung parenchyma, **Suppl.3.A8**
Lung scan abnormalities, Regional ventilation and perfusion lung scan abnormalities in atopic asthmatics following allergen challenge: comparison with airway function and gas exchange, **Suppl.3.A46**
Lung scintigraphy, Role of spiral volumetric computed tomographic scanning in the assessment of patients with clinical suspicion of pulmonary embolism and an abnormal ventilation/perfusion lung scan, **23**
Lung sounds, Use of tracheal auscultation for the assessment of bronchial responsiveness in asthmatic children, **317**
Lung storage, Comparison of a modified bicarbonate buffer and EuroCollins solution for hypothermic storage of rat lungs: effect on lung function, **Suppl.3.A69**
Lung tolerance, Pulmonary effects of short term selenium deficiency, **479**
Lung transplantation
Comparison of a modified bicarbonate buffer and EuroCollins solution for hypothermic storage of rat lungs: effect on lung function, **Suppl.3.A69**
Partial resolution of acute interstitial pneumonia in native lung after single lung transplantation, **1158**: *commentary*, **1164**
Pregnancy following a single lung transplantation, **1162**: *commentary*, **1164**
Quantitative PCR for the diagnosis of CMV disease in lung and heart transplant, **Suppl.3.A23**
Radiolabelled neutrophil scans following pulmonary transplantation, **Suppl.3.A23**
Referral for lung transplantation: experience of a Birmingham Adult Cystic Fibrosis Centre between 1987 and 1994, **302**: *letters*, **873**, **1068**
Results of pulmonary transplantation in patients with cystic fibrosis colonised by multiply resistant pseudomonads, **Suppl.3.A23**
Lung tumours
Endocrine cells in tumour-bearing lungs, **721**
Reduced beta adrenoceptor density in vivo in human lung tumours: a preliminary study with positron emission tomography, **727**
Lung volume, Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**
Lung volume reduction surgery, Lung volume reduction surgery in chronic obstructive pulmonary disease, **Suppl.2.29**
LY293111, Effect of a leukotriene B_4 receptor antagonist, LY293111, on allergen induced responses in asthma, **1178**
Lymph node tuberculosis, Management of lymph node TB in England and Wales 1993, **Suppl.3.A31**
Lymphangiectasis
Generalised lymphangiectasia: pulmonary presentation in an adult, **767**
Lymphangiomatosis presenting with bronchial cast formation, **765**
Lymphangioleiomyomatosis, Lymphangioleiomyomatosis: a UK survey, **Suppl.3.A66**
Lymphangiomatosis, Lymphangiomatosis presenting with bronchial cast formation, **765**
Lymphangitis carcinomatosa, Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma, **552**
Lymphocytic alveolitis, Flow cytometric analysis of cytokine production in the lymphocytic alveolitis of sarcoidosis, **Suppl.3.A12**
Lymphocytopenia, *Pneumocystis carinii* in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia, **446**: *commentary*, **448**

MacLeod's syndrome, Adenoid cystic carcinoma of the left main bronchus mimicking MacLeod's syndrome, **451**
Macrophage, Inhibition of the alveolar macrophage oxidative burst by a diffusible component from the surface of the spores of the fungus *Aspergillus fumigatus*, **389**
Magnetic phrenic nerve stimulation, Diaphragm strength measured using magnetic phrenic nerve stimulation in the intensive care unit, **Suppl.3.A45**
Magnetic stimulation, Clinical assessment of diaphragm strength by cervical magnetic stimulation of the phrenic nerves, **1239**
Malignancy
Malignant pleural effusion infected with Salmonella enteritidis, **104**; *commentary*, **107**
Pleural empyema and malignancy – another dimension, *commentary*, **107**
Malignant melanoma
Primary malignant melanoma of the bronchus, **223**; *commentary*, **226**
Yet more to see down the bronchial tree?, *commentary*, **226**
Manganese superoxide dismutase, Manganese superoxide dismutase mRNA expression is decreased in LPS-stimulated alveolar macrophages from cigarette smokers, **Suppl.3.A52**
Massive osteolysis, Bilateral chylothorax complicating massive osteolysis (Gorham's syndrome), **1277**: *commentary*, **1279**
Mast cells, Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects, **64**
Matrix metalloproteinases
Effect of *Mycobacterium tuberculosis* and its components on macrophages and the release of matrix metalloproteinases, **306**
Matrix metalloproteinases in emphysema, **Suppl.3.A51**
Matrix metalloproteinases expression by alveolar macrophages in emphysema, **Suppl.3.A51**
Maximum relaxation rate, Effect of maximum ventilation on abdominal muscle relaxation rate, **510**
Mechanical ventilation
Gastric intramural pH in mechanically ventilated patients, **606**
Nosocomial pneumonia during mechanical ventilation: *letter*, **771**
Techniques in mechanical ventilation: principles and practice, **756**
Mediastinal lymphadenopathy, Intrathoracic tuberculous lymphadenopathy: clinical and bronchoscopic features in 17 adults without parenchymal lesions, **87**: *letter*, **967**
Mediastinal masses, Transtracheal aspiration using rigid bronchoscopy and a rigid needle for investigating mediastinal masses, **197**
Medical Research Council, The Medical Research Council Breathlessness Score is useful in selecting COPD patients for pulmonary rehabilitation, **Suppl.3.A24**
Mesothelioma
Clinical features and epidemiology of malignant pleural mesothelioma in Glasgow 1987–92, **Suppl.3.A68**
Finger clubbing in malignant pleural mesothelioma, **Suppl.3.A68**
Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma, **552**
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural meosthelioma tissue, **1074**
Mesothelioma cells, In vivo transfer of the β-galactosidase gene into malignant mesothelioma cells induces tumour rejection, **Suppl.3.A6**
Meta-analysis, Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks, **364**: *letter*, **1283**
Metabisulphite, Effect of allergen challenge on airway responsiveness to histamine and sodium metabisulphite in mild asthma, **1185**

Metabolic acidaemia, Is ventilatory breakaway in heavy exercise really due to metabolic acidaemia? **Suppl.3.A20**
Metalloproteinases, Effect of *Mycobacterium tuberculosis* and its components on macrophages and the release of matrix metalloproteinases, **306**
Metered dose inhaler
Comparison of pMDI plus Nebuhaler and Turbohaler in asthmatic patients with dysphonia, **Suppl.3.A74**
Lung bioavailability of generic and innovator salbutamol metered dose inhalers, **325**: *letter*, **658**
Non-CFC salbutamol metered dose inhaler performance with a spacer device, **Suppl.3.A75**
Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**
Methacholine, Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate, **793**
Methotrexate, Experience with long-term methotrexate in steroid-dependent asthma over six years, **Suppl.3.A61**
Methylprednisolone, Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**
Middle East, Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome, **193**
Migration inhibitory factor, Epithelial cells are a source for macrophage migration inhibitory factor – potential role in acute respiratory distress syndrome, **Suppl.3.A54**
Mild lung disease, A mild variant of cystic fibrosis, **Suppl.2.51**
Mineral oil immersion, Severe lipoid pneumonia following attempted suicide by mineral oil immersion, **652**: *commentary*, **656**
Mineral particles, Analysis and interpretation of inorganic mineral particles in "lung" tissues, **327**
Mini-Wright peak expiratory flow meter, Potential effects of correction of inaccuracies of the mini-Wright peak expiratory flow meter on the use of an asthma self-management plan, **403**
Monnal D, Quality of sleep during NIPPV: comparison between the Monnal D and the Papworth ventilator, **Suppl.3.A79**
Morphine, Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease, **596**
Mortality
Accuracy of mortality data for interstitial lung diseases in New Mexico, USA, **717**
Community acquired pneumonia: aetiology and usefulness of severity criteria on admission, **1010**
Influence on mortality trends of 'false positive' asthma death certification in elderly subjects, **Suppl.3.A22**
Mortality rates from cryptogenic fibrosing alveolitis in seven countries, **711**
Predicting death from pneumonia: *editorial*, **970**
Rate of decline of forced expiratory volume in one second (FEV_1) predicts mortality from coronary heart disease in men and women, **Suppl.3.A23**
Respiratory symptoms, smoking and mortality in older men and women: an epidemiological study, **Suppl.3.A16**
Motor neurone disease, The effect of ventilatory intervention in acute respiratory failure in motor neurone disease, **Suppl.3.A10**
Mucosa, Effect of prostaglandin E_2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa, **919**
Multidisciplinary team, Waiting times in lung cancer: what is achievable by a multidisciplinary team? **Suppl.3.A7**
Multidrug resistance, Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours, **526**
Multidrug resistant tuberculosis, Rapid detection of MDR-TB in clinical samples, **Suppl.3.A32**
Multiple actuations
Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, **981**
Multiply resistant pseudomonads, Results of pulmonary transplantation in patients with cystic fibrosis colonised by multiply resistant pseudomonads, **Suppl.3.A23**
Multipuncture method, Administration of the BCG vaccination using the multipuncture method in schoolchildren – a comparison with the intradermal method, **Suppl.3.A9**
Myasthenia gravis
Myasthenia gravis presenting with stridor, **108**
Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome, **193**
Mycobacteria
Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis, **137**
Growth of acid fast L forms from the blood of patients with sarcoidosis, **530**
Mycobacterium avium, Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts, **932**
Mycobacterium kansasii
Pulmonary *Mycobacterium kansasii* infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis, **1248**
Pulmonary *Mycobacterium kansasii* infection: comparison of radiological appearances with pulmonary tuberculosis, **1243**
Mycobacterium tuberculosis
Comparison of IS6110-RFLP and spoligotyping for the ability to type strains of *M. tuberculosis*, **Suppl.3.A33**
DNA fingerprinting of *Mycobacterium tuberculosis*: a tool for prevention and control, **Suppl.3.A34**
Epidemiology and molecular ecology of *Mycobacterium tuberculosis* from clinical sources: DNA fingerprinting of *M. tuberculosis* isolates from clinical specimens, **Suppl.3.A33**
Pulmonary *Mycobacterium kansasii* infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis, **1248**
Pulmonary *Mycobacterium kansasii* infection: comparison of radiological appearances with pulmonary tuberculosis, **1243**

Naloxone, Effects of naloxone of upper airway collapsibility in normal sleeping subjects, **851**
Named nurse programme, A named nurse programme for the care of patients with lung cancer, **Suppl.3.A57**
Nasal continuous positive airway pressure
Automatic nasal continuous positive airway pressure titration in the laboratory. Patient outcomes, **Suppl.3.A77**
Comparison of different levels of nasal continuous positive airway pressure in patients with severe congestive heart failure in sinus rhythm and atrial fibrillation, **Suppl.3.A21**
Quality of life before and after nasal continuous positive airway pressure treatment for obstructive sleep apnoea, **Suppl.3.A4**
Response of bed-partners and patients to nasal continuous positive airway pressure for obstructive sleep apnoea, **Suppl.3.A78**
Nasal epithelial cells, Fluticasone propionate and beclomethasone dipropionate attenuate ozone-induced release of inflammatory cytokines from nasal epithelial cells of atopic rhinitic subjects, **Suppl.3.A39**
Nasal intermittent positive pressure ventilation
Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease, **1048**
Dips in overnight arterial saturation during NIPPV: relationships with sleep stages and ventilators, **Suppl.3.A11**
Nasal intermittent positive pressure ventilation in patients with cystic fibrosis and hypercapnic respiratory failure, **Suppl.3.A24**
Patterns of abnormality on overnight oximetry before and during NIPPV, **Suppl.3.A10**
Quality of sleep during NIPPV: comparison between the Monnal D and the Papworth ventilator, **Suppl.3.A79**
Randomised crossover study of inspiratory positive airway pressure on gas exchange and dyspnoea during nasal ventilation in stable COPD, **Suppl.3.A10**
Natriuretic peptides, A role for natriuretic peptides in the diagnosis of pulmonary thromboembolism, **Suppl.3.A36**
Navelbine
Navelbine in the treatment of non-small cell lung cancer, **Suppl.3.A55**
Phase II of cisplatin, ifosfamide and increasing dosage of navelbine in unresectable non-small cell lung cancer, **Suppl.3.A55**
Nebuhaler
Comparison of pMDI plus Nebuhaler and Turbohaler in asthmatic patients with dysphonia, **Suppl.3.A74**
Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**
Systemic effects of high dose inhaled steroids (budesonide,

beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**

Nebulised acetylcysteine, Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy, **429**

Nebulised antibiotics, Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks, **364**: *letter*, **1283**

Nebulised drug, Physiotherapy and nebulised drug use in a Birmingham adult cystic fibrosis unit: patient practice, knowledge and adherence, **Suppl.3.A48**

Nebulisers
- Compliance in an assessment programme for domiciliary nebulised bronchodilators in patients with chronic obstructive airways disease, **Suppl.3.A28**
- Do home nebulisers prevent readmission for asthma, **Suppl.3.A28**
- Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**

Nedocromil sodium, Nedocromil sodium attenuates bronchial epithelial cell-induced eosinophil adhesion and release of sICAM-1 from endothelial cells *in vitro*, **Suppl.3.A39**

Negative pressure ventilation
- Intermittent negative pressure ventilation in the treatment of hypoxic hypercapnic coma in chronic respiratory insufficiency, **1077**
- Negative pressure ventilation in acute hypercapnic chronic obstructive pulmonary disease: *editorial*, **1069**

Neonatal respiratory distress syndrome
- Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome, **907**
- Steroids, surfactant and lung disease: *editorial*, **880**

Neopterin, Urinary neopterin excretion as a marker of activity in sarcoidosis, **Suppl.3.A70**

The Netherlands, Cost of care of patients with cystic fibrosis in The Netherlands in 1990–1, **298**

Neuraminidase, *Pseudomonas aeruginosa* adherence to cystic fibrosis respiratory epithelium is reduced by anti-asialo GM1 antibody and neuraminidase inhibition, **Suppl.3.A57**

Neurogenic inflammation, Angiotensin converting enzyme inhibitor-induced cough and substance P, **199**

Neurological complications, Neurological complications of severe illness and prolonged mechanical ventilation, **Suppl.2.40**

Neurone-specific enolase, Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis, **92**

Neutral endopeptidase inhibitor, Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide, **71**

Neutrophil adhesion, Interleukin 1β induces neutrophil adhesion to human pulmonary artery endothelial cells, **Suppl.3.A53**

Neutrophil β_2-integrin expression, Circulating neutrophil β_2-integrin expression and intracellular oxidative metabolism in community acquired pneumonia, **Suppl.3.A3**

Neutrophil elastase
- Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis, **619**
- Secretory leukoprotease inhibitor: partnering α_1-proteinase inhibitor to combat pulmonary inflammation, **1273**

Neutrophil IL-8 receptors, Cross-desensitisation of neutrophil IL-8 receptors involves differential receptor subtype regulation, **Suppl.3.A54**

Neutrophil migration, An *in vitro* model of neutrophil migration across human pulmonary artery endothelial monolayers, **Suppl.3.A53**

Neutrophils
- Airways obstruction, chronic expectoration, and rapid decline of FEV_1 in smokers are associated with increased levels of sputum neutrophils, **267**
- Dysregulation of calcium metabolism in human neutrophils exposed to the *Pseudomonas aeruginosa* pigment 1-hydroxyphenazine, **Suppl.3.A58**
- Effect of a leukotriene B_4 receptor antagonist, LY293111, on allergen induced responses in asthma, **1178**
- Mechanisms of cigarette smoke induced increased airspace permeability, **465**
- Neutrophil responsiveness in cystic fibrosis patients is affected by clinical state, **Suppl.3.A58**
- Protease content of circulating neutrophils from patients with cystic fibrosis, **Suppl.3.A58**
- Radiolabelled neutrophil scans following pulmonary transplantation, **Suppl.3.A23**
- Responsiveness of circulating neutrophils from acutely infected and stable cystic fibrosis patients to stimulation, **Suppl.3.A58**
- Short term effect of nebulised human recombinant DNAse on neutrophil inflammatory products in cystic fibrosis, **Suppl.3.A59**

Never-smoking adults, Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population, **277**

NF-kappa B, NO or no NO in asthma?, **218**

Night time respiratory recording, Comparison of partially attended night time respiratory recordings and full polysomnography in patients with suspected sleep apnoea/hypopnoea syndrome, **1043**

Night tracheal sound monitoring, Evaluation of nocturnal bronchoconstriction by all night tracheal sound monitoring, **694**

Nitric oxide
- Exhaled nitric oxide: a new lung function test: *editorial*, **233**
- Exhaled nitric oxide is normal in sarcoidosis patients with active alveolitis, **Suppl.3.A18**
- Exhaled nitric oxide is not elevated in patients with cystic fibrosis or bronchiectasis compared to normals, **Suppl.3.A19**
- Influence of breathhold on peak and plateau concentrations of nitric oxide in the exhaled air of adults, **Suppl.3.A17**
- Inhaled nitric oxide worsens gas exchange in pulmonary fibrosis associated pulmonary hypertension, **Suppl.3.A18**
- Measurement of lower respiratory tract nitric oxide: validity of using values at 75% of exhaled volume, **Suppl.3.A17**
- Nitric oxide in exhaled air of cigarette smokers, **Suppl.3.A18**
- NO or no NO in asthma? **218**
- Non-invasive assessment of response to inhaled nitric oxide in normal subjects, **Suppl.3.A18**
- Pulmonary hypertension: NO therapy? **762**
- Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension, **855**

Nitrogen dioxide
- Effect of fluticasone propionate aqueous nasal spray on allergen-induced inflammatory changes in the nasal airways of allergic rhiitics following exposure for six hours to 400ppb nitrogen dioxide, **Suppl.3.A40**
- Effect of loratadine on nitrogen dioxide-induced release of pro-inflammatory mediators from cultured human bronchial epithelial cells, **Suppl.3.A39**

Nocturnal asthma, Evaluation of nocturnal bronchoconstriction by all night tracheal sound monitoring, **694**

Nocturnal hypoventilation (hypoxia), Autonomic dysfunction in patients with nocturnal hypoventilation, **Suppl.3.A11**

Nocturnal hypoxaemia, The effect of regression dilution bias on the nocturnal hypoxaemia v blood pressure relationship, **Suppl.3.A79**

Non-Hodgkin's lymphoma
- Co-existing conjunctival non-Hodgkin's lymphoma and pulmonary sarcoidosis, **444**: *commentary*, **448**
- Pleural non-Hodgkin's lymphoma arising in a patient with a chronic pyothorax, **103**; *commentary*, **107**

Non-invasive positive pressure ventilation
- Criteria for non-invasive ventilation in chronic obstructive pulmonary disease. Who is eligible? **Suppl.3.A20**
- Domiciliary ventilation in chronic obstructive pulmonary disease: where are we? *editorial*, **455**
- Long term effects of non-invasive intermittent positive pressure ventilation on chronic ventilatory failure due to COPD, **Suppl.3.A10**

Non-invasive ventilation, Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease, **Suppl.2.35**

Non-small cell lung cancer
- Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes: *editorial*, **231**
- ^{18}F-Fluorodeoxyglucose PET scans in lung cancer, **Suppl.2.16**
- Navelbine in the treatment of non-small cell lung cancer, **Suppl.3.A55**
- New prognostic factors in resectable non-small cell lung cancer, **638**
- Phase II of cisplatin, ifosfamide and increasing dosage of navelbine in unresectable non-small cell lung cancer, **Suppl.3.A55**
- Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model, **894**

Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement, **846**
Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by the CHART Steering Committee, **1262**
Non-steroidal anti-inflammatory drugs, Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma, **799**
Non-tuberculous mycobacterial infection, Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis, **137**
Normative Aging Study, Relationship of serum IgE concentration to level and rate of decline of pulmonary function: the Normative Aging Study, **787**
Northern Ireland, Death from airways obstruction: accuracy of certification in Northern Ireland, **293**
Nosocomial pneumonia, Nosocomial pneumonia during mechanical ventilation: *letter*, **771**
Notices, **110**, **228**, **344**, **454**, **556**, **658**, **772**, **1068**, **1170**
Nurse practitioner
Defining the role of the respiratory nurse specialist in the South West Region, **Suppl.3.A62**
Named nurse programme for the care of patients with lung cancer, **Suppl.3.A57**
Unrecognised needs of patients with end stage pulmonary disease may be identified by the respiratory nurse practitioner in the primary setting, **Suppl.3.A63**
Nurse specialist
Audit of a respiratory nurse tuberculosis service, **Suppl.3.A34**
Impact of an asthma nurse specialist on patients admitted to hospital with acute severe asthma, **Suppl.3.A27**
Nutrition
Long term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre, **1023**
Nutrition, diabetes, pancreatic function and survival in Birmingham cystic fibrosis clinic, **Suppl.3.A47**
Nutrition and survival in cystic fibrosis: *editorial*, **971**

OASYS-2, Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma, **484**
Obliterative bronchiolitis
Epstein-Barr virus associated graft failure following heart/lung transplantation, **1160**: *commentary*, **1164**
Pregnancy following a single lung transplantation, **1162**: *commentary*, **1164**
Occupation, Occupation and chronic obstructive pulmonary disease, **947**
Occupational asthma
Comparison of soybean epidemic asthma and occupational asthma, **743**
Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma, **484**
Occupational asthma in a coal miner, **867**
Occupational asthma due to latex in health care workers, **1280**
Occupational asthma due to latex in a hospital administrative employee, **452**
Occupational asthma: measures of frequency from four countries, **435**: *letter*, **1168**
The diagnosis of occupational asthma from serial measurements of lung function at and away from work, **857**
Occupational disease
Increase in non-specific bronchial hyperresponsiveness as an early marker of bronchial response to occupational agents during specific inhalation challenges, **472**
Occupational irritants, Respiratory irritants encountered at work, **541**
Occupational lung disease
Epidemic outbreak of interstitial lung disease in aerographics textile workers – the "Ardystil syndrome": a first year follow up, **94**
Exposure of crystalline silica and risk of lung cancer: the epidemiological evidence, **97**: *letter*, **772**
New developments in occupational lung disease, **96**
Odense Schoolchild Study, Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: the Odense Schoolchild Study, **503**
One lung anaesthesia, Acute lung injury following lung resection: is one lung anaesthesia to blame? *editorial*, **114**
Opioid modulation, Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide-induced bronchoconstriction, **159**
Opportunistic micro-organisms, Interactions between opportunistic micro-organisms and HIV in the lung: *editorial*, **875**
Orbit, Co-existing conjunctival non-Hodgkin's lymphoma and pulmonary sarcoidosis, **444**: commentary, **448**
Ototoxicity, Minimisation of aminoglycoside toxicity in patients with cystic fibrosis, **369**
Oxidant/antioxidant imbalance, Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease: *editorial*, **348**
Oxidants, Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**
Oxidative stress, The effect of intravenous antibiotic therapy on markers of oxidative stress in cystic fibrosis, **Suppl.3.A59**
Oximetry
Comparison of oximetry and transcutaneous carbon dioxide levels in patients undergoing fibreoptic bronchoscopy, **Suppl.3.A70**
Patterns of abnormality on overnight oximetry before and during NIPPV, **Suppl.3.A10**
Oxygen concentrator
Evaluation of domiciliary long-term oxygen therapy with oxygen concentrators, **Suppl.3.A65**
Patient acceptability of a combined oxygen concentrator and nebuliser unit, **Suppl.3.A66**
Oxygen cost of breathing, Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis, **126**
Oxygen delivery, Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking, **831**
Oxygen saturation, Assessment of oxygen supplementation during air travel, **202**
Oxygen stimulated DNA synthesis, Serum dependence of oxygen stimulated DNA synthesis in human fetal airway smooth muscle cells: implications for the pathogenesis of bronchopulmonary dysplasia, **Suppl.3.A15**
Ozone
Effect of ozone, thunderstorms and other weather conditions on the respiratory function of asthmatics, **Suppl.3.A1**
Fluticasone propionate and beclomethasone dipropionate attenuate ozone-induced release of inflammatory cytokines from nasal epithelial cells of atopic rhinitic subjects, **Suppl.3.A39**
Modelling the interaction between ozone and pulmonary epithelial lining fluid antioxidants, **Suppl.3.A52**

p53, Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, **887**
P-glycoprotein, Detection of the multidrug resistance marker P-glycoprotein by immunohistochemistry in malignant lung tumours, **526**
Panbronchiolitis, Diffuse panbronchiolitis in an Asian immigrant, **1065**
Pancreatic function, Nutrition, diabetes, pancreatic function and survival in a Birmingham cystic fibrosis clinic, **Suppl.3.A47**
Papworth ventilator, Quality of sleep during NIPPV: comparison between the Monnal D and the Papworth ventilator, **Suppl.3.A79**
Paraquat poisoning
Cyclophosphamide treatment of paraquat poisoning: *editorial*, **659**
Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**
Partial agonist, Effects of prior treatment with salmeterol and formoterol on airway and systemic β_2 responses to fenoterol, **585**
Particle size
Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**
Particle size selection device for use with the Turbohaler, **537**
Particulate air pollution
Acute effects of summer air pollution on respiratory function in primary school children in southern England, **1109**
Diesel exhaust particulates enhance the release of pro-inflammatory mediators from human bronchial epithelial cells *in vitro*, **Suppl.3.A54**
Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**

Particulate air pollution, **Suppl.2.3**
Pro-inflammatory effect of particulate air pollution (PM_{10}) in vivo and in vitro, **Suppl.3.A53**
Suspended particulate matter and health: new light on an old problem: *editorial*, **1174**

Passive smoking, Atopy, bronchial hyperresponsiveness, and peak flow variability in children with mild occasional wheezing, **272**

Patient-administered serial spirometry, Long term performance of a hand held spirometer, **973**

Patient knowledge, Knowledge of adult patients with cystic fibrosis about their illness, **34**

Peak expiratory flow
Comparison of mean daily diurnal variation in peak expiratory flow and FEV_1, **Suppl.3.A43**
Development of OASYS-2: a system for the analysis of serial measurement of peak expiratory flow in workers with suspected occupational asthma, **484**
Potential effects of correction of inaccuracies of the mini-Wright peak expiratory flow meter on the use of an asthma self-management plan, **403**
Randomised controlled assessment of a 'Windmill Trainer' device in the measurement of PEF in children, **Suppl.3.A61**

Peak expiratory flow meters, Number preference in reading peak expiratory flow meters, **Suppl.3.A42**

Peak flow meters, Effect of altitude on spirometric parameters and the performance of peak flow meters, **175**

Peak inspiratory flow, Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients, **433**: correction, **1068**

Penicillin resistance, Antibiotic resistant *Streptococcus pneumoniae*, **Suppl.2.45**

Peripheral blood stem cell transplant, Lung function is generally preserved following peripheral blood stem cell transplant, **Suppl.3.A47**

Peritoneal mesothelioma, Lymphangitis carcinomatosa complicating primary malignant peritoneal mesothelioma, **552**

Peritoneal ventilation, Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride, **82**

Peroxynitrite
Peroxynitrite is a vasodilator of rat pulmonary arteries at concentrations that do not cause endothelial dysfunction, **Suppl.3.A35**
Role of poly-ADP ribosyltransferase in the vasodilator actions of peroxynitrite, **Suppl.3.A35**

pH, Gastric intramural pH in mechanically ventilated patients, **606**

Phenobarbitone, Compliance with oral corticosteroids during steroid trials in chronic airways obstruction, **323**

Phonomyogram, Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**

Phosphodiesterase inhibitors, Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?, **647**

Phrenic nerve stimulation
Clinical assessment of diaphragm strength by cervical magnetic stimulation of the phrenic nerves, **1239**
Effects of lung volume and fatigue on evoked diaphragmatic phonomyogram in normal subjects, **705**

Physiology, Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma, **993**

Physiotherapist, The combined role of the respiratory health practitioner and the physiotherapist in reducing bed occupancy in patients with chronic respiratory disease, **Suppl.3.A63**

Physiotherapy, Knowledge and compliance with respiratory physiotherapy techniques in adults with bronchiectasis, **Suppl.3.A68**

Pigeon fanciers lung, Antibody levels in saliva of patients with pigeon fanciers lung, **Suppl.3.A71**

Platelet activating factor, Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients, **155**

Platinum salts, Outcome of occupational asthma due to platinum salts, **Suppl.3.A41**

Pleural disease, New developments in asbestos-related pleural disease, **210**

Pleural effusion
Gorham's syndrome: a usually fatal cause of pleural effusion treated successfully with radiotherapy, **1275**: *commentary*, **1279**
Malignant pleural effusion infected with *Salmonella enteritidis*, **104**; *commentary*, **107**
Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis, **92**
Pleural effusion and toxocariasis, **106**; *commentary*, **107**
Pleural empyema and malignancy - another dimension, *commentary*, **107**
Pleural fluid accumulation due to intra-abdominal endometriosis: a case report and review of the literature, **1062**: *commentary*, **1064**

Pleural infection, Pleuropulmonary infection with chest wall infiltration by *Eikenella corrodens*, **871**

Pneumococcal pneumonia, Clinical picture of community-acquired *Chlamydia pneumoniae* pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia, **185**: *letter*, **967**

Pneumococcal polysaccharide vaccine, The simultaneous administration of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with chronic respiratory disease, **Suppl.3.A14**

Pneumomediastinum
Ecstasy induced pneumomediastinum, **960**: *commentary*, **962**
Pneumomediastinum following Politzer's manoeuvre: *letter*, **1169**
Pneumomediastinum secondary to use of a high speed air turbine drill during a dental extraction, **339**; *commentary*, **340**

Pneumonia
Analysis of decisions by European general practitioners to admit to hospital patients with lower respiratory tract infections, **1017**
Circulating neutrophil β_2-integrin expression and intracellular oxidative metabolism in community acquired pneumonia, **Suppl.3.A3**
Clinical picture of community-acquired *Chlamydia pneumoniae* pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia, **185**: *letter*, **967**
Community acquired pneumonia: aetiology and usefulness of severity criteria on admission, **1010**
Community acquired pneumonia in adults: a study comparing clinical features and outcome in Africa (Republic of Guinea) and Europe (France), **385**
Comparison of bronchoscopic diagnostic techniques with histological findings in brain dead organ donors without suspected pneumonia, **929**
Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients, **179**
Nosocomial pneumonia during mechanical ventilation: *letter*, **771**
Predicting death from pneumonia: *editorial*, **970**
Severe lipoid pneumonia following attempted suicide by mineral oil immersion, **652**: *commentary*, **656**
Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia, **378**

Pneumonitis
"Crack lung" caused by an impure preparation, **959**: *commentary*, **962**
Hypersensitivity pneumonitis induced by a smut fungus *Ustilago esculenta*, **650**: *commentary*, **656**

Pneumothorax
Lung disease induced by drug addiction: *letter*, **556**
Pneumomediastinum secondary to use of a high speed air turbine drill during a dental extraction, **339**; *commentary*, **340**
Pulmonary diseases and HIV infection: *letter*, **228**
Treatment of pneumothorax during pregnancy, **338**; *commentary*, **340**
Video assisted thoracic surgery for spontaneous pneumothorax, **Suppl 2.23**

Poisoning
Cyclophosphamide treatment of paraquat poisoning: *editorial*, **659**
Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**

Politzer's manoeuvre, Pneumomediastinum following Politzer's manoeuvre: *letter*, **1169**

Pollen, Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms, **575**

Pollution
Free radical activity and pro-inflammatory effects of particulate air pollution (PM_{10}) in vivo and in vitro, **1216**
Suspended particulate matter and health: new light on an old problem: *editorial*, **1174**

Poly-ADP ribosyltransferase, Role of poly-ADP ribosyltransferase in the vasodilator actions of peroxynitrite, **Suppl.3.A35**
Polymerase chain reaction
Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis, **320**
Quantitative PCR for the diagnosis of CMV disease in lung and heart transplant, **Suppl.3.A23**
Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural meosthelioma tissue, **1074**
Polyneuropathy, Neurological complications of severe illness and prolonged mechanical ventilation, **Suppl.2.40**
Polysomnography
Comparison of partially attended night time respiratory recordings and full polysomnography in patients with suspected sleep apnoea/hypopnoea syndrome, **1043**
Home oximetry versus full polysomnography in the detection of obstructive sleep apnoea, **Suppl.3.A4**
Portable mouth pressure meter, Measurement of sniff nasal inspiratory pressure using a portable mouth pressure meter, **Suppl.3.A45**
Positron emission tomography
^{18}F-Fluorodeoxyglucose PET scans in lung cancer, **Suppl.2.16**
Reduced beta adrenoceptor density in vivo in human lung tumours: a preliminary study with positron emission tomography, **727**
Post inflammatory fibrosis, Mortality rates from cryptogenic fibrosing alveolitis in seven countries, **711**
Postpneumonectomy pulmonary oedema, Acute lung injury following lung resection: is one lung anaesthesia to blame? *editorial*, **114**
Prednisolone
Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care, **1087**
Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung, **1210**
Measurement of serum prednisolone and cortisol in patients with severe asthma, **Suppl.3.A61**
Steroids in exacerbations of asthma: tablets or inhalers? *editorial*, **1071**
Pregnancy
Acute asthma during pregnancy, **411**
Effect of pregnancy on maternal cystic fibrosis vs nulliparous severity matched controls, **Suppl.3.A50**
Pregnancy following a single lung transplantation, **1162**: *commentary*, **1164**
Treatment of pneumothorax during pregnancy, **338**; *commentary*, **340**
Prevalence, Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys, **590**
Primary pulmonary hypertension, Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension, **89**
Priming effect, Priming effect of platelet activating factor on leukotriene C_4 from stimulated eosinophils of asthmatic patients, **155**
Printing sprayers, Epidemic outbreak of interstitial lung disease in aerographics textile workers – the "Ardystil syndrome": a first year follow up, **94**
Prognostic factors
New prognostic factors in resectable non-small cell lung cancer, **638**
Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model, **894**
Prolonged mechanical ventilation, Neurological complications of severe illness and prolonged mechanical ventilation, **Suppl.2.40**
Propranolol, Attenuation of propranolol-induced bronchoconstriction by nebulised frusemide, **Suppl.3.A40**
Prostaglandin E_2
Cultured human airway smooth muscle cells release PGE_2 in response to bradykinin, growth factors and arachidonic acid, **Suppl.3.A38**
Differential release of 8-isoprostanes and prostaglandin E_2 by human pulmonary artery, **Suppl.3.A36**
Effect of prostaglandin E_2 on eicosanoid release by human bronchial biopsy specimens from normal and inflamed mucosa, **919**
Prostaglandin E_2 production by ovine tracheal epithelium: control by cyclic nucleotides, **Suppl.3.A38**
Prostaglandins
8-iso $PGF_{2\alpha}$ constricts and dilates rat pulmonary artery, **Suppl.3.A36**
Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5'-monophosphate challenge in asthma, **799**
Protease, Protease content of circulating neutrophils from patients with cystic fibrosis, **Suppl.3.A58**
Protected bronchoalveolar lavage, Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia, **378**
α_1-Proteinase inhibitor, Secretory leukoprotease inhibitor: partnering α_1-proteinase inhibitor to combat pulmonary inflammation, **1273**
Pseudomonads, Results of pulmonary transplantation in patients with cystic fibrosis colonised by multiply resistant pseudomonads, **Suppl.3.A23**
Pseudomonas aeruginosa
Dysregulation of calcium metabolism in human neutrophils exposed to the *Pseudomonas aeruginosa* pigment 1-hydroxyphenazine, **Suppl.3.A58**
Inflammatory markers and clinical response to intravenous antibiotics in adults with cystic fibrosis colonised with *Burkholderia cepacia* and *Pseudomonas aeruginosa*, **Suppl.3.A49**
Pseudomonas aeruginosa adherence to cystic fibrosis respiratory epithelium is reduced by anti-asialo GM1 antibody and neuraminidase inhibition, **Suppl.3.A57**
Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal *Pseudomonas aeruginosa* beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry, **733**
The clinical significance of the auxotrophic phenotype of *Pseudomonas aeruginosa* in cystic fibrosis, **Suppl.3.A49**
The role of ELISA in the early diagnosis of *Pseudomonas aeruginosa* infection in cystic fibrosis, **Suppl.3.A49**
Pseudomonas cepacia, Outcome for patients colonised with *Burkholderia cepacia* in a Birmingham adult cystic fibrosis clinic and the end of an epidemic, **374**
Pulmonary alveolar proteinosis, Bronchoalveolar lavage with trypsin in pulmonary alveolar proteinosis, **769**
Pulmonary arteriovenous malformations, A reduction in functional endoglin leads to pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia, **Suppl.3.A37**
Pulmonary artery
8-iso $PGF_{2\alpha}$ constricts and dilates rat pulmonary artery, **Suppl.3.A36**
Differential release of 8-isoprostanes and prostaglandin E_2 by human pulmonary artery, **Suppl.3.A36**
Pulmonary artery endothelial cells, Interleukin 1-β induces neutrophil adhesion to human pulmonary artery endothelial cells, **Suppl.3.A53**
Pulmonary artery endothelial monolayers, An *in vitro* model of neutrophil migration across human pulmonary artery endothelial monolayers, **Suppl.3.A53**
Pulmonary capillary blood volume
Pulmonary capillary blood volume in patients with probable pulmonary Kaposi's sarcoma, **204**
Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension, **855**
Pulmonary diseases, Asthma and other pulmonary diseases in former elite athletes, **288**
Pulmonary embolism
Continuous volume computed tomography in pulmonary embolism: the answer, or just another test? *editorial*, **1**
Role of spiral volumetric computed tomographic scanning in the assessment of patients with clinical suspicion of pulmonary embolism and an abnormal ventilation/perfusion lung scan, **23**
Pulmonary endocrine cells, Endocrine cells in tumour-bearing lungs, **721**
Pulmonary eosinophilia, Pulmonary eosinophilia due to *Trichomonas tenax*, **554**
Pulmonary epithelial lining fluid antioxidants, Modelling the interaction between ozone and pulmonary epithelial lining fluid antioxidants, **Suppl.3.A52**
Pulmonary fibrosis
Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection, **312**

Calibrating the calibrators: *editorial*, **969**
Computed tomography-guided bronchoalveolar lavage in idiopathic pulmonary fibrosis, **841**
Elevated expression of insulin-like growth factor binding protein-3 in bronchoalveolar lavage fluid of patients with pulmonary fibrosis, **Suppl.3.A12**
Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis, **315**
Inhaled nitric oxide worsens gas exchange in pulmonary fibrosis associated pulmonary hypertension, **Suppl.3.A18**
T lymphocytes and silica-induced pulmonary inflammation and fibrosis in mice, **1036**

Pulmonary function, Pulmonary function before and after anterior spinal surgery in adult idiopathic scoliosis, **534**

Pulmonary function laboratories, A re-audit of pulmonary function laboratories, **Suppl.3.A69**

Pulmonary function tests
Pulmonary function in children with systemic lupus erythematosus, **424**
Review of the impact pulmonary function testing has in a large teaching hospital in Birmingham, **Suppl.3.A69**

Pulmonary haemodynamics, Doppler assessment of pulmonary haemodynamics in chronic hypoxic lung disease: *editorial*, **9**

Pulmonary hypertension
Cell signalling in pulmonary vascular cells: do not shoot the messenger!, **864**
Coronary ligated rabbit as a model for pulmonary hypertension secondary to heart failure: role of 5-hydroxytryptamine, **Suppl.3.A35**
Inhaled nitric oxide worsens gas exchange in pulmonary fibrosis associated pulmonary hypertension, **Suppl.3.A18**
Pulmonary hypertension: NO therapy? **762**
Reduction of pulmonary capillary blood volume in patients with severe unexplained pulmonary hypertension, **855**

Pulmonary infection
Pleuropulmonary infection with chest wall infiltration by *Eikenella corrodens*, **871**
Pulmonary *Mycobacterium kansasii* infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis, **1248**
Pulmonary *Mycobacterium kansasii* infection: comparison of radiological appearances with pulmonary tuberculosis, **1243**

Pulmonary lymphangiectasis, Generalised lymphangiectasia: pulmonary presentation in an adult, **767**

Pulmonary nodules, Whipple's disease presenting with lung involvement, **343**

Pulmonary oedema, Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan, **739**

Pulmonary rehabilitation
Are activity monitors sensitive enough to detect speeds prescribed to patients with COPD? **Suppl.3.A25**
Could inspiratory pressure support be a useful adjunct in pulmonary rehabilitation? **Suppl.3.A26**
Do anxiety and depression affect outcome of rehabilitation in severe chronic obstructive pulmonary disease, **Suppl.3.A25**
Do patients with chronic obstructive pulmonary disease attending a pulmonary rehabilitation programme adhere to their prescribed home exercise programme? **Suppl.3.A25**
Long-term benefits of pulmonary rehabilitation in elderly patients with chronic obstructive pulmonary disease, **Suppl.3.A16**
Medical Research Council Breathlessness Score is useful in selecting COPD patients for pulmonary rehabilitation, **Suppl.3.A24**
Pulmonary rehabilitation at home: *editorial*, **117**: *letter*, **1068**
Randomised controlled trial of outpatient pulmonary rehabilitation in COPD: preliminary results, **Suppl.3.A24**

Pulmonary sarcoidosis, Glucocorticosteroids and pulmonary sarcoidosis: *editorial*, **229**

Pulmonary thromboembolism, A role for natriuretic peptides in the diagnosis of pulmonary thromboembolism, **Suppl.3.A36**

Pulse therapy, Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**

Pustular psoriasis, Sternocostoclavicular hyperostosis presenting with thoracic sinus formation, **550**

Pyothorax, Pleural non-Hodgkin's lymphoma arising in a patient with a chronic pyothorax, **103**; *commentary*, **107**

Quadriplegia, Transdiaphragmatic pressure in quadriplegic individuals ventilated by diaphragmatic pacemaker, **420**

Quality of life
Assessing the quality of life of asthma in family practice, **Suppl.3.A63**
Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease, **39**
Do white European and Indian-subcontinent asthmatics differ in their quality of life? **Suppl.3.A30**
Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study, **825**
Impact of obstructive airways disease on quality of life in older adults, **520**
Quality of life in adults with cystic fibrosis, **936**
Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia, **44**
Quality of life in patients with lung cancer: an important prognostic factor, **Suppl.3.A8**
Quality of life in patients with lung cancer: does the treatment matter? **Suppl.3.A56**
Smoking and quality of life among adult patients prescribed bronchodilators, **Suppl.3.A66**

Questionnaire
Development of a validated snoring questionnaire: repeatability of questions, **Suppl.3.A77**
Northampton asthma survey: results of a postal questionnaire, **Suppl.3.A62**

Radiotherapy
Gorham's syndrome: a usually fatal cause of pleural effusion treated successfully with radiotherapy, **1275**: *commentary*, **1279**
Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by the CHART Steering Committee, **1262**

Rebound airway responsiveness, Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease, **684**

Recombinant DNase
Effect of nebulised recombinant DNase on neutrophil elastase load in cystic fibrosis, **619**
Role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems, **750**

Reflex, Impaired reflex responses to airway occlusion in the inspiratory muscles of asthmatic subjects, **490**

Renal blood flow, Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease, **516**

Renal function, Enhanced survival in small cell lung cancer with dose modification according to renal function, **Suppl.3.A55**

Respiratory disease
Chlamydia pneumoniae antibody titres are significantly associated with the use of steroid medication in respiratory disease, **Suppl.3.A14**
Simultaneous administration of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in patients with chronic respiratory disease, **Suppl.3.A14**

Respiratory distress syndrome
Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome, **907**
Steroids, surfactant and lung disease: *editorial*, **880**

Respiratory dreams and nightmares, Respiratory dreams and nightmares: Altounyan address, **882**

Respiratory failure
Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease, **1048**
Gastric intramural pH in mechanically ventilated patients, **606**
Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease, **Suppl.2.35**
Respiratory failure due to tracheobronchomalacia, **224**; *commentary*, **226**

Respiratory function
Effect of ozone, thunderstorms and other weather conditions on the respiratory function of asthmatics, **Suppl.3.A1**
Premorbid infant respiratory function and wheezing in the first year of life: a population based study in London, **Suppl.3.A15**

Respiratory health practitioner, The combined role of the respiratory health practitioner and the physiotherapist in reducing bed occupancy in patients with chronic respiratory disease, **Suppl.3.A63**
Respiratory irritants, Respiratory irritants encountered at work, **541**
Respiratory muscle fatigue, Effect of maximum ventilation on abdominal muscle relaxation rate, **510**
Respiratory muscles, Impaired reflex responses to airway occlusion in the inspiratory muscles of asthmatic subjects, **490**
Respiratory nurse practitioner
Defining the role of the respiratory nurse specialist in the South West Region, **Suppl.3.A62**
Unrecognised needs of patients with end stage pulmonary disease may be identified by the respiratory nurse practitioner in the primary setting, **Suppl.3.A63**
Respiratory symptoms
Antioxidant status in children with different respiratory symptoms, **Suppl.3.A15**
Respiratory symptoms, smoking and mortality in older men and women: an epidemiological study, **Suppl.3.A16**
Respiratory tract, Lipocortin 1: glucocorticoids caught in the act?, **1057**
Respiratory tract infection, Respiratory tract infection in the community. Does a chest radiograph influence treatment? **Suppl.3.A13**
Resting energy expenditure, Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis, **126**
Reverse transcriptase-polymerase chain reaction, Growth hormone and insulin-like growth factor-1 gene expression in bronchoalveolar lavage cells using RT-PCR, **Suppl.3.A12**
rhDNase, In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, **119**
Rheology, In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, **119**
Rheumatoid arthritis, Neurone-specific enolase levels in pleural effusions in patients with rheumatoid arthritis, **92**
Rhinoviruses, Pre-exposure of a rhinoviral-infected human bronchial epithelial cell line to cytokines affects surface ICAM-1 levels, **Suppl.3.A2**
Rhizopus, Occupational asthma in a coal miner, **867**
Runners, Exercise-induced bronchospasm at low temperature in elite runners, **628**

Safety, Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks, **664**
Salbutamol
Comparison of the effect of non-chlorofluorocarbon-containing salbutamol and conventional chlorofluorocarbon salbutamol in asthmatic children, **Suppl.3.A73**
Comparison of the systemic effects of salbutamol and terbutaline when inhaled from a metered dose inhaler or as a dry powder in healthy volunteers, **Suppl.3.A72**
Effect of acute hyperoxia on the bronchodilator response to salbutamol in stable asthmatic patients, **853**
Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, **981**
Effect of salbutamol on input impedance measurements in laryngectomized subjects during tidal breathing, **Suppl.3.A46**
Lung bioavailability of generic and innovator salbutamol metered dose inhalers, **325**: *letter*, **658**
Non-CFC salbutamol metered dose inhaler performance with a spacer device, **Suppl.3.A75**
Optimal particle size for β_2 agonist and anticholinergic aerosols in patients with severe airflow obstruction, **977**
Saliva, Antibody levels in saliva of patients with pigeon fanciers lung, **Suppl.3.A71**
Salmeterol
Effect of salmeterol on sleep architecture of asthmatic patients of different ages, **Suppl.3.A17**
Effects of prior treatment with salmeterol and formoterol on airway and systemic β_2 responses to fenoterol, **585**
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease, **689**
Evaluation of the β_2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol, **54**
Salmeterol in smokers with COPD: *letter*, **110**
Salmeterol tachyphylaxis in steroid treated asthmatic subjects, **1100**
Salmonella enteritidis, A malignant pleural effusion infected with *Salmonella enteritidis*, **104**; *commentary*, **107**
Salt intake, Usual dietary salt intake and asthma in children: a case-control study, **59**
Sarcoidosis
British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment, **238**
Co-existing conjunctival non-Hodgkin's lymphoma and pulmonary sarcoidosis, **444**: *commentary*, **448**
Deletion polymorphism in the angiotensin I converting enzyme gene as a genetic risk factor for sarcoidosis, **777**
Exhaled nitric oxide is normal in sarcoidosis patients with active alveolitis, **Suppl.3.A18**
Flow cytometric analysis of cytokine production in the lymphocytic alveolitis of sarcoidosis, **Suppl.3.A12**
Gamma/delta cells in tissue from patients with sarcoidosis, **1123**
Glucocorticosteroids and pulmonary sarcoidosis: *editorial*, **229**
Growth of acid fast L forms from the blood of patients with sarcoidosis, **530**
Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis, **1253**
Induced sputum from patients with sarcoidosis is more cellular than that from control subjects, **Suppl.3.A12**
Pneumocystis carinii in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia, 446: *commentary*, **448**
Urinary neopterin excretion as a marker of activity in sarcoidosis, **Suppl.3.A70**
School absence, Descriptive study of cough, wheeze and school absence in childhood, **630**
Schools, Current management of asthma in primary and secondary schools in Wolverhampton, **Suppl.3.A30**
Science matters, Science matters: introduction, **217**
Scoliosis, Pulmonary function before and after anterior spinal surgery in adult idiopathic scoliosis, **534**
Scorpion venoms, Scorpion venoms: taking the sting out of lung disease, **546**
Scotland
Increasing incidence of tuberculosis in the young and elderly in Scotland, **140**
Management of lung cancer in South East Scotland, **569**
Management of pulmonary tuberculosis in adults notified in Scotland in 1993, **Suppl.3.A31**
Rising incidence of primary lung adenocarcinoma in north east Scotland, **Suppl.3.A56**
Scottish national survey of tuberculosis notifications 1993 with special reference to the prevalence of HIV seropositivity, **78**
Seasonality, Seasonality of tuberculosis: the reverse of other respiratory diseases in the UK, **944**
Secretory leukoprotease inhibitor, Secretory leukoprotease inhibitor: partnering α_1-proteinase inhibitor to combat pulmonary inflammation, **1273**
Selectins, Selectins and their counter receptors: a bitter sweet attraction, **1155**
Selenium deficiency, Pulmonary effects of short term selenium deficiency, **479**
Self-refer, Characteristics of those asthmatics who repeatedly self-refer to the accident and emergency department, **Suppl.3.A29**
Sensory nerves, Airway sensory nerves: a burning issue in asthma?, **335**
Serevent Accuhaler, Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**
Severe life threatening asthma
Risk of severe life threatening asthma: *editorial*, **1073**
Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity, **1093**
Severity assessment
Community acquired pneumonia: aetiology and usefulness of severity criteria on admission, **1010**
Predicting death from pneumonia: *editorial*, **970**
Sheepskins, House dust mite allergen accumulation on sheepskins, **Suppl.3.A42**
Sickness Impact Profile, Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study, **825**

Signal transduction, Function at the junction: dynamic interactions between lung cells and extracellular matrix, **956**
Silica, Pulmonary infiltration after exposure to home renovation dust: histopathology and microanalysis, **654**: *commentary*, **656**
Silica exposure, Exposure of crystalline silica and risk of lung cancer: the epidemiological evidence, **97**: *letter*, **772**
Silicosis
Effect of exposure to silica on human alveolar macrophages in supporting growth activity in type II epithelial cells, **781**
Silicosis presenting as bilateral hilar lymphadenopathy, **1165**
T lymphocytes and silica-induced pulmonary inflammation and fibrosis in mice, **1036**
Simian virus 40, Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural meosthelioma tissue, **1074**
Skiing, Asthma and other pulmonary diseases in former elite athletes, **288**
Skin tests, Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts, **932**
Sleep, The effect of salmeterol on sleep architecture of asthmatic patients of different ages, **Suppl.3.A17**
Sleep apnoea
Automatic nasal continuous positive airway pressure titration in the laboratory. Patient outcomes, **Suppl.3.A77**
Dental implications of obstructive sleep apnoea, **Suppl.3.A78**
Detection of cortical EEG arousals from a neural network analysis, **Suppl.3.A76**
Epidemiology of sleep apnoea, **Suppl.2.65**
Facilities for investigation and treatment of sleep apnoea in the UK, **Suppl.3.A4**
Home oximetry versus full polysomnography in the detection of obstructive sleep apnoea, **Suppl.3.A4**
Quality of life before and after nasal continuous positive airway pressure treatment for obstructive sleep apnoea, **Suppl.3.A4**
Referral sources and outcomes from 1 years home oximetry studies in patients with suspected sleep apnoea, **Suppl.3.A77**
Relationship between autonomic arousals, EEG arousals, respiratory events and subjective sleepiness in patients undergoing investigation for obstructive sleep apnoea, **Suppl.3.A76**
Response of bed-partners and patients to nasal continuous positive airway pressure for obstructive sleep apnoea, **Suppl.3.A78**
Survey of sleep service provision in North Thames Region, UK, **Suppl.3.A79**
Sleep apnoea/hypopnoea syndrome
Comparison of partially attended night time respiratory recordings and full polysomnography in patients with suspected sleep apnoea/hypopnoea syndrome, **1043**
Effect of chronic continuous positive airway pressure therapy on upper airway size in patients with sleep apnoea/hypopnoea syndrome, **190**
Effects of naloxone of upper airway collapsibility in normal sleeping subjects, **851**
HLA-typing in patients with sleep apnoea/hypopnoea syndrome, **Suppl.3.A78**
Relationship between autonomic arousals, EEG arousals, respiratory events and subjective sleepiness in patients undergoing investigation for obstructive sleep apnoea, **Suppl.3.A76**
Respiratory dreams and nightmares: Altounyan address, **882**
Validation and clinical use of home sleep studies in the sleep apnoea/hypopnoea syndrome, **Suppl.3.A4**
Sleep service provision, A survey of sleep service provision in North Thames Region, UK, **Suppl.3.A79**
Sleep study service, Audit of a sleep study service 1993–1995, **Suppl.3.A79**
Small cell bronchogenic carcinoma, A malignant pleural effusion infected with *Salmonella enteritidis*, **104**; *commentary*, **107**
Small cell lung cancer
Enhanced survival in small cell lung cancer with dose modification according to renal function, **Suppl.3.A55**
Phase II study of an intensive modified 'ICE' regimen in patients with good prognosis small cell lung cancer, **Suppl.3.A54**
Smoke inhalation injury, Assessment of short and long term morbidity following smoke inhalation injury, **Suppl.3.A43**
Smokers (smoking)
Airways obstruction, chronic expectoration, and rapid decline of FEV_1 in smokers are associated with increased levels of sputum neutrophils, **267**
Atopy, bronchial hyperresponsiveness, and peak flow variability in children with mild occasional wheezing, **272**
Cigarette smoke enhances house dust mite allergen (*Der p*1)-induced changes in permeability of human bronchial epithelial cell cultures, **Suppl.3.A51**
Effects of cigarette smoking and duration of work on the lung function of coal miners, **Suppl.3.A43**
Endothelin-1 levels in induced sputum from asthmatics, normal subjects and smokers – comparison with plasma and saliva levels, **Suppl.3.A81**
Epithelial permeability *in vivo* and *in vitro* and TNFα in non-smokers and smokers, **Suppl.3.A52**
Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study, **825**
Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population, **277**
Manganese superoxide dismutase mRNA expression is decreased in LPS-stimulated alveolar macrophages from cigarette smokers, **Suppl.3.A52**
Mechanisms of cigarette smoke induced increased airspace permeability, **465**
Nitric oxide in exhaled air of cigarette smokers, **Suppl.3.A18**
Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease: *editorial*, **348**
Relationship of serum IgE concentration to level and rate of decline of pulmonary function: the Normative Aging Study, **787**
Respiratory symptoms, smoking and mortality in older men and women: an epidemiological study, **Suppl.3.A16**
Salmeterol in smokers with COPD: *letter*, **110**
Smoking and quality of life among adult patients prescribed bronchodilators, **Suppl.3.A66**
Tobacco: the Third World War – advice from General Sun Tzu, **562**
Two dimensional protein patterns of bronchoalveolar lavage fluid from non-smokers, smokers, and subjects exposed to asbestos, **1028**
Smooth muscle cells
Angiotensin II causes proliferation of rat pulmonary microvascular smooth muscle cells, **Suppl.3.A35**
Cultured human airway smooth muscle cells release PGE_2 in response to bradykinin, growth factors and arachidonic acid, **Suppl.3.A38**
Interleukin-1β causes induction of cyclooxygenase-2 in cultured human airway smooth muscle cells, **Suppl.3.A39**
Synthesis of cyclic guanosine monophosphate in cultured human airway smooth muscle cells, **Suppl.3.A38**
Tuberous sclerosis 2 gene product tuberin is constitutively expressed in human airway smooth muscle and upregulated by serum, **Suppl.3.A67**
Smut, Hypersensitivity pneumonitis induced by a smut fungus *Ustilago esculenta*, **650**: *commentary*, **656**
Sniff nasal inspiratory pressure, Measurement of sniff nasal inspiratory pressure using a portable mouth pressure meter, **Suppl.3.A45**
Snoring
Development of a validated snoring questionnaire: repeatability of questions, **Suppl.3.A77**
Effect of snoring on respiratory effort measured indirectly by beat to beat blood pressure, **Suppl.3.A76**
Epidemiology of sleep apnoea, **Suppl.2.65**
Mandibular positioning devices for the control of snoring, **Suppl.3.A5**
Social deprivation
Asthma, its treatment and social deprivation – the effect on growth in children, **Suppl.3.A14**
Do white European and Indian-subcontinent asthmatics differ in their quality of life? **Suppl.3.A30**
Sodium channel blockers, Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis mouse, **1229**
Sodium dithionite urine test, Pulse therapy with cyclophosphamide and methylprednisolone in patients with moderate to severe paraquat poisoning: preliminary report, **661**
Sodium metabisulphite
Comparison of three inhaled non-steroidal anti-inflammatory drugs on the airway response to sodium metabisulphite and adenosine 5′-monophosphate challenge in asthma, **799**

Respiratory sensation during bronchial challenge testing with methacholine, sodium metabisulphite, and adenosine monophosphate, **793**
Soybean epidemic asthma, Comparison of soybean epidemic asthma and occupational asthma, **743**
Spacer device
Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants, **985**
Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, **981**
Inhalational drug delivery from seven different spacer devices, **835**
Non-CFC salbutamol metered dose inhaler performance with a spacer device, **Suppl.3.A75**
Specialist care, In-patients with lung cancer: a study of the extent of non-referral to specialist care, **Suppl.3.A7**
Spiral CT scanning, Spiral computed tomographic scanning of the chest with three dimensional imaging in the diagnosis and management of paediatric intrathoracic airway obstruction, **1005**
Spiral volumetric computed tomography, Role of spiral volumetric computed tomographic scanning in the assessment of patients with clinical suspicion of pulmonary embolism and an abnormal ventilation/perfusion lung scan, **23**
Spirometer
COPD guidelines and general practice – use of spirometers, **Suppl.3.A44**
Long term performance of a hand held spirometer, **973**
Spirometry
Assessment of a new transtelephonic portable spirometer, **407**
Effect of altitude on spirometric parameters and the performance of peak flow meters, **175**
Long term performance of a hand held spirometer, **973**
Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population, **277**
Relationship of serum IgE concentration to level and rate of decline of pulmonary function: the Normative Aging Study, **787**
Symptomatic and spirometric change during exacerbations of chronic obstructive pulmonary disease, **Suppl.3.A19**
Splanchnic circulation, Peritoneal ventilation in rabbits: augmentation of gas exchange with cisapride, **82**
Spoligotyping, A study of the epidemiology of sputum-positive pulmonary tuberculosis in Harare, Zimbabwe – analysis by spoligotyping, **Suppl.3.A33**
Spontaneous pneumothorax, Lung disease induced by drug addiction: *letter*, **556**
Spores, Binding of *Aspergillus fumigatus* spores to lung epithelial cells and basement membrane proteins: relevance to the asthmatic lung, **1203**
Sports, Asthma and other pulmonary diseases in former elite athletes, **288**
Sputum
Airways obstruction, chronic expectoration, and rapid decline of FEV_1 in smokers are associated with increased levels of sputum neutrophils, **267**
Blood and sputum sol inflammatory markers, **Suppl.3.A80**
Cell counts in spontaneous sputum during exacerbations of asthma and COPD, **Suppl.3.A80**
Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest, **914**
Endothelin-1 levels in induced sputum from asthmatics, normal subjects and smokers – comparison with plasma and saliva levels, **Suppl.3.A81**
Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy, **429**
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis, **119**
Induced sputum from patients with sarcoidosis is more cellular than that from control subjects, **Suppl.3.A12**
Induced sputum profiles in asthma of differing severity, **Suppl.3.A80**
Inflammatory activity in sputum chronic bronchitis and bronchiectasis during clinical stability, **Suppl.3.A81**
Reproducibility of induced sputum cell counts and fluid phase ECP, **Suppl.3.A80**
Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD, **1000**
Sputum leukotriene B_4 during infective exacerbations of chronic bronchitis, **Suppl.3.A81**
Use of a sputum colour chart in the assessment of bronchial inflammation, **Suppl.3.A82**
Staging, Factors affecting long term survival following resection for lung cancer, **1266**
Staphylococcal pneumonia, Radiographic features of staphylococcal pneumonia in adults and children, **539**
Stents (stenting)
Airway Wallstent for the treatment of tracheobronchial malignancies, **1127**
Chemodectoma of the trachea, **341**
Expandable metal stents for non-malignant bronchial obstruction, **963**
Respiratory failure due to tracheobronchomalacia, **224**; *commentary*, **226**
Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope, **248**
Yet more to see down the bronchial tree? *commentary*, **226**
Sternocostoclavicular hyperostosis, Sternocostoclavicular hyperostosis presenting with thoracic sinus formation, **550**
Steroids
Acute steroid trials in COPD: lessons from the ISOLDE trial, **Suppl.3.A44**
Chlamydia pneumoniae antibody titres are significantly associated with the use of steroid medication in respiratory disease, **Suppl.3.A14**
Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care, **1087**
Moderately severe asthma controlled at a significantly lower dose from a new CFC-free steroid inhaler, **Suppl.3.A73**
Phase III open parallel group study to compare the effects of inhaled fluticasone proprionate (500mcg bd) and budesonide (800mcg bd) on bone density measurements over 1 year in stable chronic asthmatics, **Suppl.3.A72**
Steroids, surfactant and lung disease: *editorial*, **880**
Steroids in exacerbations of asthma: tablets or inhalers? *editorial*, **1071**
Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**
Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**
Streptococcus pneumoniae
Antibiotic resistance in *Streptococcus pneumoniae*: one hospital's experience, **Suppl.3.A13**
Antibiotic resistant *Streptococcus pneumoniae*, **Suppl.2.45**
Streptokinase, The systemic fibrinolytic activity of intra-pleural streptokinase in humans, **Suppl.3.A67**
Stridor
Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma, **869**
Myasthenia gravis presenting with stridor, **108**
Subcutaneous emphysema, Pneumomediastinum secondary to use of a high speed air turbine drill during a dental extraction, **339**; *commentary*, **340**
Substance P, Angiotensin converting enzyme inhibitor-induced cough and substance P, **199**
Suicide attempt, Severe lipoid pneumonia following attempted suicide by mineral oil immersion, **652**: *commentary*, **656**
Sulphur dioxide, Evidence for opioid modulation and generation of prostaglandins in sulphur dioxide-induced bronchoconstriction, **159**
Superoxide anion, Inhibition of the alveolar macrophage oxidative burst by a diffusible component from the surface of the spores of the fungus *Aspergillus fumigatus*, **389**
Superoxide dismutase, Pulmonary effects of short term selenium deficiency, **479**
Supplemental oxygen, Assessment of oxygen supplementation during air travel, **202**
Surfactant
Effect of contact avoidance or treatment with oral prednisolone on bronchoalveolar lavage surfactant protein A levels in subjects with farmer's lung, **1210**
Steroids, surfactant and lung disease: *editorial*, **880**
Surfactant protein levels, Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome, **907**
Surfactant replacement therapy, Surfactant replacement therapy, **1137**
Surgery
Delays in the diagnosis and surgical treatment of lung cancer, **903**

Surgical treatment of 125 patients with non-small cell lung cancer and chest wall involvement, **846**

Survival
Factors affecting long term survival following resection for lung cancer, **1266**
Long term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre, **1023**

Suspended particulate matter, Suspended particulate matter and health: new light on an old problem: *editorial*, **1174**

SV40, Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural meosthelioma tissue, **1074**

Systemic lupus erythematosus, Pulmonary function in children with systemic lupus erythematosus, **424**

T cell lymphoma, Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma, **869**

T cells
Gamma/delta cells in tissue from patients with sarcoidosis, **1123**
T lymphocytes and silica-induced pulmonary inflammation and fibrosis in mice, **1036**

T lymphocytopenia, *Pneumocystis carinii* in a patient with pulmonary sarcoidosis and idiopathic CD4+ T lymphocytopenia, **446**: *commentary*, **448**

Tachyphylaxis, Salmeterol tachyphylaxis in steroid treated asthmatic subjects, **1100**

Temperature, Effect of outdoor temperature on daily lung function and exacerbations in patients with COPD, **Suppl.3.A19**

Terbutaline
Comparison of the systemic effects of salbutamol and terbutaline when inhaled from a metered dose inhaler or as a dry powder in healthy volunteers, **Suppl.3.A72**
Effect of regular terbutaline on the airway response to inhaled budesonide, **989**
Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease, **684**

Textile workers, Epidemic outbreak of interstitial lung disease in aerographics textile workers – the "Ardystil syndrome": a first year follow up, **94**

Theophylline
Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma?, **647**
Potentiation of the bronchoprotective effects of vasoactive intestinal peptide, isoprenaline, and theophylline against histamine challenge in anaesthetised guinea pigs by adrenomedullin, **1199**

Theophylline assay system, Comparison of a desktop and a laboratory theophylline assay system in clinical practice, **Suppl.3.A61**

Thin-section spiral volumetric CT, Thin-section spiral volumetric CT for the assessment of lobar and segmental bronchial stenosis, **Suppl.3.A70**

Thiorphan, Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriuretic peptide, **71**

Thoracic sinus, Sternocostoclavicular hyperostosis presenting with thoracic sinus formation, **550**

Thoracic surgery, Video assisted thoracic surgery for spontaneous pneumothorax, **Suppl.2.23**

Thoracotomy, Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy, **429**

Thorax, Annual Report October 1995 to September 1996, **1177**

Three-dimensional imaging, Spiral computed tomographic scanning of the chest with three dimensional imaging in the diagnosis and management of paediatric intrathoracic airway obstruction, **1005**

Threshold loading device, Reliability of a commercially available threshold loading device in healthy subjects and in patients with chronic obstructive pulmonary disease, **601**

Thunderstorms
Causes of thunderstorm-related asthma, **Suppl.3.A1**
Effect of ozone, thunderstorms and other weather conditions on the respiratory function of asthmatics, **Suppl.3.A1**

Thymectomy, Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome, **193**

Thymoma, Myasthenia gravis presenting with stridor, **108**

Tidal breathing, Effect of salbutamol on input impedance measurements in laryngectomized subjects during tidal breathing, **Suppl.3.A46**

Tidal breathing parameters, Tidal breathing parameters in the first week of life and subsequent cough and wheeze, **815**

Tobacco, Tobacco: the Third World War – advice from General Sun Tzu, **562**

Topical treatment, Topical treatment of life threatening haemoptysis from aspergillomas, **253**

Toxocariasis, Pleural effusion and toxocariasis, **106**; *commentary*, **107**

Tracheal aspirates, Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome, **907**

Tracheal carcinoma, High dose-rate intraluminal radiotherapy for tracheal carcinoma, **Suppl.3.A55**

Tracheal epithelium, Prostaglandin E_2 production by ovine tracheal epithelium: control by cyclic nucleotides, **Suppl.3.A38**

Tracheobronchial endometriosis, Bronchoscopic and angiographic findings in tracheobronchial endometriosis, **1060**: *commentary*, **1064**

Tracheobronchial malignancies, An Airway Wallstent for the treatment of tracheobronchial malignancies, **1127**

Tracheobronchial tumours, Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope, **248**

Tracheobronchitis, Aspergillus laryngotracheobronchitis presenting as stridor in a patient with peripheral T cell lymphoma, **869**

Tracheobronchomalacia
Respiratory failure due to tracheobronchomalacia, **224**; *commentary*, **226**
Yet more to see down the bronchial tree? *commentary*, **226**

Transcutaneous carbon dioxide, Comparison of oximetry and transcutaneous carbon dioxide levels in patients undergoing fibreoptic bronchoscopy, **Suppl.3.A70**

Transdiaphragmatic pressure, Transdiaphragmatic pressure in quadriplegic individuals ventilated by diaphragmatic pacemaker, **420**

Transgenic mice, Modification of nasal membrane potential difference with inhaled amiloride and loperamide in the cystic fibrosis mouse, **1229**

Transphrenic spread, Transphrenic dissemination of actinomycosis, **449**

Transtelephonic spirometer, Assessment of a new transtelephonic portable spirometer, **407**

Transtracheal needle aspiration, Transtracheal aspiration using rigid bronchoscopy and a rigid needle for investigating mediastinal masses, **197**

Triamcinolone acetonide, Adrenal suppression with inhaled fluticasone propionate and triamcinolone acetonide in normal subjects, **Suppl.3.A72**

Trichomonas tenax, Pulmonary eosinophilia due to *Trichomonas tenax*, **554**

Trypsin, Bronchoalveolar lavage with trypsin in pulmonary alveolar proteinosis, **769**

Tuberculin positivity, Tuberculin testing in two Liverpool social clubs: the effects of a tuberculosis outbreak on background positivity, **624**

Tuberculin responses, Inverse association between tuberculin responses and atopic disorder, **Suppl.3.A1**

Tuberculosis
Audit of a respiratory nurse tuberculosis service, **Suppl.3.A34**
Audit of tuberculosis treatment, **Suppl.3.A34**
Comparison of characteristics of patients and treatment outcome for pulmonary non-tuberculous mycobacterial infection and pulmonary tuberculosis, **137**
Comparison of polymerase chain reaction for IS6110 and Amplicor in the diagnosis of tuberculosis, **320**
Culture positive tuberculosis in HIV seropositive patients in the UK, 1993–94, **Suppl.3.A9**
Cutaneous TB – a 15 year prospective series 1981–95, **Suppl.3.A31**
Distribution of cases in a borough with a high incidence of tuberculosis, **Suppl.3.A32**
Drug resistant tuberculosis in England and Wales, 1993–1995, **Suppl.3.A8**
Effect of *Mycobacterium tuberculosis* and its components on macrophages and the release of matrix metalloproteinases, **306**
Evaluation of a directly observed six month fully intermittent

treatment regimen for tuberculosis in patients suspected of poor compliance, **1130**
Hepatotoxicity of antituberculosis drugs: *editorial*, **111**: *letters*, **873**, **1168**
High resolution computed tomographic findings in pulmonary tuberculosis, **397**
How valuable are routine bronchial washings for TB studies? **Suppl.3.A32**
Increased inflammatory cytokines and new collagen formation in cutaneous tuberculosis and sarcoidosis, **1253**
Increasing incidence of tuberculosis in the young and elderly in Scotland, **140**
Intrathoracic tuberculous lymphadenopathy: clinical and bronchoscopic features in 17 adults without parenchymal lesions, **87**: *letter*, **967**
Lack of skin test reactivity to common mycobacterial antigens in human immunodeficiency virus infected individuals with high CD4 counts, **932**
Long-term trends in tuberculosis: comparison of age-cohort data in Hong Kong and England and Wales, **Suppl.3.A9**
Management of lymph node TB in England and Wales 1993, **Suppl.3.A31**
Management of pulmonary TB in England and Wales in 1993, **Suppl.3.A31**
Management of pulmonary tuberculosis in adults notified in Scotland in 1993, **Suppl.3.A31**
Programme of directly observed therapy for tuberculosis in London, **Suppl.3.A32**
Rapid detection of MDR-TB in clinical samples, **Suppl.3.A32**
Recent increases in tuberculosis notifications in Liverpool: the influence of immigration, **Suppl.3.A33**
Risk factors for drug resistance in patients with tuberculosis in England and Wales 1993–94, **Suppl.3.A8**
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study, **132**
Scottish national survey of tuberculosis notifications 1993 with special reference to the prevalence of HIV seropositivity, **78**
Seasonality of tuberculosis: the reverse of other respiratory diseases in the UK, **944**
Study of the epidemiology of sputum-positive pulmonary tuberculosis in Harare, Zimbabwe – analysis by spoligotyping, **Suppl.3.A33**
Tuberculin testing in two Liverpool social clubs: the effects of a tuberculosis outbreak on background positivity, **624**
Tuberculosis in health care workers in the West Midlands 1992 to 1995, **Suppl.3.A9**
Understanding the different inflammatory responses to live and dead BCG: a prerequisite for improved vaccine design, **Suppl.3.A34**

Tuberin, The tuberous sclerosis 2 gene product tuberin is constitutively expressed in human airway smooth muscle and upregulated by serum, **Suppl.3.A67**

Tuberous sclerosis, The tuberous sclerosis 2 gene product tuberin is constitutively expressed in human airway smooth muscle and upregulated by serum, **Suppl.3.A67**

Tumour-bearing lungs, Endocrine cells in tumour-bearing lungs, **721**

Tumour necrosis factor, Mechanisms of cigarette smoke induced increased airspace permeability, **465**

Tumour necrosis factor α, Interleukin 10 (IL-10) regulation of tumour necrosis factor α (TNF-α) from human alveolar macrophages and peripheral blood monocytes, **143**

Tumour suppressor genes, Presence of human papillomavirus DNA and abnormal p53 protein accumulation in lung carcinoma, **887**

Turbohaler
Bricanyl Turbohaler, Serevent Accuhaler and Foradil aerolizer comparative drug delivery, **Suppl.3.A73**
Comparison of pMDI plus Nebuhaler and Turbohaler in asthmatic patients with dysphonia, **Suppl.3.A74**
Home assessment of peak inspiratory flow through the Turbohaler in asthmatic patients, **433**: correction, **1068**
Particle size selection device for use with the Turbohaler, **537**
Systemic effects of high dose budesonide (4 mg) taken by four inhaler systems and orally, **Suppl.3.A72**
Turbohaler: objective assessment of patient generated flow, **Suppl.3.A75**

Turbuhaler, Peak inspiratory flow through Turbuhaler in chronic obstructive pulmonary disease, **Suppl.3.A75**

Two dimensional gel electrophoresis, Two dimensional protein patterns of bronchoalveolar lavage fluid from non-smokers, smokers, and subjects exposed to asbestos, **1028**

Upholstered chairs, Reducing exposure to cat allergen in hospitals: the effect of regular vacuum cleaning on *Fel d* 1 in upholstered chairs, **Suppl.3.A41**

Upper airway dilators, Effects of naloxone of upper airway collapsibility in normal sleeping subjects, **851**

Upper airway size, Effect of chronic continuous positive airway pressure therapy on upper airway size in patients with sleep apnoea/hypopnoea syndrome, **190**

Ustilago esculenta, Hypersensitivity pneumonitis induced by a smut fungus *Ustilago esculenta*, **650**: *commentary*, **656**

Vaccination, The effect of influenza vaccination on airway responsiveness in patients with stable asthma, **Suppl.3.A2**

Vaccine design, Understanding the different inflammatory responses to live and dead BCG: a prerequisite for improved vaccine design, **Suppl.3.A34**

Vascular remodelling, Cell signalling in pulmonary vascular cells: do not shoot the messenger!, **864**

Vasodilation, Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension, **89**

Venoms, Scorpion venoms: taking the sting out of lung disease, **546**

Ventilation
Domiciliary ventilation in chronic obstructive pulmonary disease: where are we? *editorial*, **455**
Gastric intramural pH in mechanically ventilated patients, **606**
Negative pressure ventilation in acute hypercapnic chronic obstructive pulmonary disease: *editorial*, **1069**
Neurological complications of severe illness and prolonged mechanical ventilation, **Suppl.2.40**
Non-invasive ventilation for exacerbations of respiratory failure in chronic obstructive pulmonary disease, **Suppl.2.35**
Nosocomial pneumonia during mechanical ventilation: *letter*, **771**
Techniques in mechanical ventilation: principles and practice, **756**

Ventilator-associated pneumonia
Nosocomial pneumonia during mechanical ventilation: *letter*, **771**
Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia, **378**

Ventilatory breakaway, Is ventilatory breakaway in heavy exercise really due to metabolic acidaemia? **Suppl.3.A20**

Ventilatory capacity, Longitudinal effects of change in body mass on measurements of ventilatory capacity, **699**

Video assisted thoracic surgery, Video assisted thoracic surgery for spontaneous pneumothorax, **Suppl.2.23**

Vocal cord dysfunction, Functional upper airways obstruction: two patients with persistent symptoms, **965**

Volumatic spacer
Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device, **981**
Systemic effects of high dose inhaled steroids (budesonide, beclomethasone and fluticasone) taken via large volume spacer, **Suppl.3.A71**

Wallstent, An Airway Wallstent for the treatment of tracheobronchial malignancies, **1127**

Weather conditions, Effect of ozone, thunderstorms and other weather conditions on the respiratory function of asthmatics, **Suppl.3.A1**

Wheeze (wheezing)
Atopy, bronchial hyperresponsiveness, and peak flow variability in children with mild occasional wheezing, **272**
Bronchiolitis and asthma in infancy and early childhood **Suppl.2.60**
Descriptive study of cough, wheeze and school absence in childhood, **630**
Evaluation of nocturnal bronchoconstriction by all night tracheal sound monitoring, **694**
Factors affecting symptom frequency in adolescents with wheeze, **Suppl.3.A22**
Premorbid infant respiratory function and wheezing in the first year of life: a population based study in London, **Suppl.3.A15**

Risk factors for adult onset wheezing, **Suppl.3.A22**
Study of the aetiology of wheezing illness at age 16 in two national British birth cohorts, **670**
Wheezing illness in childhood – the changing contribution of non-virus-associated wheeze, **Suppl.3.A22**
Whipple's disease, Whipple's disease presenting with lung involvement, **343**
Whitehouse report, Cancer care delivery: are the standards in the Whitehouse report attainable, **Suppl.3.A7**
'Windmill trainer' device, Randomised controlled assessment of a `Windmill Trainer' device in the measurement of PEF in children, **Suppl.3.A61**
Women, The impact of severe asthma on the lives of women, **Suppl.3.A64**
Work, Respiratory irritants encountered at work, **541**

X-rays, Radiographic features of staphylococcal pneumonia in adults and children, **539**
Xanthine, Pro-oxidant hypoxanthine and xanthine in the plasma of patients with ARDS, **Suppl.3.A53**

Zielke VDS instrumentation, Pulmonary function before and after anterior spinal surgery in adult idiopathic scoliosis, **534**


1.0
1.1
1.25
1.4
1.6
2.8
3.2
3.6
4.0
2.5
2.2
2.0
1.8